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The aim of this thesis is to enhance knowledge about solute clearance during
haemodialysis and to provide insight into factors that may influence dialysis
efficiency. By improving the understanding of the kinetics of solute removal the
limitations of current dialysis therapy will be better understood, and suggestions can
be made for future improvements in the delivery of dialysis.
Methods
The history of dialysis technique and adequacy measurement is detailed. The origin
and potential problems with urea kinetic modelling, including the effect of high
haematocrit on adequacy, are explored.
Mathematical modelling is utilised to provide potential explanations for the clearance
characteristics of phosphate and beta2-microglobulin during chronic dialysis. The
phosphate model is explored further with studies in acute renal failure and the effect
of dialysis on intra-erythrocytic phosphate concentrations is assessed. Diurnal
variation in phosphate concentration is explored.
The effect of different dialysis modalities on beta2-microgloblin levels and
symptoms of dialysis related amyloid is studied. Dialysis related amyloid deposition
is investigated by a scintigraphic imaging technique.
Results
Haematocrit. High haematocrit is not found to have a significant effect on the
clearance of solutes across a wide range ofmolecular size.
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Phosphate. A four-pool model that can be applied in both acute and chronic renal
failure is proposed to explain the observed kinetic behaviour of phosphate. Studies of
intracellular phosphate concentrations fail to demonstrate release of phosphate from
erythrocytic stores during dialysis. Diurnal variation in phosphate concentration is
demonstrated in subjects with normal renal function and also in advanced chronic
kidney disease.
Beta2-microglobulin. A multi-pool model explains the kinetic behaviour of beta2-
microglobulin during dialysis. Beta-2-microglobulin deposition is assumed to be a
staged process with some deposits easily accessible during dialysis and some more
resistant to depuration. Patients receiving high-flux dialysis or haemodiafiltration are
shown to have lower circulating beta2-microglobulin levels and less symptomatic
dialysis related amyloid, but evidence of amyloid deposition is still found when
assessed by a scintigraphic imaging technique. Age and duration of dialysis are
shown to be the best predictors of symptomatic amyloid deposition.
Conclusions
The results of the studies in this thesis indicate that, for solutes such as phosphate
and beta2-microglobulin which have complex intra-dialytic kinetics, current dialysis
techniques are insufficient to achieve adequate solute removal. It will be necessary to
deliver longer or perhaps more frequent dialysis therapy in order to achieve this goal.
Mathematical modelling facilitates understanding of the pathophysiology of the
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1.1 The Development of Theory
The concept of using dialysis for long-term replacement of renal function is still a
relatively new idea. The Greeks were clearly aware of the pathology of renal failure
when they described "uraemia" which literally means urine in the blood. Their
fascination with steam baths to "purify" the body of toxins was probably not entirely
without basis.
I '2
In 1855 a German physiologist Adolf Fick first described the process of diffusion ' ,
but it was Thomas Graham, a professor at Glasgow's Anderson University, who first
used the term "dialysis". He described the process ofdiffusion across an ox bladder
that served as a semi-permeable membrane3. The pioneering work of these scientists
formed the basis of the later application of these theories to human dialysis.
The first artificial kidney was utilised in 1913 when Abel and his colleagues removed
blood from a rabbit, poisoned with salicylic acid, and passed this through a dialyser
made of colloidin tubes derived from cotton, encased within a glass container filled
with saline. The blood was removed via an arterial cannula and returned to a vein
and the animals survived at least in the short term. Although they considered such a
device for human use, development was not continued due to the outbreak ofwar and
problems with obtaining a supply of leeches to act as anticoagulant4.
Figure 1.1. The dialysis apparatus used
by Abel in 1913.
[Reproduced with permission from5 ]
19
After the war, interest in dialysis was rekindled and, in 1924, George Haas
performed the first human dialysis treatment. He dialysed his patient for 15 minutes
with no adverse effects during the treatment. He dialysed a total of seven patients
over a four-year period all of whom ultimately died of renal failure. He achieved
anticoagulation in the early days using hirudin obtained from the saliva of leeches.
This caused many problems when administered to humans and latterly Haas used
heparin. This anticoagulant was isolated from dog livers by an American named
Maclean in 19166. The ability to produce heparin in large quantities in purified form
n
was achieved by 1937 .
1.2 The Development of Acute Dialysis 1940s-1960
In 1943, two Dutch nephrologists, Kolff and Berk, built the first practical
haemodialysis machine. Kolffhad originally become interested in developing a
kidney machine as a young man, and based his ideas on the work ofAbel. He was
restricted by the German occupation during the war and was forced to use any
available materials including the drum of a washing machine. The discovery of
cellophane (used commercially as sausage skin) gave Kolff an ideal dialysis
membrane. The machine he finally devised consisted of 30-40 meters of cellophane
tubing on a rotating drum contained in a 100 litre stationary tank. When the drum
rotated, blood was drawn through the cellophane tubes and dialysis occurred as the
tubes were exposed to the dialysis bath.
20




Although the first sixteen ofKolff s patients died, he is credited with performing the
first successful human dialysis in 1945. The patient, a woman with septicaemia and
acute renal failure, survived and died several years later of unrelated causes.
In 1946, Alwall produced a modified version of the Kolff rotating drum that, for the
first time, permitted controlled ultrafiltration to occur. It consisted of 10 metres of
cellophane stretched over a metal frame suspended in a stationary tank. The
cellophane was more able to withstand pressure because of its encasement between
metal sheets and the containment of the entire apparatus within a closed container





a) [Reproduced with permission from5] b) Edren: www.edren.org
[reproduced with permission]
Haemodialysis was used for the first time in the UK at the Hammersmith Hospital
after the Second World War. Kolff donated one of the five rotating drum dialysers he
had made to permit nephrologists in the UK to become familiar with his renal
replacement therapy. A report of the successful treatment of 12 cases of acute renal
o
failure was published by Bywater and Joekes in 1946 . Despite their initial success,
dialysis was still viewed with suspicion. The traditional therapies for renal failure of
protein and fluid restriction remained dominant9 and dialysis was not pursued as a
potential therapy in the UK for another 10 years.
Kolff s dialysis machine was also taken to the Peter Brent Brigham Hospital in
Boston at the invitation ofGeorge Thom. There, Carl Walters and John Merrill
modified it and it became the Kolff-Brigham machine. This was the first widely used
machine and was taken overseas during the Korean War (1950-53) to successfully
treat 31 cases of acute renal failure in the field. This helped to establish dialysis as a
22





Photo by Jim Curtis
www.homedialysis.org
[reproduced with permission]
In 1956, after spending some time with John Merrill in Boston, Frank Parsons
returned to Leeds General Infirmary and was influential in rekindling the interest in
haemodialysis in the UK. By 1958 there were three units in the UK with dialysis
facilities - Leeds, Hammersmith and Halton Air Base. Edinburgh Royal Infirmary
followed with the opening of an Artificial Kidney Unit in 1958. This unit purchased
a Kolff-Travenol machine which was a more advanced design incorporating a 'twin
coil'. This machine was more compact and could be pre-sterilised, reduced the
resistance within the dialysis circuit and had better ultrafiltration control than the
older models. However, a blood pump was required to maintain transmembrane
pressure and the machine was prone to membrane rupture. The priming volume of
the circuit caused problems with volume depletion and, as a result, the patients were
exposed to large volumes ofblood products. Despite these issues, the first dialysis
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was performed successfully in Edinburgh in May 1959 and, by the end of that year,
there were six haemodialysis units in the UK.
The survival from acute renal failure was in the region of 52% in these early days,
which compared favourably to the 100% mortality before dialysis was possible. The
treatments were long -between eight and twelve hours. Fluid removal was not very
well regulated and tended to be assessed by dialysing patients in weigh beds. The
amount of fluid removal was altered manually by changing the pressure in the
dialysis compartment.
The choice ofwhich patients to dialyse was largely empirical. The patients had to be
well enough to tolerate a therapy that was not without complication, so patients
presenting with uraemic encephalopathy were often not treated. In the early days, the
treatments tended to occur only when patients developed overt signs of uraemia and
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many patients only ever received one dialysis session. The problem with dialysis
disequilibrium was recognised early on and a move towards shorter more regular
treatments began to occur.
1.3 The development of vascular access.
Vascular access was a big problem in the early days. There were no blood pumps on
the original dialysis machines so the movement ofblood depended largely on the
pressure from arterial blood. Cannulae were inserted into an artery and a vein at the
beginning of dialysis and these vessels were then tied off at the end of the procedure.
For these reasons recurrent dialysis was rarely an option.
Haemodialysis therapy for chronic renal failure became a reality in the 1960s when
Scribner, in Washington, pioneered the "Scribner shunt" manufactured by Quinton,
Dillard and Scribner10.
Figure 1.6. The Scribner shunt
[Reproduced with permission from11 ]
This device was inserted surgically with one cannula sutured into in a vein and
another into an artery. These were connected exteriorly with a piece of Teflon and
metal connectors. This permitted recurrent access to the circulation for the first time
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and the first patient to use one of these shunts survived for 11 years on
haemodialysis.
Modern day vascular access saw its origins in the arterio-venous fistula described by
Cimino and Brescia in 196612.
1.4 The Development of Chronic Dialysis -the early years- 1960s-1980s
With the advent of chronic dialysis came the need for improved hardware. The
original Kolff dialysers were essentially devoid of safety features and were very
demanding on time and staff resources to run. In recognition of the fact that more
dialysis seemed to provide better outcomes, membranes were enlarged by the use of
flat plate dialysers such as the Kiil membrane. This was made up of several layers of
flat cuprophane membrane with blood passing along alternating layers of cuprophane
rather than through membranous tubes. This enlarged the surface area available for
dialysis and could operate at very low blood pressures. The dialysate was supplied
from a large tank, chilled to prevent bacterial growth, and Kiil pioneered the use of
countercurrent dialysate flow.
Figure 1.7. The Kiil flat
plate dialyser




The use of single pass dialysate flow became widely adopted late in the 1960s. In
Seattle, Babb and co-workers designed a central water plant that was the first of its
kind and supplied their outpatient dialysis unit13. Concentrated solutes were mixed
with tap water and sodium acetate, which appeared to be superior to bicarbonate, as
it did not cause precipitation of calcium and magnesium salts.
Ultrafiltration became easier to control by the application of negative pressure to the
dialysate. Because the dialysate compartment was always at lower pressure than the
blood compartment there was never any risk of dialysate flowing into the blood.
However, the Kiil plate dialysers were time-consuming to construct and the
technicians were exposed to the risk of infection from blood contamination. A move
towards the use ofmembranes that provided a physical separation ofblood from the
machine therefore occurred. Disposable flat plate dialysers and new hollow fibre
membranes replaced the older Kiil plates and twin coil dialysers.
Figure 1.8. Disposable flat plate
dialyser
Photo by Jim Curtis
vww.homedialysis.org
[reproduced with permission]
Stewart produced the first hollow fibre membrane in 1964. Instead of the traditional
flat plate or large cellulose tubes utilised in the previous membranes these new
dialysers were made up ofmany capillary size tubes thus increasing many-fold the
surface area available for dialysis.
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Figure"!.9. Disposable hollow fibre
membrane
Photo by Jim Curtis
www.homedialysis.org
[reproduced vwth permission]
The materials available for the construction of membranes also developed over the
years. The first membranes were formed from regenerated cellulose or cellophane,
which were later replaced by the thinner cuprophane. These membranes could be
made extremely thin which provided excellent diffusive capacity for small molecules
such as urea. The relatively small pore size and marked hydrophilicity meant they
were not as good at fluid removal or middle molecule clearance. There were also
problems with complement activation due to the presence ofhydroxyl groups.
Despite these drawbacks, these membranes are still in use in some centres today due
to their low cost.
Later, modified cellulose and synthetic membranes were developed that induce less
complement activation and are considered more biocompatible. Machines were
improved with more advanced features such as controlled ultrafiltration and safety
mechanisms such as those to detect air embolisation.
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[reproduced with permission]
Figure 1.10. Early Cordis Dow haemodialysis machine.
However, despite these advances, new problems became increasingly apparent as the
prevalence of haemodialysis as a chronic therapy increased.
1.5 Historical Complications of Dialysis
Hepatitis B
The life saving properties of dialysis therapy were well recognised by the 1970s but
complications of the therapy were beginning to emerge. In the early 1970s, there was
a countrywide outbreak of hepatitis in dialysis centres, during which many patients
and staffwere infected. The renal unit at Guy's Hospital was closed due to the size of
its outbreak, and dialysis practice was altered across the country. It was recognised
that the outbreak occurred as a consequence ofblood contamination of the dialysis
machines. In addition to providing the impetus for the development of a new
generation of dialysis membranes and machines, it also highlighted the importance of
the prevention of cross-contamination ofmachines and focussed the need for
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infection control within dialysis units. When a vaccination for hepatitis B was
developed in 1982, all renal units in the UK adopted a policy of immunisation.
Aluminium toxicity
Again in the 1970s it became apparent that many dialysis patients were experiencing
adverse neurological outcomes. Alfray in the USA reported the existence of
encephalopathy in dialysis patients and correlated it to the amount of aluminium in
post-mortem studies of their brains1 . At the time, the presence of excess aluminium
was attributed to the use of aluminium containing phosphate binders. It became
apparent however, that there was a geographical distribution of this problem with the
highest incidence in the UK being in Newcastle-upon-Tyne. It was also noted that
patients in these areas had a higher incidence of osteomalacia. These problems of
dialysis "dementia"and bone disease were both ultimately attributed to the presence
of aluminium in the water supply15. When the aluminium was removed, either by
reverse osmosis or by de-ionisation of the water, the problem was reduced
dramatically. A precedent was therefore set to provide purified water for the
purposes of dialysis.
Acetate vs. Bicarbonate
Sodium acetate had been used instead of sodium bicarbonate in dialysis fluid through
the 1960s and 70s to prevent precipitation of calcium and magnesium salts. It
became apparent that some patients dialysed against acetate developed vascular
instability presumably due to acetate accumulation. For this reason a move was made
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in the 1980s back towards bicarbonate dialysate which was facilitated by the design
of new machines with accurate proportioning systems.
1.6 The Development of Chronic Dialysis - the later years -1980s and on
The pioneers of early dialysis were less concerned with reducing morbidity as, in the
early days, dialysis was considered purely as a life saving treatment applied to acute
situations.
The definition of dialysis proposed by de Palma in 1971 encompassed the ideals of
chronic dialysis therapy.
"Dialysis permits the patient to be fully rehabilitated, to have a
satisfactory nutritional intake and a sufficient production of red
blood cells, to maintain normal blood pressure values and to
prevent the development ofneuropathy"16.
It was clear even when de Palma detailed his objectives, that dialysis therapy was
sub-optimal in achieving those goals.
Native renal function is predominately a convective process with superimposed
specific absorption and excretion mechanisms. The original dialysis modalities were
diffusive in nature, depending entirely on the passage on solutes down a
concentration gradient across a semi-permeable membrane. The diffusive clearance
of a solute is determined by the concentration gradient across the membrane and the
properties of the membrane itself including the surface area, the thickness and the
size of the pores. Diffusion can remove small molecules but for larger molecules, this
process becomes less efficient. It was noted in the 1960s and 70s that even when
patients achieved good urea clearance they still often complained of neuropathy. This
observation led to the assumption that toxins that could not be removed by
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conventional dialysis were present in these individuals and ultimately led to the
development of the "middle molecule" theory and the development of enhanced
dialysis therapies.
Membranes that are more permeable to water permit enhanced convection. For
solutes smaller than the size of the membrane pores, convective removal is in direct
proportion to the concentration of solute in the fluid passing across the membrane.
For larger molecules, the removal is determined by the sieving coefficient, which is a
function of the size of the molecule in relation to the size of the membrane pores.
Convective removal is far more efficient than removal by diffusion for larger
molecules.
1.7 The concept of dialysis adequacy
Wolfprovided the first description of haemodialysis adequacy in 1951 although he
concentrated solely on the performance of the membrane17. He studied a Kolff-
Brigham dialyser in vitro and published kinetic equations to describe to removal of
solute from the "blood" circulating through the machine. He described in detail the
clearance of urea when the dialysate bath was fresh and introduced the concept of
dialysance to describe the way in which solute was cleared when there was solute
present in the dialysate. He related the kinetic parameters of the artificial kidney to
the function of the native kidney and noted the different dialysance measurements for
different solutes. His work was technically very advanced and can still be directly
applied to haemodialysis today.
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Further assessment of dialyser function was provided by Michaels in 1966 with his
1 8
analysis of the mass transfer coefficient . This gives the theoretical clearance of a
dialyser at infinite blood and dialysate flows and permits the clearance of a solute at
a given blood and dialysate flow to be predicted. For diffusive therapies, his
equations are still applicable today but inaccuracies have entered into these equations
with the increased prevalence of convective dialysis therapies. Several authors have
attempted to provide correction factors to take ultrafiltration and changes in
haematocrit into account, but, at best, the equations are a close approximation19'20.
The first publication trying to correlate dialyser function to patient outcome appeared
in 1971 when Babb devised the square meter/hour theory. He stated that patients
needed a minimum exposure to dialysis of 21m -hours in the course of a week to
prevent the development of complications21. The following year the same group
introduced the concept of "middle molecules" in dialysis therapy22. They proposed
that larger molecules that diffuse more slowly across a membrane depend on long
duration of dialysis for adequate removal and that the accumulation of these so called
"middle molecules" is responsible for some of the toxic effects of renal failure.
In 1973, the Federal Government in the United States took over funding of the
chronic dialysis programme, which prompted research into the most cost-effective
way of delivering the service.
In 1974, Gotch and Sargent for the first time put forward their recommendations for
urea kinetic modelling as a way of prescribing and monitoring haemodialysis
therapy. The origins of these equations will be considered in chapter 2.
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This technique was used in the protocol of the National Co-operative Dialysis Study
(NCDS). The results of this landmark study were published in 198323. It had a 2x2
factorial design with patients randomised to a low or high time averaged urea
(TACurea) to examine small solute clearance, and a long or short dialysis treatment as
a surrogate for middle molecule clearance. It showed that patients had a better
outcome if their TACurea value was lower but failed to show a significant difference
for patients dialysing for 4.5 hours compared to 3 hours. This was part of the reason
that the move towards shorter hours of haemodialysis in the United States continued,
but it was always apparent that the reduction ofurea was not the only relevant
parameter. There were patients with low TACurea who did poorly and others with a
high TACurea who were very well. The study could be criticised on several counts.
The study was short (24-48 weeks), there were small numbers (165), all patients
were <60 and none were diabetic. The arm of the study with high TACurea and short
hours was terminated early due to an excess mortality in this group. This study was
however, for a long time, the only prospective study looking at outcomes on different
dialysis schedules, but it remained unusual to monitor dialysis using urea kinetics.
In 1985 Gotch and Sargent re-analysed the NCDS data24 and for the first time could
give a marker of "adequate" haemodialysis on the basis ofKt/V where K is the
dialyser clearance, t is the time on dialysis and V is the distribution volume of urea.
They analysed the data in terms of a step function and suggested that improvements
in outcome continued up to a Kt/V of 1.0 and patients with a Kt/V <0.8 did badly.
Figure 11. This was the first time that body mass (expressed as V) and therefore
nutritional status was correlated to dialysis outcome. This finding was subsequently
used as a marker against which to measure future achievements.
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Keshaviah further analysed the data in 1993 and fitted an exponential curve to the
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Figure 1.11. Gotch analysis of NCDS
data showing step function
[reproduced with permission from 26]
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Some of the advantages of using urea kinetic modelling to prescribe dialysis dose are
• the facility to measure dialysis efficiency by comparing the prescribed to
delivered dialysis dose
• the correlation with markers ofnutritional status
• the ability to individualise dialysis treatments based on body mass.
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Some of the disadvantages are
• the necessity to understand the mathematical concepts underlying the
modelling process
• the need to rely on the potentially inaccurate measurements of dialyser
clearance (K)
• the errors introduced when an anthropometric volume is utilised in the
initial prescription
Because of these complexities, several other measures of dialysis adequacy have
been proposed.
In 1991 Lowrie and Lew advocated the use of the urea reduction ratio (URR) to
simplify the monitoring of dialysis adequacy27. A URR of 63% gives essentially the
same amount of dialysis as a single pool Kt/V of 1.2 and the two parameters are
often quoted together. The URR gives no information about nutritional status and no
information about solute clearance other than for urea. It takes no account of solute
clearance by ultrafiltration and does not recognise the contribution of residual renal
function. It is not possible to accurately alter the dialysis prescription if the URR is
sub-optimal and there is no way of comparing prescribed to delivered dose of
dialysis. Despite these drawbacks, the URR has been widely used due to its
simplicity. Many of the errors that are encountered when using the URR result in the
dose of dialysis delivered being higher than would be predicted by formal urea
kinetic modelling so the patient is relatively protected.
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How much is enough?
At present, there is a general consensus in the guidelines about the amount of dialysis
that should be prescribed. K-DOQI (2006) recommends aminimum single pool Kt/V
?o
of 1.2, with a target of 1.4 ; the UK guidelines recommend an equilibrated Kt/V of
9Q
1.2 (spKt/V 1.3) , with similar recommendations from the European Best Practice
guidelines (2002)30.
There are many studies that suggest that increasing the delivered dialysis dose above
the spKt/V of 1.2-1.4 currently recommended is beneficial. The Japanese Registry
•> 1
has demonstrated a reduction in mortality with Kt/V measurements up to 1.8 . The
experience from Tassin where the spKt/V averages 1.67 demonstrates improved
outcomes with higher Kt/V32. The benefit ofhigher Kt/V is not universally
acknowledged, as there seems to be a point at which increasing the Kt/V further does
not improve mortality. This may relate to the use ofV as the denominator in the Kt/V
calculation which could represent a confounding factor due artificially low estimates
ofV in malnourished patients. The V in the original Gotch and Sargent Kt/V
equation is calculated from three blood samples (pre-post-pre dialysis) and gives a
dynamic V that represents the catabolic activity of an individual. Due to the
complexity ofmeasuring V, an anthropometric measure ofV such as the Watson
volume is frequently utilised , but this is a static V that gives only an estimate of
solute distribution volume. TheWatson formula is based on a historical set of data
that may not be accurate when applied to the highly co-morbid, ethnically diverse
dialysis population that now exists. If a measure of catabolic activity, rather than a
static volume was used as the denominator in the dialysis prescription, a different set
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of adequacy values would be generated, with the net effect of providing
proportionally less dialysis in small individuals compared to their larger peers.
Despite many studies and much anecdotal evidence of improved outcomes with
higher Kt/V, the optimal dose of dialysis is still debated and there is resistance to
increasing the current targets for dialysis adequacy.
In an effort to clarify the optimal dose of haemodialysis the National Institute of
Diabetes and Digestive and Kidney Diseases (NIDDK) commissioned the
Haemodialysis [HEMO] study, the results ofwhich were published in 200234. This
study recruited 1846 prevalent dialysis patients to a 2x2 prospective randomised
study of low dose vs. high dose dialysis (to assess small solute clearance) and low-
flux vs. high-flux membranes (to assess middle molecule clearance) and followed
them for a mean of 2.84 years. No significant difference was found in the incidence
of hospitalisation or in all cause mortality between the dose groups. However,
women in the high dose group (achieved equilibrated Kt/V 1.53) had a significantly
lower mortality than those in the standard dose group (achieved equilibrated Kt/V
1.16), p=0.02. Even though differences in body size could not be implicated by the
authors of this report35, the suspicion of a denominator effect remains.
In terms ofmiddle molecule clearance, no significant difference could be
demonstrated between the outcomes in the high-flux and low-flux groups as a whole.
In subgroup analysis, there was a 20% reduction in cardiovascular mortality in the
high dose group, p=0.04. In patients who had dialysed for in excess of 3.7 years
before inclusion in the trial, a 36% reduction in mortality on high-flux dialysis
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(p=0.001) was seen, particularly if they had been treated with low-flux membranes
•3 C
before the trial began . Additionally, in post-hoc analysis it was shown that the pre-
dialysis level of beta2-microglobulin was a predictor ofmortality regardless of the
flux of the membrane. This gives currency to the argument that improved middle
IT
molecule clearance confers long term survival advantage .
While the HEMO study did not show current dialysis practice to be detrimental, it
also did not show any adverse outcomes in the patients receiving higher dialysis
doses or using high-flux membranes. It has fuelled debate about whether Kt/V or
URR are the correct dosing parameters and whether they should be viewed with
caution in certain sub-groups of patients. The HEMO study has rekindled interest in
the use ofmore frequent dialysis as a potential means of improving outcomes.
1.8 The Development of New Dialysis Techniques
i) High-flux versus high-efficiency therapy
The flux of a membrane refers to the ultrafiltration coefficient or hydraulic
permeability of the membrane. Traditional cellulose membranes are considered to be
low-flux as the maximum ultrafiltration rate is approximately 5-6 ml/hr/mmHg/nT.
Newer synthetic membranes are generally high-flux with ultrafiltration coefficients
in excess of 20ml/hr/mmHg/m . It is vital to use volumetric control with these
membranes, as the there is potential for excessive ultrafiltration.
The term efficiency refers to the enhanced diffusive clearance of solute brought
about by an increase in blood and dialysate flows. High-flux membranes with a large
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surface area tend to be used in high efficiency dialysis but it should be noted that
high efficiency dialysis could be achieved with a low-flux membrane.
ii) The Development ofHaemodiafiltration
Native renal function is mainly a convective process tempered by specific absorption
mechanisms. The ideal renal replacement therapy should therefore mimic this as
closely as possible. This has led to the development of the technique of
haemodiafiltration, which permits good solute clearance across the spectrum of
metabolic size by a combination of diffusion and convection. For small molecules
the most important factor is diffusive clearance with a 40% increase when blood flow
increases from 300 to 500ml/min, with only minor increases seen when the
membrane surface area or convection are increased. Formiddle molecules, however,
38it is the increase in convection that influences solute removal most .
Where HDF is used there are two practical options to be considered which have
different implications for solute removal.
In predilutional HDF, extra fluid is added before the dialyser and removed by
ultrafiltration across the dialyser. Pre-dilution HDF is better for middle molecule
clearance but small molecule clearance is reduced because of haemodilution. The
huge volumes of infusate involved limit the use of pre-dilution techniques but this is
less of a consideration with on-line production of fluid.
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In post-infusion HDF, fluid is removed by ultrafiltration across the dialyser and is
then resubstituted in the venous bubble trap post-dialyser. Figure 13.
Figure 1.13. Schematic of post-dilution HDF therapy
Post dilution HDF is the technique most commonly used in practice. It has been
demonstrated that urea clearance in post-dilutional HDF is equivalent to that seen in
high-flux haemodialysis. The increase in convection is most important for middle
molecules with improved clearances up to a post-dilution substitution volume of
lOOml/min. Infusion rates of lOOml/hr permit beta2-microglobulin removal twice
that ofhigh-flux dialysis. Further increases show no further benefit possibly due to
the effect of increased haematocrit. The fraction of plasma flow that can be diverted
for convective purposes is around 35%. This equates to a post-dilution infusion
volume of 60-100ml/min38.
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To maximise the benefits of the pre and post infusion techniques some have
advocated a mixture of the two approaches. A mid-dilution membrane has been
designed to take advantage ofpre and post-dilution HDF features. There is a double
core so blood flows through the dialyser twice with infusion fluid being added at the
distal end. The first pass through the membrane is thus in post-dilution mode and the
second pass is in pre-dilution mode. Minor reductions in urea clearance but a further
significant increase in beta2-microglobulin clearance is achieved when compared to
post-dilutional HDF39.
While there are yet no randomised, controlled studies that prove that HDF has a
beneficial effect on morbidity or mortality, there are equally no studies that prove it
is detrimental. There are many anecdotal reports of improved outcomes. Given the
growing acceptance of the technique and abating concerns relating to cost and safety,
the technique is likely to become much more prevalent in the coming years. At
present only 1-1.5% of patients in the UK receive this therapy vs. about 14 % in Italy
and a much higher proportion in Japan. The technique has not been licensed in the
United States due to FDA concerns about the infusion of dialysate directly into the
blood stream.
With the growing acceptance of the technique of haemodiafiltration comes a
responsibility to prove that it is a superior technique as, theoretically, it may
favourably influence some of the complications experienced by long-term dialysis
patients.
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1.9 Complications ofModern Dialysis Therapies
i) CardiovascularMortality
The substantial increase in morbidity and mortality seen in dialysis patients can
largely be attributed to a very significant increase in cardiovascular risk. There is
now undisputed evidence that the presence of renal failure causes a disproportionate
increase in the risk of cardiovascular death with 40-50% of deaths in dialysis patients
being directly attributed to a cardiovascular event. The widely quoted study
performed by Foley et al demonstrates that dialysis patients at the age of 25-34 have
a similar cardiovascular risk to normal controls at the age of >85 and a 100-fold risk
when compared to control subjects of the same age40, Figure 14.
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Figure 1.14 Cardiovascular mortality (death due to arrhythmia, cardiac arrest, myocardial
infarction, atherosclerotic disease and pulmonary oedema) in US dialysis patients.
[reproduced with permission from ]
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While dialysis patients share many of the same traditional risk factors for
cardiovascular disease such as smoking, hypercholesterolaemia, hypertension and
diabetes, with the general population, some additional influences are unique to the
dialysis population. In patients without renal dysfunction, most cardiac morbidity
arises from atherosclerotic coronary artery disease. The aetiology in renal
dysfunction is different, with the calcification arising in the medial layers of small
and medium sized blood vessels leading to increased arterial stiffness. One of the
main problems with addressing cardiovascular risk in the dialysis population is the
lack of good randomised controlled trials of interventions in this group. Care needs
to be taken when extrapolating the results ofprevention trials carried out in the
general population, as the risk factors for cardiovascular disease in patients with
renal failure on dialysis are clearly different from the general population. For
example, it is undisputed that lowering cholesterol in the general population
improves cardiovascular outcomes but studies looking at the effects of lowering
cholesterol in dialysis patients have been largely negative41.
Two of the non-traditional risk factors that are considered to be ofmost importance
in dialysis patients are the impact of altered bone metabolism and the presence of
chronic inflammation.
a) Divalent Ion Metabolism
Data from the USRDS identified an elevated serum phosphate and calcium x
phosphate product as an independent risk factor for mortality42. Excess
cardiovascular mortality has been confirmed in many subsequent studies43'44 and
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there is increasing evidence that altered divalent ion metabolism predisposes to
increased premature coronary vessel calcification45'46.
At present, there are no prospective randomised controlled trials that demonstrate
improved cardiovascular outcomes with improved control ofmineral metabolism.
HDF removes phosphate more efficiently than HD but the actual change in serum
phosphate levels probably relates more to internal phosphate transfer within cells and
body compartments. Although the phosphate concentration may be reduced rapidly
in the early part ofHD this may be offset by intra and interdialytic rebound.
There have been a number of observational studies looking at the effect of using
calcium containing phosphate binders and non-calcium containing phosphate binders
which would suggest a reduction in coronary calcification when non-calcium
containing compounds are used47. The Dialysis Clinical Outcomes Revisited Study
(DCOR) did not demonstrate improved mortality in a group treated with non-calcium
containing phosphate binders although they were able to demonstrate improved
survival in a post-hoc analysis ofpatients receiving the non-calcium containing




The role of inflammation in increasing cardiovascular risk is incompletely
understood. It has been demonstrated that elevations in CRP are associated with
increased cardiovascular risk in both the general population and in dialysis patients48"5 .
In dialysis patients the biocompatibility of the dialysis circuit and the quality of the
water supply have come under scrutiny as these are potential sources of chronic
exposure to pro-inflammatory stimuli.
Membranes
Traditional cellulose membranes, which were the first hollow fibre membranes to be
developed, cause marked complement activation during their use. This
bioincompatability is attributed to the presence of hydroxyl groups on the membrane.
In an attempt to improve on this, modified cellulose membranes were developed that
replaced the hydroxyl groups with acetate. These certainly caused less complement
activation but enhanced hydraulic permeability of newer membranes permitted back-
diffusion of dialysate into the blood stream. Technical advances have seen the
development of synthetic membranes which have the same benefits of
biocompatibility but have an asymmetric membrane structure. This ensures a
hydrophobic layer that limits the potential for back-diffusion of potential pyrogens
into the blood stream. There is an increasing body of evidence that the use ofnewer
high-flux membranes is beneficial in terms ofmortality36'51'54
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Water Quality
There is a potential for bacteria and endotoxin to be present in the water supply and
the exposure of dialysis patients to large volumes ofwater (approximately 500 litres
per week), together with the use ofhigh-flux dialysers that permit back-filtration of
fluid, makes the quality ofwater ofparamount importance. In haemodiafiltration, the
problem with back-filtration does not occur but some of the dialysate is infused
directly into the blood stream emphasising that even minor contamination of the
water supply can have a negative impact on the patient. Theoretically, the use of
ultrapure water should reduce the level of inflammation in dialysis patients but there
is no conclusive evidence that this reduces cardiovascular mortality.
In addition to the problems with microbiological purity, there are also potential
issues with chemical contamination of the water supply. The problem with
aluminium contamination as detailed previously is only one of a number of issues
with the water supply. In the presence of chloramines profound haemolysis or
erythropoetin resistance can occur55, excess calcium or magnesium can cause a
"hard-water syndrome" where the patient suffers nausea, vomiting and muscular
cramps, and copper can cause headaches, hepatic damage or haemolysis. The
American Association ofMedical Instrumentation (AAMI) publish guidelines on the
acceptable levels ofwater contaminants56, Table 1. These standards are accepted by
the UK Renal Association who recommend that chemical quality is assessed every 3
months.
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ii) Dialysis related amyloid
Patients on long-term dialysis develop amyloidosis that has beta2-microglobulin as
an integral component. This has a predilection for peri-articular deposition and leads
to disabling arthropathies and classically carpal tunnel syndrome. There are also
reports of visceral deposition although this is much less frequent. The prevalence
depends on the diagnostic method employed but is generally accepted to be 20-30%
cn
at 2-3 years and >90% after greater than 7 years of dialysis . Elevated circulating
levels ofbeta2-microglobulin are a pre-requisite for the development of dialysis
related amyloid and it is clear that, because beta2-microglobulin is a "middle
molecule", it is poorly cleared by predominately diffusive low-flux therapies.
CO
Convective therapies such as HDF have been shown to enhance removal , but
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whether improved removal of P2m translates into a lower incidence of dialysis
related amyloidosis is uncertain. There is some evidence that the use of high-flux
membranes may delay the onset of dialysis related amyloid with several cross-
sectional and longitudinal studies suggesting that the incidence of carpal tunnel
syndrome is lower than in those treated with convective modalities of dialysis54'59"61.
The pathophysiology of Ap2m is incompletely understood although there is
increasing evidence that complex polymerisation of the beta2-microglobulin
molecule with collagen and glycosaminoglycans occurs. At a more advanced stage
an interaction of the Maillard type with advanced glycosylation end products (AGEs)
occurs which seems to render the deposits much more resistant to proteolytic
degradation. At this stage there appears to be a marked influx of inflammatory cells,
which may explain the onset of symptoms.
The best strategies for preventing and treating Ap2m have not yet been fully
established. At present, the only form of renal replacement therapy that provides
clear symptomatic benefit is transplantation. Although it is clear that haemodialysis
is sub-optimal in removing beta2-microglobulin, the kinetics of P2m removal in
dialysis patients have not been fully elicited. The factors limiting beta2-
microglobulin removal in haemodialysis warrant further study, as there is an
increasing cohort of patients who are destined to receive dialysis for many years as
their only form of renal replacement therapy.
49
1.10 Conclusions
The nephrology community has clearly come a long way from the pioneering work
ofAbel, Haas and Kolff and the advances in available technology are a testament to
the ingenuity of the scientific and engineering communities that have been involved
in dialysis from the outset. While much is still unknown about the precise nature of
uraemic toxins and why certain substances accumulate, it is becoming ever clearer
that advances in dialysis techniques are required to reduce morbidity and mortality
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2.1 Background
The concept ofmass balance is integral to the understanding ofmathematical
modelling. In order to derive a mathematical model for any system it is first
necessary to understand all the factors that contribute to the system in terms of inputs
and outputs. A pictorial representation of the model being considered should be
constructed before any mathematics are applied. It is often easiest to start with a very
simplified version of the model being considered and add more complex factors as
the model is developed. This is the approach I have used both in my initial review of
the urea kinetic model and in the subsequent development of the models for
phosphate and beta2-microglobulin kinetics.
2.2 Single pool urea kinetic model
The human body in the simplest terms can be considered as a single pool of fluid.
The concentration of solutes throughout this pool is considered uniform. Assuming
that no solute is generated that would increase the concentration, and no water is
removed or added, the solute concentration at the end of a period of dialysis can be
calculated if the removal rate is known. Conventional dialysis occurs by a process of
diffusion such that the removal rate is dependant on the concentration gradient across
the dialysis membrane. The pictorial representation of this is shown overleaf.
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Mass (M) = concentration (C) x volume (V)
Removal rate = KC
t
Flux 1 (F,)
Figure 2.1. Schematic representation of single pool kinetics
Assuming that the concentration of the solute in the dialysate is zero, the mass
balance equation can be written accordingly.
where M is the mass, K is the removal rate and C is the concentration in the body
fluid.
To predict the concentration at a given time this equation requires to be differentiated











C dt ~ V
(5)
integrate both sides
with respect to t
(6)
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C = e v ■eA (8)
when t=0 C — e = Cn (9)
Therefore (10)
This is the equation of a first order differential equation and demonstrates the origin
of the dimensionless parameter Kt/V. When this is plotted graphically the
exponential decline in solute concentration can be appreciated. The slope of the line
is determined by the clearance characteristics of the membrane utilised and the size
of the patient as assessed by their body "volume". As the body is being considered as
















Figure 2.2. Graphical representation of single pool kinetics
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This most simplistic mass balance equation can be applied to the dialysis process but
has clear limitations. The inherent problems are
1. The volume of the system may not be constant
2. The patient may still have significant residual renal function
3. There may be an ongoing generation of solute during the dialysis process and
in the interdialytic period
4. The distribution of solutes within the body is not constant and more than one
pool of fluid is involved. In addition to the removal by the dialysis process
the solute concentration in the extracellular space is changing because of
intracellular to extracellular solute shifts
5. The effect ofultrafiltration on haematocrit and the resultant effect on solute
clearance across the haemodialyser may need to be taken into account
6. The levels of solute in the blood may vary with time of day, posture or
concomitant drug therapy
These different issues will be addressed in turn.
2.3 Single pool model with variable volume
Once again the starting point is a pictorial representation of the system which in this
case is identical to Figure 1.
However in this set of equations the effect of changing volume needs to be taken into
account.
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As for the single pool model a mass balance equation can be written such that
—- = -Fx=-KC (11)
dt 1
V-+C— = -KC (12)
dt dt
but the change in volume is effected by the ultrafiltration rate, Qu so









rearrange = -- — (16)
dt V0 -Qu t
dC dt
separating the terms =———— (17)
-(K+Q.)C V„-Q,t
K and Qu are constants = Ktotai
f—=f—^— (18)'-K,omlC 'v0-Q„t
substitute variables -Ktotal C-u (19)
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— = -Qu (22)
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56
* \—du =—— f^-dz (23)j a n j 7Ktota,J u QUJ z
*
-Inu ——— lnz + ^4 (24)
Klotal Qu
1
M-K„arC) = -±-ln(y0-Qu-t) + A (25)V lUlUl 1 ~
^ total
























but ^total -K + Qu
o II




This equation now describes the situation of varying volume during dialysis therapy.
There is still no movement of solute between different body compartments as the
assumption currently is that the fluid within the body all contains solute at identical
concentration.
time (mins)
Figure 2.3. Graphical representation of single pool variable volume kinetics.
V=30 litres in both models. Qu=25 ml/min in variable volume model.
The different lines on the graph compare the expected solute concentrations in the
constant volume and the variable volume models. As would be expected in the
situation where volume is changing the solute clearance is higher due to the
additional removal of solute by convection.
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2.4 Single pool model with variable volume and residual renal function
Where there is residual renal function the renal clearance of solute can be considered
alongside the dialyser clearance of solute such that K=Kd +Kr
M=C x V
Removal rate = KrC Removal rate = IQC
Flux 2 (F2) Flux 1 (Fi)
Figure 2.4 Schematic representation of single pool kinetics in the presence of residual renal
function






For the purposes ofmodelling it is assumed that, during dialysis, residual renal
clearance can be arithmetically summed with dialyser clearance to give total
effective clearance.
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2.5 Single pool model with variable volume and residual renal function
and interdialytic generation
The final situation that needs to be considered when dealing with the single pool
model is the situation that arises when there is ongoing generation of solute, G.
Between dialysis treatments there is ongoing generation of solute from the ingestion
of food and normal metabolic processes.
Figure 2.5. Schematic representation of single pool kinetics with urea generation.
As before the differential equations for this system can be written.
Flux 3 (F3)=G
M=CV






Vq ~ Qut—— + CQU = G - KC
at
(37)
dC G-C(Kd + Kr + Qu) (38)




G~KtotalC V0 - Qut
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dC r dt
G - KtotalC ~ J V0 - Qut
substituting terms
1 rl , 1 rl
Ktotal Qu
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This equation fully describes the single pool model in the presence of residual renal
function, a variable volume and urea generation.
2.6 The two pool model and the introduction ofmodelling software
In all single pool equations, an assumption has been made that there is no transfer of
solute between the intracellular and extracellular compartments during the dialysis
process. While this may be true for some large solutes, it is clearly not the case for
small solutes such as urea and that move freely between body compartments. It
reality urea is in equilibrium such that under initial conditions it is equally distributed
between the intracellular and extracellular compartments. Once the dialysis process
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begins, solute is removed from the extracellular compartment according to the
removal equations detailed above. At this point, a process of passive diffusion
between the intracellular and extracellular compartments begins. The transfer of
solute is a bi-directional process with a rate determined by the mass transfer
coefficient for that solute, Kje.
The mass balance for these equations is represented pictorially below.
Flux 3 (F3) =G
Extracellular Flux 4 (F4) = Kje(Q-Ce) Intracellular
Me=CeVe MpQVi
Flux 1 (F,) + Flux 2 (F2) = (Kd+Kr)Ce
Figure 2.6. Schematic representation of two-pool kinetics
In the two-pool model the predicted extracellular concentration of solute falls more
rapidly as the theoretical volume ofdistribution is lower. This is tempered by solute
influx from the intracellular space. Assuming that dialyser clearance is greater than
intracellular to extracellular mass transfer, the predicted solute removal during
dialysis is greater as shown in Figure 7.
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Figure 2.7. Comparison of
concentration profiles predicted
by single pool and two-pool
kinetics.
10'
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time (mins)
The concentrations in the intracellular and extracellular compartments will drop at
different rates during dialysis due to resistance to diffusion across the cell membrane.
When the dialysis process stops there is a differential between the intracellular and
extracellular solute concentrations. The removal of solute from the extracellular
space has ceased but the intracellular to extracellular transfer of solute will continue
until a new equilibrium is reached.
The period during which the re-equilibrium is occurring is known as the rebound
period.
10
representation of intracellular and
extracellular concentration profiles
during dialysis showing the rebound




The presence of the rebound period makes it difficult to provide an accurate model of
solute kinetics that can be easily utilised in clinical practice. Ideally, the model
should predict the solute concentration at the end of the rebound period. If the pre
and post dialysis solute concentrations alone are used, the prediction is invalidated,
as solute clearance will be overestimated. Several different correction formulae have
been devised to circumvent the problem resulting in the concept of the equilibrated
Kt/V (eKt/V), which aims to predict the solute concentration at the end of the
rebound period from samples taken in the immediate post-dialysis period.
time
Figure 2.9. Graphical representation of theoretical concentration profiles in single pool,
double pool and equilibrated kinetic models
The commonly used formulae for predicting the equilibrated urea are the Daugirdas
and Schneditz rate equation62, the Smye method63 and the Tattersall equation64. The
methodology in each is different but, in common, each uses a blood sample taken in
the immediate post dialysis period to predict the urea concentration when
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re-equilibrium is largely complete. When adequacy of dialysis is referred to in the
work presented here, the Tattersall equation has been used.
Kt Kt
e— = sp—
V t + tp ^56)
t
(57)
Clearly, these complexities make the interpretation of solute kinetics difficult to
apply at the bedside. Once two pools are involved, it becomes complex to solve the
equations analytically as separate equations have to be written to explain the changes
in the solute concentrations in the intracellular and extracellular compartments.
For the intracellular compartment
(58)
and for the extracellular compartment
-f- = F, + F, - CP, + F2)=Kle(C, (CeKmtal) (59)at
For the intracellular space the change is volume is considered to be negligible so




For the extracellular space
v'^r+c'^r=K" (C< - c«) - > <62)at at
-Qu1)~~r~ + CeQu =Kie(Ci-C,)-(C,K) <«>
at
dCe Kie(Ct - Ce) - Ce(K + Qu) (64)
dt K(0) ~ QJ
The presence of two varying concentration parameters makes this difficult to solve
analytically and it is necessary to introduce computer simulation software. The
software used throughout the studies described in this thesis is VisSim, (Visual
solutions Inc). This programme allows the equations to be solved iteratively by the
Runge Kutta method. Details of the modelling technique are given in Chapter 3 on
general methodology.
2.7 The effect of rising haematocrit on solute clearance
The fifth potential problem identified when considering solute clearance is the effect
of rising haematocrit. In the modern era where haemoglobin levels tend to run almost
in the normal range, patients can have a haematocrit of 35% or even higher at the
beginning of dialysis. The effect ofultrafiltration particularly in therapies such as
post-dilutional HDF is to raise the haematocrit. While the clearance ofurea is not
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thought to be adversely affected by this65'66, the effect on larger molecules has not
been extensively investigated. The study presented in chapter four aims to clarify the
effect ofhaematocrit on a range of solutes of different molecular size. Both high-flux
dialysis and haemodiafiltration have been assessed to identify whether there is a
difference between the two treatments. This study is presented as part of the general
methodology section as the results impact on the other studies presented in the thesis.
2.8 The influence of varying solute levels in the interdialytic period on
solute clearance during dialysis
The sixth identified problem with solute kinetics would arise if the concentration of
the solute in question had an inherent biological rhythm. It is well recognised that
many solutes exhibit a diurnal variation in their concentration but, at present, no
allowance is made for this when assessing solute concentration in dialysis patients. In
the context of haemodialysis, this is potentially most significant for phosphate and its
regulating hormones. It has been repeatedly demonstrated that phosphate exhibits
Z7.Z0
diurnal variation in normal individuals ' , but it has never been convincingly
demonstrated whether this diurnal variation is maintained in end-stage renal failure
and it is certainly not taken into account. The study described in chapter 5 assesses
the diumal variation in patients with stage 5 Chronic Kidney Disease and compares
this to age and sex matched controls. The study was designed to give information
about the diurnal variation in phosphate in patients with advanced renal impairment









Each of the studies in this thesis has some elements ofmethodology that are unique
to that study and these aspects of methodology are discussed within each chapter.
Some of the methods and statistical analyses are common to all chapters and are
discussed here.
3.1 Setting
The majority of the studies described in the thesis were carried at the Lister Hospital,
a 500 bed District General Hospital in Stevenage. The dialysis unit serves as a
tertiary referral centre for a population of 1.3 million and at the time of the studies,
there were approximately 300 patients receiving haemodialysis therapy. Around 120
of these patients were dialysed at the Lister Hospital itself, with the remainder being
dialysed at satellite units in Luton and St Albans.
In the studies of beta2-microglobulin additional studies were carried out at the Royal
Free Hospital and its satellite unit at Barnet Hospital. The Royal Free Hospital is a
teaching hospital in north London that catered for a dialysis population of
approximately 300 at the time of the study.
3.2 Dialysis techniques
Dialysis treatments were mainly carried out using Fresenius 2008 or 4008 dialysis
machines. In the Lister Hospital, either haemodiafiltration or high-efficiency high-
flux dialysis was delivered utilising biocompatible membranes (HF80, ARH9,
18GWS, Polyflux, KF201, PAN11). At the Royal Free Hospital and Barnet Hospitals
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until 6 months before the studies patients dialysed using low-flux membranes (F6,
F8, GFS 16+). At the time of the study, all patients were dialysing using high-flux
membranes (ARH9, HF60LS, HF80LS) although some of these were utilised in a
low-efficiency configuration termed "intermediate-flux haemodialysis", IFHD. All
the water utilised was ultrapure and conformed to Renal Association standards (see
page 48). In all centres, a central water plant supplied the water.
The standard composition of dialysate used unless there was a clinical indication to
do otherwise was K+ 2.0mmol/l, glucose 5.5mmol/l, HCO3" 35mmol/l, Ca2+
1.25mmol/l. If there was a clinical need one of the other dialysate compositions
detailed in table 1 was used.








1 2 1.25 5.5
2 2 1.35 5.5
3 1 1 5.5
4 2 1 5.5
5 3 1.5 0
6 1 1.35 5.5
7 3 1.75 0
Dialysate flow was 800ml/min in the patients receiving high-efficiency high-flux
dialysis or haemodiafiltration and 500ml/min in those receiving low-efficiency
intermediate-flux dialysis.
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The blood pump speed was set to the highest tolerated blood flow for the vascular
access employed, and the HDF fraction, where utilised, was calculated from 35% of
the plasma flow and reinfused into the venous bubble trap in post-dilution mode.
Dialysate collections were made in their entirety by diverting the drain fluid into a
250-litre container that was placed on a weigh scale. The volume of the collected
dialysate was considered equivalent to its weight and concentrations of solutes were
measured by sampling in triplicate from this tank after thorough mixing.
At the time of these studies being undertaken, there was a policy at the Lister
Hospital of reusing dialysis membranes. Membranes were treated with peracetic acid
(Renalin, Minntec Inc, USA) and tested for membrane integrity before each dialysis
session. After 2002 this practice was abandoned due to a change in medical device
legislation. Disposable membranes were used throughout at the Royal Free Hospital
sites.
At the Lister Hospital, all patients received dialysis according to a modelled
prescription. Monthly measurements of urea kinetics were made utilising a three
sample (pre-post-pre) technique. Residual renal function was taken into account by
measuring the volume of urine passed in a two-day dialysis break and assessing the
concentration of urea in this fluid. The target equilibrated Kt/V for each dialysis
session was 1.2 and the predicted dialysis time was calculated from rearrangement of
the equation Kt/V, where K is the dialyser clearance predicted by the manufactures
literature and V is the Watson volume. The efficiency of dialysis was then monitored
by measuring the delivered Kt/V, and alterations made in the prescription to keep the
dialysis dose on target.
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Patients at the Royal Free Hospital all received four hours of dialysis if this achieved
a URR of 65% or four and a half hours if dialysis adequacy fell below this target.
Monitoring of dialysis adequacy was carried out on a monthly basis at all centres.
3.3 Blood and dialysate sampling technique during dialysis
When blood and dialysate samples were taken during dialysis the following protocol
was used.
1. Needle the fistula
2. Take a sample from the "A" fistula needle.
3. Start the dialysate collection.
4. Start dialysis and record exact time.
5. Take blood samples from the "A" and "V" sample ports at the times detailed
recording the exact time each sample is taken.
6. At end of treatment, stop dialysis. Start stopwatch. Put machine into bypass.
7. Terminate dialysate collection. Reconnect dialysate drain line to drain.
8. After 90 seconds of no blood flow restart blood pump at 150ml/min. Cancel
alarms if necessary
9. At two minutes on stopwatch, take further samples from "A" port.
10. Finish dialysis as usual.
11. Record weight of dialysate.
12. Stir fluid using paddle for 2 minutes ensuring bottom layers well mixed and
collect samples in triplicate.
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Method for taking blood from fistula needle
Withdraw 10ml blood from fistula needle and keep in syringe. Take 2ml sample into
sample tube. Re-inject 10ml sample. Flush with 5ml saline.
Method for taking blood from sample ports on dialysis
Clean sample port with sterile swab. Withdraw 2ml using needle and sample tube.
Do not slow blood pump for sampling.
The post-dialysis blood sample was taken 2 minutes after the end of dialysis using a
slow-flow method. The following equation was utilised to convert the urea
concentration to one that could be used in the calculation of an equilibrated Kt/V64.
c* = c0-
\ v /
Recirculation was assessed by saline dilution techniques either via an integral
module on the dialysis machine in the Royal Free units or by a Transonics ultrasound
device at the Lister Unit.
Method to measure haematocrit
Obtain blood from "A" and "V" sample ports as above and transfer into three
separate heparinised capillary tubes. Analyse using the microhaematocrit centrifuge,
Hawksley, England. Insert capillary tubes into centrifuge and spin for 3 minutes at
5000rpm. Read results manually on microcentrifuge reader and take average of three
values.
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3.4 Laboratory measurement of solutes
Measurement of Extracellular Phosphate
The serial nature of the blood sampling in this work presented a challenge for the
processing of the blood samples. There was concern that, by leaving the samples
until the end of the study the results of the earlier samples may be affected due to
haemolysis and release of inorganic phosphate from the cells. It was also noted early
on that if samples were spun immediately there was a tendency for the supernatant to
clot, which prevented the sample being analysed successfully. This was assumed to
be the effect of heparin utilised in the dialysis circuit. It was not known whether
keeping the samples at room temperature or at 4°C would influence the results.
A series of studies were conducted to determine
1. Whether leaving samples to sit before centrifiigation was detrimental.
2. If refrigerating samples improves stability.
3. To determine the stability of phosphate measurements over longer periods of
time and to investigate if storage temperature has any influence on this.
The results of these analyses revealed that fibrin clot developed for up to 120
minutes post-dialysis, which is presumably the length of time before the effect of
heparin has completely worn off. It was apparent that prolonged delays in
centrifugation caused the phosphate concentration to fall significantly and there was
a tendency for samples stored at room temperature for in excess of four hours to have
higher values although not significantly. Once the samples were centrifuged, the
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phosphate concentrations were stable for up to 24 hours. The standard method of
processing all samples for analysis of phosphate was therefore to leave samples at
room temperature for 60 minutes before centrifugation. All samples were stored at
4°C after centrifugation and processed in a single run at the end of each study.
Two different autoanalysers were utilised in the course of this work. This was
unavoidable due to a refurbishment of the laboratory. The QA for the phosphate
assay on the two analysers was very similar. Table 2
Table 3.2 QA Measurements of Autoanalysers
Beckman LX20 Olympus AU600
Mean (mmol) SD CV% Mean (mmol) SD CV
0.54 0.03 5.7 0.50 0.04 7.1
1.11 0.05 4.1 1.12 0.04 3.5
1.85 0.03 1.7 2.03 0.05 2.7
Measurement of Intracellular Phosphate
The method of Challa et al69 was used to measure plasma and whole blood phosphate
concentration. Red cell phosphate concentration was assumed to be the difference
between these two values. Details of the techniques used are given in Chapter 8.
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Beta2-microglobulin measurement
At the outset of these studies the beta2-microglobulin assays at the Lister Hospital
were carried out by a nephelometric technique on a Beckman Array analyser. A
similar method was utilised at the Royal Free Hospital using a Beckman Image
analyser. The technique was time consuming as samples had to be pre-diluted to 1:6
and very operator dependant due to this manual processing of samples. It was also an
expensive technique. There were problems at the lower end of the analytical range
with the limit of sensitivity being lmg/1. I felt that this might cause problems when
analysing dialysate samples. For these reasons I investigated other potential methods
of assaying the samples.
Other automated techniques that could have been utilised in the lab were an
automated microparticle enzyme immunoassay on the Abbott Asxym analyser but
this proved to be cost prohibitive.
Radioimmunoassay lacked sensitivity at the lower end of the analytical range.
ELISA kits were commercially available with sensitivity down to 0.lmg/1 and it
appeared that a comparable degree of sensitivity could be achieved with a
luminometric technique.
I undertook a comparison of the nephelometric technique (lab standard at the time of
these studies) with the luminometric and ELISA techniques.
The laboratory did not own a luminometer but a desktop luminometer was loaned by
Cambridge Life Science to facilitate the experiment. Reagents were purchased from
the same company. ELISA kits were purchased from IBL Hamburg. Samples were
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run concurrently on the Beckman Array (the current standard), on the Berthold
Luminometer and on ELISA plates.
Luminometer
The initial studies using the luminometer were acceptable with a satisfactory
standard curve achieved. (Figures 1,2). All samples were run in duplicate and the
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Figure 3.1. Standard curve of beta2-microglobulin concentrations obtained with luminometer
1 2 3 4 5 6
standard number (log concentration)
Figure 3.2. Standard curve of beta2-microglobulin concentrations obtained with luminometer
(log transformation)
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When the results were compared with the Beckman Array analyser a close
correlation within the normal range was found although there was a correction factor
of 1.71 and a poorer correlation at higher values. Figure 3.
Beckman Array
Figure 3.3 Correlation between luminometer and Beckman Array
The luminometric technique was very time-consuming and, additionally, the reagents
were not entirely reliable with several batches giving ambiguous results. For these
reasons the luminometric technique was abandoned.
ELISA
The ELISA technique was set up to run on an automated analyser that had recently
been obtained by the immunology lab at the Lister Hospital. Unfortunately, this
malfunctioned repeatedly making it impossible to continue with this method.
At the time of these studies, the autoanalysers in the biochemistry laboratory were
being upgraded and the Beckman LX20 analyser was replaced with an Olympus
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AU600. This facilitated the use of a turbidimetric method of measuring beta2-
microglobulin, which ran in a fully automated manner on this machine. The
correlation between the results from the Beckman Array and the Olympus
autoanalyser were very close (figure 4, r~=0.97) within the range of values of
interest. The laboratory have now adopted this technique as their standard and have
adjusted the normal ranges accordingly with the application of a correction factor of
1.2.
Beckman Array
Figure 3.4. Correlation between Beckman Array and Olympus Autoanalyser for
Beta2-microglobulin
The normal range with this assay is 0-3.0mg/l and the average interassay co-efficient
of variation was 10.05%.
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Measurement ofMyoglobin
When I began this work the laboratory at the Lister Hospital did not routinely carry
out estimates of myoglobin concentration. 1 introduced a turbimetric technique than
ran on the Olympus autoanalyser and this has continued to be used as an in-house
assay. The normal range was quoted as 0-85(J.g/l with an average interassay co¬
efficient of variation of 10.1%.
3.5 Statistics
Statistical methods employed were parametric and non-parametric as appropriate
including Students t-test, Mann-Whitney U-test, Kruskal-Wallis test, Friedman's test
and Bonferroni and Dunn's post-hoc analyses to compare multiple samples. For the
work on diurnal variation, harmonic periodic regression analysis was used and cross-
correlation analysis was employed. All statistical analyses were carried out using
Minitab version 14. GraphPad Prism version 4 and Sigma Plot 2000 were used for
graphical representations.
In all statistical tests a p value of <0.05 was deemed significant.
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3.6 Biological Modelling Course
A structured program of mathematical tuition was devised by Dr Paul Chamney,
which took the form of regular tutorials. The programme is detailed below. Through
this program, the concepts of dialysis adequacy and mathematical modelling of the
dialysis process were explored and this permitted me to take the modelling studies
forward independently.
Main Concepts
• Course intended to provide introduction to basic ideas behind modelling
• Applied maths utilised where possible with explanation of key physical
concepts underpinning mathematical theory
• Special emphasis on techniques relevant to dialysis
• Topics generally applicable to pharmacological systems
• UseofVisSim
• Development of data analysis techniques with limited statistics
Details of the content of the individual modules covered during this aspect of my
research are given in Table 3.
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Table3.3.BiologicalM del ingCoursefoll w dduringResea ch
Module1
Massbal nceprinciples
Concentration,mass,volumeflux,Kirchoffslaws,definiti ncleara ce,effect veclearance,dialysercirc i s, accumulation&depletion
Module2
Functions,graphs,slopesand areas
Plottingstandardfunctions.Slope ,areaoffs ,equ tionfstraightline ,f ridebehindcalc lus,int c t, quadratics,hyperbolas,asympt pe ,log rithmic,inversesqu re,ev npow s.
Module3
BasicAlgebra
Indices&logs.Linearfactor ,quadr tic ,solution ,logarithmicrelat onship
Module4
Simultaneousequations
Solvingsimultaneousequa ionsin2dim nsio sa d3d me ions.Vect rsa dtriceforsolu i nsflin r equations.
Module5
Basicdifferent alc lculus
Findingderivativesofsimplfunction ,chrule,productanqu tientr les,massbal nce,accumula ionnd storageelements,laeffec ,parti ldifferen ia ion
Module6
Basicintegralc lculus













Findingparametersigeneralex ression ,m nsqu r derror
Module11
Ratesofchange









All the modelling of solute kinetics undertaken in this thesis utilised computerised
modelling software, VisSim (Visual Solutions Inc.). When constructing the models
the first step was to understand the system under investigation and to draw a
schematic diagram of the solute fluxes involved. Next, the mass balance equations
and basic differential equations required to describe the system were written. The
equations were then imported as 'blocks' and 'connectors' into the modelling
software.
For example in the simplest case of single pool kinetics with constant volume the
graphical representation is
Mass = concentration x volume
Removal rate = KC
r
F,
The mass balance equation is
dM = -F]
the differential equation is
y dC_ _ _kc
dt
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and the wiring diagram is
^ C(t) >'
>
> / * dC\dt > 1/S
K * -X
V
When the simulation is run, the resultant output can be plotted as a graph or observed
as a data series and predicts the time course of data that is expected from a particular
set of differential equations.
The raw data collected during experiments is introduced as an input to the software
and the observed time course of solute clearance can be visualised and compared to
different theoretical models.
The use of such modelling software allows models to be constructed based on
physiological principles. Assumptions can be made about parameters that can not
measured, to determine whether the proposed mechanism is in agreement with the
observed data.
For each of the models the standard deviation between the data and the model can be
calculated via the expression
This provides an objective measure of the degree of fit between the raw data and the
proposed model over the whole treatment period.
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The use of this software allows very complex models to be constructed without the
need for all parameters to be measured. It facilitates understanding of biological
systems and, while the precise physiological mechanisms often can not be proven,
hypotheses can be suggested from the observed time course of the data permitting
further directed research. It allows models to be graphically represented in a manner
that is easily understood without the need to interpret complex mathematical
equations. This modelling technique has been utilised in the studies examining
phosphate and beta2-microglobulin kinetics, but the same process could theoretically
be applied to any solute that can be physically measured during the dialysis process.
3.8 Research Protocols and Ethics
All the studies presented in this body of work have been approved by the Ethics
Committees of the East and North Herts NHS Trust and have received approval from
the Research and Development Committee of that organisation. In additional Ethical
Approval was granted by the Royal Free & Hampstead NHS Trust for the studies in
Chapters 10 & 11 and the Ethics Committee of Roche Pharmaceuticals approved the
study in Chapter 5.
All patients involved in the studies gave written informed consent and all studies
adhered to the Declaration ofHelsinki.
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Section 3
Haematocrit and Solute Clearance
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Chapter 4
The Effect of High Haematocrit on the
Efficiency of High-Flux Dialysis Therapies.
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The Effect of High Haematocrit on the Efficiency of High-Flux Dialysis
Therapies.
4.1 Background
Standard low-flux haemodialysis is entirely a diffusive process where solutes are
cleared from the blood according to the concentration difference across the
dialyser membrane, the size of the membrane pores and the thickness of the
membrane. Ultrafiltration rates are limited to the volume required to maintain
euvolaemia, which is on average 1-2 litres. The newer high-flux therapies
introduce an element of convection to the dialysis process. All solutes that can
pass through the pores on the membrane are removed dependant on the volume of
fluid that passes through the membrane and their sieving co-efficient. The high
ultrafiltration co-efficient of the membranes may lead to marked
haemoconcentration during the dialysis process. This is particularly the case in
haemodiafiltration (HDF) where up to 35% of the dialysed plasma volume is
ultrafiltered during a treatment. This can be equivalent to 20-30 litres of
ultrafiltrate that is replaced by infusion of physiological replacement fluid into the
venous bubble trap after the dialysis membrane, Figure 1.
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Sterile infusate
Figure 4.1. Schematic representation of dialysis circuit showing sampling ports
Patients on erythropoetin therapy maintain a near to normal haemoglobin and
haematocrit (hct) and this potentially has a significant impact on the clearance of
solute during the dialysis process. This may be relevant if the increased haematocrit
at the end of dialysis makes the process less efficient. The concept of dialysis
adequacy is based on the measured clearance of urea, a small molecule distributed
in an essentially uniform manner throughout body water compartments. New
concepts of adequacy also focus on the removal of largermolecules such as beta2-
microglobulin (P2m) that diffuse less freely. While changes in haematocrit are not
thought to be ofmajor significance in the clearance of low molecular weight
substances during dialysis65'66, the impact on higher molecular weight substances has
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not been assessed. The majority ofprevious work has measured haematocrit in low-
flux (LFHD) or high-flux dialysis (HFHD). The specific effect on solute clearance
across the range ofmolecular size in haemodiafiltration (HDF) has not been
extensively investigated.
The clearance of the dialysis membranes quoted in the product literature assumes
a constant haematocrit throughout dialysis. Hence, while this may give an
accurate estimation of clearance at the beginning of a treatment, there may be
inaccuracies by the end. Additionally, the clearances in the product literature tend
to be quoted in terms of pure diffusive clearance and take no account of the
contribution of convection, which, for larger solutes, is a major component of total
clearance.
In order to extend the concept of dialysis adequacy, particularly in relation to
haemodiafiltration, it is necessary to fully understand the impact ofhigh
ultrafiltration rates on haematocrit and dialyser solute clearance during the
haemodialysis process.
This study was designed to ascertain the degree of haemoconcentration caused by
ultrafiltration during high-flux haemodialysis and haemodiafiltration and to study
the effect of this haemoconcentration on solute clearance.
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4.2 Subjects and Methods
Twelve patients were studied with six patients undergoing high-flux haemodialysis
and six patients undergoing on-line post-dilutional haemodiafiltration. The patients
were stable on haemodialysis for aminimum of three months, and had stable
vascular access. Any patient with a haematocrit >35% was eligible for inclusion in
the study. The baseline characteristics of the subjects are detailed in Table 1.
Table 4.1. Baseline characteristic of patients.
HDF HD
Age (years) 63.5±16.5 67.019.2 p=ns
M:F 3:3 3:3
Qb (mi/min) 350.0±77.4 366.7198.3 p=ns
Qd (ml/min) 800±0 80010 p=ns
Td (min) 208.0+41.3 186.8170.8 p=ns
UF (ml) 2166.7±1555.2 175011143.2 p=ns
Qu (ml/min) 10.3±6.7 8.8±3.4 p=ns
Kt/V 1,5±0.4 1.210.2 p=0.04
KRU (ml/min) 0.411.0 0.710.7 p=ns
Qhdf (ml/min) 75.0118.7 0 p<0.001
Where Qb=blood flow, Qd=dialysate flow, Td=total dialysis duration, UF=total ultrafiltration
volume, Qu=ultrafiltration rate, KtA/=most recently recorded dialysis adequacy,
KRU=residual renal clearance of urea and Qhdf =rate of post-dialyser infusion of fluid.
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Measurement of haematocrit
Three simultaneous blood samples were taken in Sarstedt monovette tubes every 30
minutes from the arterial sample port before the dialyser membrane, from a sample
port immediately after the dialysis membrane and from the venous sample port after
the sterile infusate had been re-infused. (Sample ports 1,2 &3, Figure 1). In this way,
the maximum haematocrit reached within the dialysis membrane during
haemodiafiltration, and the effective haematocrit to which the patient is exposed was
measured. It is not possible to directlymeasure the maximal haematocrit reached
within the dialyser membrane during high-flux haemodialysis due to the changing
pressure profile within the membrane, Figure 2. In the first part of the membrane,
there is ultrafiltration that exceeds the desired weight loss and this is then
compensated for by backfiltration in the latter part of the membrane. The maximal





















Figure 4.2 Backfiltration seen in high flux dialysis is not seen with on-line haemodiafiltration




















The haematocrit was measured in triplicate using amicrohaematocrit centrifuge
(Hawksley, England).
Measurement of solute clearance
Blood sample analysis for urea and phosphate was carried out using a Beckman
LX20 autoanalyzer in the pathology lab at the Lister Hospital. Beta2-microglobulin
(11.8kD) and myoglobin (17kD) concentrations were assayed in-house using an
immunoturbidimetric method on an Olympus AU600 autoanalyser.
The total dialyser clearance was measured in two ways. The first method used
separate equations to describe the individual components of diffusion and convection
while the second method used an equation that incorporated an element of
interaction between the two types of clearance.
Method 1
The diffusive clearance KLdiff ofurea, phosphate, myoglobin and P2m across the
dialysis membrane was calculated from the concentrations measured at the arterial
and venous sample ports according to the equation
QbjCb, -Cb0)
Cb:Kdjf = [Equation 1]
where Qb=blood flow rate; Cbp concentration of solute in blood at inlet (sample port 1); Cb0=
concentration of solute in blood at outlet (sample port 3).
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An assumption is made at this point that pure diffusion is occurring and no
ultrafiltration is taking place.
This does not reflect the true situation, as blood is not a homogenous fluid. There are
red cells suspended in the plasma so the distribution of solute has to be considered
the product of the aqueous fraction x the blood flow rate. In addition, the water
content ofblood can be considered to be in two compartments, the plasma water and
the intracellular red cell water. To factor this into the equation the following
calculations are needed.
Hct
Plasma water flow rate = Qb(1 - [Equation 2]
where Fp=plasma fraction
Hct
Red cell water flow rate =Qb(-^^)Fr [Equation 3]
where Fr=red cell fraction
Hct
Total blood water flow rate = Qb[Fp - yyy- (Fp - Fr)] [Equation 4]
If there is no transfer across the red cell membrane, the effective flow rate is equal to
the plasma flow rate. However, if there is transfer across the red cell membrane
during haemodialysis, this needs to be taken into consideration. The factor y
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represents the fraction of red cell water involved in the dialysis process. If the red
cell membrane is completely impermeable to the solute y =zero and if the red cell
membrane is completely permeable to the solute y =1. y has been measured at 1.11
for urea due to a reversibly bound pool ofurea within the red cell and for phosphate
10
is essentially zero . It was also assumed to be zero in the calculations for myoglobin
and (^-microglobulin.
The equation for effective blood flow rate then becomes
Qb{effective) =Qb[Fp-~(Fp - }Fr)] [Equation 5]
This needs to be substituted back into the original equation to accurately assess the
diffusive clearance of a solute.
v _ Qb(effective)(Cbi - Cba)
diff ~ Cb.
[Equation 6]
Convective clearance of solute Kuf is calculated from the formula
Kuf = Qu
fCb,b
v Cbi\ ' y
[Equation 7]
where Qu is the ultrafiltration rate in ml/min.
When there is no diffusion occurring this simplifies to
Kuf = Qn [Equation 8]
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For each solute in question calculations were made using these independent
equations and the total clearance estimated from
Ktotal






The results from these calculations are likely to be an over-estimation of true
clearance, as, in high-flux therapies and particularly in haemodiafiltration, the
interaction between simultaneous diffusion and convection needs to be taken into
account. Total clearance is usually lower than the sum of the two component parts.
Method 2
Many different equations can be utilised to describe the combined effect of diffusive
and convective clearance. Ficheux et al have validated a linear model to predict the
effect of convection on urea clearance in HDF but this can only be applied to small
molecules71. The equation proposed by Villarroel19, although an over-simplification,
takes into account the sieving coefficients of larger molecules.
Ktotal ~ Kd0 + TrQu [Equation 10]
Where Kd0=diffusive clearance in the absence of ultrafiltration (equivalent to equation 6) and
TrQu=convective clearance. Qu=ultrafiltration rate in ml/min and T^transmittance coefficient.
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Tr can be calculated experimentally from the equation
f
Tr - S 1-
Qbt J [Equation 11 ]\
Where S is the sieving coefficient, calculated under conditions of pure convection from
where CF=concentration of solute in the dialysate and Cbpconcentration of solute at the
dialyser inlet.
It was not possible to calculate these values during this study so values quoted in the
literature were used. It was assumed that S=1 for urea and phosphate, S=0.65 for
beta2-microglobulin and S=0.33 for myoglobin72. It was assumed that S remained
constant during dialysis.
It is clear from equations 10 and 11 that convective clearance has an inter¬
relationship with diffusive clearance. By calculating clearance using Method 2, it is
probable that a more accurate representation of total clearance can be obtained which




GraphPad Prism version 4.00 forWindows, (GraphPad Software, San Diego
California USA) was used for all graphical data and non-parametric statistical
analysis.
The comparison of solute clearance between HD and HDF calculated using
method 1 was carried out using the Marin-Whitney test. The difference between the
total clearance measurements obtained bymethods 1 and 2 was compared using the
Mann-Whitney test.
The change in haematocrit in the two groups was compared using the repeated
measures Friedman test with Dunn's post test multiple comparisons for intra-
individual measurements, and with the Mann-Whitney test for inter-group
analysis.
The relationship between haematocrit and clearance was examined in two ways.
Initially serial mean clearance values were examined using the repeated measures
Friedman test with Dunn's post test multiple comparisons to determine whether a
significant change in clearance occurred during dialysis. Next the haematocrit and
solute clearance at 30 minutes and at the end of dialysis were examined to
calculate the percentage change in these parameters for each solute in the two
groups with comparisons conducted using the Mann-Whitney test.
Since the duration of the dialysis sessions varied from 140 to 250 minutes,
clearance values at 30, 60, 90, and 120 minutes together with the final clearance
value for each session were compared.
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Figure 4.3 Rise in arterial haematocrit during dialysis in HD and HDF. "denotes significance
when compared to value at t=30. *=p<0.05, +=p<0.01, **=p<0.001. Error bars
represent SEM.
There was no significant difference between the arterial haematocrit in the two
groups either at the beginning or at the end of treatment. There was a significant
difference between the arterial haematocrit (sample port 1) and the post-dialyser
haematocrit before re-infusion of fluid (sample port 2) within each group. The
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haematocrit post-dialyser at the end of the dialysis treatment was higher in HDF
when compared to HD although in absolute terms this failed to reach significance,
Table 2.
Table 4.2. Comparison of haematocrit before and at the end of dialysis and at different
sample ports in the two treatment groups. *denotes significance compared to arterial
baseline values
HDF HFHD P
Initial arterial hct % 40.3±4.4 40.313.6 ns
Final arterial hct % 46.2±6.6* 46.414.4* ns
Post-dialyser hct % 53.719.3* 48.414.5* ns
Venous hct % 48.716.2* 48.414.2* ns
When the percentage change in haematocrit across the dialyser was examined at all
time points, the rise was significantly higher in HDF. After re-infusion of



















Figure 4.4 Percentage change in haematocrit within dialyser (sample port 2-sample port 1)




The clearance ofurea and phosphate when calculated according to equation 9 is
comparable in HD and HDF. The higher total clearance of the middle molecules P2m
and myoglobin in HDF is as a result of the increase in convective transport, Table 3.
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Table 4.3 Comparison of average total clearance values (ml/min) in HDF and HD using
method 1
HDF HD P
urea 258.3±51.1 236.6±52.0 0.11
phosphate 149.3±35.3 151.4±26.8 0.64
(32microglobulin 59.3±33.4 45.2+19.7 0.05
myoglobin 33.1 ±44.7 13.4±20.1 0.03
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Figure 5 shows total clearance data obtained by method 1 for all four solutes. There
was no detectable change in total clearance over time for urea, (32m or myoglobin in
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Figure 4.5 Total dialyser clearance obtained by method 1 for solutes at five time intervals
during dialysis in HD and HDF groups combined. *denotes p<0.001. Error bars
represent 95% CI.
When analysed using the separate equations for diffusion and convection it appeared
that, in HD, total clearance ofphosphate at the end-point of dialysis was significantly




30 60 90 120 td 30 60 90 120 td
HFHD HDF
Figure 4.6 Total clearance of phosphate in HD and HDF obtained by method 1. 'denotes
p<0.001. Error bars represent 95% CI.
In terms of potential phosphate removal this equates to a 1.47±0.75mmol decrease.
The total measured mass removal for the treatments was 20.89±9.38mmol. This
reduction in phosphate clearance was not seen in HDF but was replicated in the









Total clearance measurements using the combined equation of the second method are
shown in Figure 7. There were no significant changes in clearance values during
























30 60 90 120 td 30 60 90120td 30 60 90120td 30'
urea phosphate Beta2- myoglobin
microglobulin
Figure 4.7 Total dialyser clearance obtained by method 2 for solutes at five time intervals
during dialysis in HD and HDF groups combined. Error bars represent 95% CI.
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Comparison of different methods of calculating total clearance in HD and
HDF
When calculating the clearance of small solutes (urea and phosphate) with a sieving
coefficient of approximately 1 there is no difference in the clearance measurements
obtained with the two methods of calculation.
For larger solutes with sieving coefficients less than unity, the use of the combined
equation in method 2 resulted in lower calculated levels of clearance, Table 4.
The total clearance ofbeta2-microglobulin and myoglobin, although lower when
calculated using method 2, was not significantly different to the value obtained with
method 1.
Table 4.4 Comparison of solute clearances (ml/min) calculated by methods 1 and 2
Method 1 Method 2 p
urea 236.6±52.0 236.6±52.0 ns
phosphate 151.4±26.8 151.4±26.8 ns
HD
(32microglobulin 45.2±19.7 42.8±19.6 ns
myoglobin 13.4±20.1 7.9±20.0 ns
urea 258.3±51.1 258.3±51.1 ns
phosphate 149.3±35.3 149.3±35.3 ns
HDF
[^microglobulin 59.3±33.4 56.7±33.7 ns
myoglobin 33.1 ±44.7 27.2±45.3 ns
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Percentage change in clearance method
There was no difference between HD and HDF treatments in terms of the percentage
rise in arterial hct (12% vs. 13%; p=0.669). The percentage change in clearance was
measured using clearance values taken at 30 minutes and those at the end of dialysis.
There were no statistically significant differences between HD and HDF with respect




The finding of a significant increase in arterial haematocrit was expected and
occurred in all haemodialysis sessions studied. The haematocrit immediately after
the dialyser was higher in HDF. The increase in haematocrit had no impact on the
patient per se, as re-infusion ofultrapure dialysate into the venous bubble trap
corrected haematocrit before blood returned to the patient.
The structure of the membrane is of critical importance in the presence ofhigh
haematocrit. The blood flow and wall shear rates are lowest in the peripheral
fibres of a membrane where the dialysate flow is highest73 and, unless blood flow
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rates are increased to compensate, rises in blood viscosity are likely to exacerbate
this problem74, Figure 8.
The high fluid flux across the dialysis membrane in HDF could presumably act to
improve the velocity ofblood through the peripheral fibres making HDF less
prone to the potential reduction in efficiency. Advances in the technology of
membrane structure aim to reduce this phenomenon both in terms ofmaking
blood distribution more homogenous and also by optimising dialysate flow74.
Figure 4.8. Effect of rising haematocrit on blood flow within the dialysis membrane.
Typical parabolic distribution of blood flow in the fibre bundle documented by
dye injection in the blood compartment and image reconstruction by a helical
scanner. The increase in hematocrit further enhances the discrepancy
between central and peripheral fibres in terms of relative flow velocity.
[Reproduced with permission from74]
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Solute clearance
It was hypothesised that a rising haematocrit would adversely affect intra-dialyser
haemodynamics and solute clearance. The results suggest that total clearance is
not significantly influenced by rising haematocrit regardless of how clearance is
measured.
The occurrence of simultaneous diffusion and convection within the dialysis
membrane in high-flux therapies makes an accurate description of the individual
components difficult. In method 1, an attempt was made to understand which
component of clearance was dominant for each solute and to assess how this
might be influenced by rising haematocrit. The use ofmethod 2 however gives a
more accurate representation of the impact of rising haematocrit on total solute
clearance.
It is expected that the total clearance should be less than the sum of its constituent
parts, as diffusion and convection have influences on each other during the course
of dialysis that may affect the efficiency of each individual process.
As diffusion occurs, the concentration of a solute in the blood compartment falls
and, as the degree of convection relies on solute concentration, this may be
adversely affected.
Conversely, convective removal of solute may reduce the potential for diffusive
removal due to a build up of a protein layer on the surface of the membrane that
can increase the resistance to diffusion.
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The comparison of the two methods of calculating solute clearance demonstrates
that there is no difference when calculating small solute removal. The tendency
for ultrafiltration to cause a build-up of a protein layer at the membrane surface
could theoretically lead to a reduction in the diffusive clearance. Jaffrin et al have
demonstrated in vitro that this is offset by the increase in solute concentration in
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this protein layer, with the two effects cancelling each other out . Their results
are applicable to urea and myoglobin and presumably also hold true for phosphate
and beta2-microglobulin.
The finding that beta2-microglobulin and myoglobin removal is lower when
calculated by method 2 was expected. The convective removal calculated using
method 1 assumes a sieving coefficient of 1 for all solutes and is thought to be an
over-estimate due a failure to take the relatively low sieving coefficients for larger
molecules into account. It should be noted that the clearances quoted are
theoretical clearances assuming that the sieving coefficient does not change
throughout dialysis.
In high-flux haemodialysis treatments, when clearance is measured by method 1,
there is a significant reduction in phosphate clearance towards the end of dialysis,
but, as this is not seen when clearance is measured by method 2, it may be largely
artefactual. Indeed, whether there are any clinical sequelae from a 7% reduction in
potential mass removal ofphosphate is debatable.
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4.6 Conclusions
This study shows that, in the course of high-flux dialysis treatments, despite
marked haemoconcentration, there is an insignificant change in the total solute
clearance ofurea, phosphate, beta2-microglobulin and myoglobin. It also
demonstrates the effect of taking into account the interaction between diffusive
and convective modalities of solute removal when assessing predominately
convective therapies.
It should be noted that this study was conducted in the era ofwidespread
erythropoetin use and all the patients had a haematocrit >35% at the beginning of
dialysis. It is entirely possible that ifpatients with lower haematocrit were
examined, the influence of a rising haematocrit would be greater.
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Section 4
Phosphate Kinetics in Dialysis
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Chapter 5
Assessment of Diurnal Variation in
Plasma Phosphate and Regulatory
Hormones in Advanced Renal Disease
Assessment of Diurnal Variation in Plasma Phosphate
and Regulatory Hormones in Advanced Renal Disease.
5.1 Background
Hyperphosphataemia is present in a large proportion ofpatients with advanced renal
failure and current treatment schedules provide inadequate control. An elevated
calcium-phosphate product has been linked to the excess cardiovascular mortality
experienced by patients with chronic renal failure42, and hyperphosphataemia plays a
central role in the development of renal bone disease75. In subjects with normal renal
ft7
function there is a marked diurnal variation of plasma inorganic phosphate levels ,
but it is not known if this diurnal variation exists in the presence of advanced renal
impairment. This makes the available data on the pathological role of
hyperphosphataemia in the pre-dialysis phase difficult to interpret. Once patients are
established on dialysis it becomes increasingly difficult to interpret phosphate levels
due to the complex nature of intradialytic phosphate kinetics and the widespread use
of vitamin D supplementation and phosphate binders.
There are three existing studies of diurnal phosphate variation in dialysis patients that
give conflicting results. The first study measured phosphate concentration in nine
dialysis patients on a non-dialysis day and demonstrated diurnal variation in six
patients76. The second study was carried out during incidental hospitalization of
dialysis patients and failed to demonstrate diurnal variation77. Both studies could
have been complicated by ongoing rebound of phosphate in the post-dialysis period.
The third study attempted to detect whether the timing of dialysis could account for
differences in pre-dialysis phosphate concentration. Higher phosphate concentrations
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were found in patients dialysed during the evening shift, which is consistent with the
no
notion of diurnal variation but not proof of this .
n(\ oa.oi
The normal circadian rhythms of PTH and Cortisol ' are thought to be maintained
in advanced renal disease, but there is very limited data in the published literature.
Under normal circumstances Cortisol exerts a phosphaturic effect due to inhibition of
the Na-Pi co-transporter in the proximal tubule82. Cortisol deficient states tend to
lead to hyperphosphataemia possibly as a direct result of changes in tubular
reabsorption of phosphate83. There is no information available on the status of this
relationship in advanced renal disease.
Variations in growth hormone (GH) are known to be very dependant on the sleep-
wake cycle and in normal individuals demonstrate only a weak circadian rhythm. It
is not known whether the same relationship between GH and sleep-wake cycles is
maintained in advanced renal disease. Elevated GH levels are often seen in renal
failure partly because of decreased renal clearance84 and partly due to disturbances in
o r
the hypothalamic-hypophyseal axes . Whether this has an impact on the normal
ability ofGH to enhance tubular reabsorption of phosphate is not known.
Many patients with advanced renal disease exhibit impaired glucose tolerance as a
result of either insulin resistance or abnormalities in insulin excretion or
degradation86"88. The ability of insulin to stimulate cellular uptake mechanisms
oq
appears however to be intact in renal failure , and may impact on plasma phosphate
concentrations.
This study was designed to investigate the nature of the diumal variation in plasma
inorganic phosphate levels in subjects with normal renal function and to study the
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effect of advanced renal failure on this. Due to the complexity of phosphate kinetics
in haemodialysis patients, it was decided to study subjects who were within weeks of
starting dialysis rather than to study patients already receiving haemodialysis. The
study additionally aimed to investigate whether there were any abnormalities in the
concentrations ofhormones known to regulate phosphate handling, and whether
there were abnormalities in calcium homeostasis, acid-base status or phosphate
excretion.
5.2 Subjects and methods
Eight subjects were studied, four subjects with normal renal function (eGFR 68-117
ml/min) and four subjects with stage 5 chronic kidney disease (eGFR 9-12 ml/min).
The eGFR was calculated from the MDRD 4 formula90.
eGFR = 186 * (creatinine) 1154 *(age) °'203 *(0.742if female) *(1.210 if African American)
Patients were matched with controls of similar age, sex and body mass index, Table
1. Patients with stage 5 chronic kidney disease were recruited from the Lister
Flospital pre-dialysis clinics. The controls with normal renal function were recruited
from Roche Pharmaceuticals volunteer panel.
Subjects were allowed to continue with their usual drug regime with the exception of
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the cessation of a beta-blocker in one patient and withdrawal of calcium supplements
in another, changes that were made one week prior to the study. No subject received
phosphate binders or vitamin D supplementation at any time.





Gender heightBMI weight2 eGFR (ml/min) Subject
Age
(years)
Gender heightBMI weight2 eGFR (ml/min)
1 61 M 27.3 10 5 60 M 26 83
2 34 M 20 12 6 34 M 22.5 117
3 59 M 22.3 9 7 60 M 24.8 70
4 63 F 27.3 10 8 63 F 32.3 68
Participants were admitted to the Roche Clinical Pharmacology Unit (CPU) at
Welwyn Garden City. The subjects all received equal portions of the same food
during the study with meals being served at 08:00, 13:00, and 18:00 and snacks at
16:00 and 21:00. Free access to water was allowed at any time. One of the subjects
had a diagnosis of coeliac disease and both he and his matched control received a
gluten free diet for the 24-hour period. Blood pressure, pulse and haemoglobin were
measured at two hourly intervals during the study to ensure safety.
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An indwelling cannula was placed in the antecubital fossa and was kept patent using
saline flushes between samples. Blood was sampled hourly for plasma phosphate
(PO42"), plasma total calcium (Ca2+), bicarbonate (HCO3") and glucose, and two
hourly for insulin, growth hormone (GH), parathyroid hormone (PTH), and Cortisol.
To ensure that changes in phosphate were not the result of haemolysis or
haemoconcentration/dilution, potassium and albumin were measured at each time
point.
A 2.5 ml venous blood sample was stored on ice after collection until centrifuged at
4°C. Plasma samples were immediately stored, in an upright position at 4°C until
processing, and serum for hormone assays was stored at -20°C. Samples for plasma
phosphate, calcium, bicarbonate, potassium, albumin and glucose were analysed in
the Lister Hospital biochemistry department using standard technique on an Olympus
AU600 auto-analyser. Hormonal assays were carried out at the Hammersmith
Hospital.
Six four-hourly aliquots of urine were collected with the total urine produced by
subjects during each sampling interval collected in polyethylene containers. The
volume of all specimens was measured and recorded at the end of each collection
interval. An aliquot of 10 ml was transferred to a polypropylene tube for each
collection interval and stored at 4°C until analysed for urea and phosphate
concentrations.
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Where U=measured concentration of phosphate in urine, V is volume of urine collected, P04
is the average plasma phosphate and t is the duration of the collection interval.
5.3 Data manipulation and Statistical Analysis
For the purposes of identifying peaks and troughs, data were smoothed by the
method ofweighted averages using the nine closest neighbours but, for all further
analysis, the raw data series were used.
Rhythm biometry
Graph Pad Prism software version 4.00 for Windows, San Diego, California, USA,
was used to fit a harmonic periodic regression equation to the data using the formula.






ACROPHASE where MESOR (acronym for Midline
Estimating Statistic Of Rhythm) is the mean
of the oscillation, n is the number of
harmonic components, A is the amplitude of
the maximum oscillatory distance from
MESOR, ACROPHASE is the temporal
location of the maximal crest with respect to
midnight and P is the oscillatory period.
AMPLITUDE
PERIOD
0 4 8 12 16 20 24
Time, t (24 hour clock)
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Harmonic periodic regression utilizes the least squares method to find the best fitting
sinusoidal wave form giving the smallest value for the sum of the squared residuals.
The basic circadian period of 24 hours was used as the baseline pattern. The
superimposed harmonics each has a period equal to a fraction of the basic rhythm
(12, 8 or 6 hours). For each combination ofharmonic waveforms, the goodness-of-fit
was estimated by R2 and the statistical significance was derived from the F-value
comparing the resultant waveform to one of zero amplitude.
Cross Correlation
Relationships between parameters were assessed using cross correlation analysis
utilizing Minitab version 14, (Minitab Inc). The discrete time point data was
interpolated to provide equally spaced measurements using the Runge Kutta 2nd order
method in VisSim version 4.5, (Visual Solutions Inc.). The time series were
compared at concurrent time points to detect any correlation. If this was not present,
lag periods of up to six hours were introduced to assess whether the correlation
improved.
The significance values were calculated from
In all analyses statistical significance was inferred when p<0.05. All values are




For all parameters measured, with the exception of potassium and insulin, there were
significant differences between the two groups, Table 2.
Table 5.2 Relationship between average values for all parameters in CKD and normal renal
function
Normal CKD P
P042" (mmol/l) 1.15 ±0.05 1.63 ±0.07 <0.001
K+ (mmol/l) 4.0 ±0.1 3.9 ±0.0 ns
HCO3" (mmol/l) 24.7 ±0.3 17.7 ±0.4 <0.001
Ca2+ (mmol/l) 2.33 ±0.01 2.26 ± 0.07 0.04
Glucose (mmol/l) 5.8 ±0.2 6.2 ±0.3 0.009
Albumin (mg/dl) 37.5 ±0.5 33.6 ± 0.7 <0.001
PTH (pmol/l) 4.4 ±0.2 38.3 ±6.0 <0.001
Cortisol (nmol/l) 303.6 ± 38.8 371.4 ± 42.7 0.02
GH (mlU/l) 10.4 ±3.3 27.3 ± 1.7 <0.001
Insulin (uU/ml) 16.9 ±3.9 19.7 ±4.6 ns
P04 excretion (mmol/24hrs) 31.4± 5.8 15.7± 7.1 0.01
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Phosphate
The mean phosphate concentration over 24 hours in the subjects with stage 5 CKD
was 1.63 ± 0.07 mmol/1 and in normal renal function was 1.15 ± 0.05 mmol/1,
p<0.001. When the average plasma phosphate value for CKD was compared to the
average value for normal renal function at each time point, values were higher
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time
Figure 5.1. Average plasma phosphate concentration (±SEM) in normal renal function • and
CKD □. *=p<0.05.
The dietary questionnaires filled out by our subjects did not reveal any individual to
have excessive phosphate intake. During the study, ingestion of food could not
explain the marked variability seen in plasma phosphate. Figure 2.
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Figure 5.2. 24-hour variation in plasma phosphate with times of meals marked.
main meals, snacks.
Marked variability in plasma phosphate was seen in all eight subjects studied. In
subjects with normal renal function, the variation from the mean was 56% (range 28-
85%) and in subjects with CKD, the variation was 17% (range 8-31%). There were
no corresponding changes in albumin or potassium to indicate sampling error.
In all subjects, there was a peak in phosphate concentration between 02:00 and
06:00. In two of the subjects, there was an additional peak between 20:00 and 21:00,
and again between 12:00 and 13:00.
A nadir in phosphate concentration was seen in all subjects between 08:00 and 12:00.
In two subjects, there was a further trough between 14:00 and 15:00. There is an
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assumed third trough in these two patients occurring around midnight but this cannot
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Figure 5.3. 24-hour variation in plasma phosphate in subjects with stage 5 CKD.
Data smoothed using weighted averages of nine closest neighbours.
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Figure 5.4. 24-hour variation in plasma phosphate in subjects with normal renal function.
Data smoothed using weighted averages of nine closest neighbours.
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Phosphate Rhythm biometry Table 3
All eight subjects exhibited both circadian and ultradian variation in phosphate
concentrations. The additive effects of four harmonic components with periods
24,12,8 and 6 hours could adequately explain each 24-hour profde, (p<0.001). The
contribution of the four harmonics to the overall waveform in one patient is shown in
figures 5 and 6.
Q. 1.2-
(0
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Figure 5.6 Resultant curve when four harmonics are combined
set R2=0.96 p<0.001
compared to raw data
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In six patients the amplitude of the 24hr waveform accounted for most of the
variation, whilst in the other two subjects (one CKD and one control) the major
influence came from the 8-hour waveform. The MESOR in the CKD patients was
significantly higher than the control subjects (p<0.05) but the amplitude of the major
oscillatory component did not differ. The acrophase of the main oscillatory
component in all subjects occurred between 23:40 and 04:40 accounting for the peak
in phosphate concentration in the early hours of the morning. The two subjects who
demonstrated three peaks in phosphate concentration were the two in whom the 8
hour oscillatory waveform was dominant.
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Only one of the subjects with CKD had plasma total calcium consistently within the
normal range. Two patients were hypocalcaemic and one was persistently
hypercalcaemic. Despite this, they all showed variability in their calcium
concentration with a 5-7% difference in the peak and trough calcium levels. The
variability in subjects with normal renal function was more pronounced 7-21% but
this was not significantly different from the variability in CKD.
Calcium Rhythm biometry
The pattern of calcium oscillation could be explained by periodic harmonic







































































































































There were differences between subjects with renal impairment and those with
normal renal function and between male and female patients. The small numbers of
subjects studied means that little can be concluded with certainty but the
observations are interesting.
Male
The 24-hour component of the periodic regression model in normal male subjects
showed an acrophase at 00:45 but in male subjects with CKD this was seen at 12:38.
For this component of the model, the peaks and troughs are therefore at opposites
sides of the 24-hour cycle. As this is a highly influential component of the model, it
results in major differences in the overall oscillations seen. Male subjects with
normal renal function have a trough calcium concentration at around midday while
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Figure 5.7. Calcium variation in 3 normal male patients and 3 CKD male patients
133
Female
In the female patients, the 24-hour component of the model was less influential with
most variation coming from the 12-hour component. There was a three-hour
difference in acrophase of the 12 hour harmonic, which is reflected, in a 3-hour
difference in the occurrence of peak and trough calcium concentration in the two
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Figure 5.8. Calcium variation in one normal female subject and one female with CKD —
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Bicarbonate
Despite two of the CKD subjects receiving oral bicarbonate supplementation, the
bicarbonate levels in the CKD group were significantly lower over the 24 hours.
(17.7 ± 0.6 mmol/1 vs. 24.7 ± 0.4 mmol/1). Bicarbonate levels were seen to follow a
circadian pattern with an acrophase of 16:34 and amplitude of 1.04 in the subjects
with normal renal function and an acrophase of 01:57 and amplitude of 1.75 in
subjects with CKD. Bicarbonate is therefore varying over a wider range and is high
during the night in CKD. In contrary bicarbonate is varying over a much narrower
range and is high during the day in normal renal function, Figure 9.
time (24 hour clock)
Figure 5.9. Plasma bicarbonate in normal and CKD
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PTH
The subjects with CKD all had significant hyperparathyroidism with an average PTH
over 24hrs of 38.3±6.0 pmol/1 compared to the normal subjects 4.4±0.2 pmol/1. In
subject 2, this was associated with an elevated plasma total calcium while in the
other three CKD subjects the plasma calcium was normal or low. The amplitude of
variation in the subjects with CKD was much higher than in those with normal renal
function with a variation from the mean of 42% in normal subjects and 100% in
CKD.
PTH Rhythm biometry Table 5
Seven of the eight subjects showed three distinct peaks in the PTH level while the
eighth showed four. The variation showed a circadian element with an acrophase at
night (range 17:32 - 06:55). All subjects showed a 12-hour periodic variation with an
acrophase during the night (range 22:53 - 08:22). Seven subjects showed an
additional harmonic with period 8 hours while in the eighth subject this period was 6
hours. The additive effect of these waveforms was a peak in PTH concentration in
the early hours of the morning that was of greater amplitude in the subjects with
CKD. This was followed by a nadir between 08:00 and 10:00. A further peak
occurred in all subjects between 18:00 and 21:00 followed by a trough between
23:00 and 01:00. Smaller fluctuations during the day that varied between subjects
could be explained by the lesser harmonic periods.
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No difference was seen in insulin levels between the two groups, but plasma glucose
was significantly higher in CKD; p<0.05. Insulin levels began to rise in all
individuals immediately after ingestion of food and peaked within one hour. Levels
decayed back to baseline over several hours. Parallel changes in plasma glucose were
seen in all subjects. No diurnal rhythm was detected for insulin or glucose.
Growth hormone
All four subjects with CKD had GH levels above the normal range. Notably one of
the male patients with normal renal function also had elevated GH levels with no
clinically apparent effect at the time of the study. Three of the subjects with CKD
and two with normal renal function including the subject with elevated GH levels
showed the expected rise in GH after the onset of sleep. The other three subjects (2
normal, 1 CKD) showed a peak at 08:00. In five subjects (3 normal, 2 CKD) the
pattern ofGH fluctuation showed an additional peak at 18:00-19:00. Trough
concentrations were seen at around 10:00 in all subjects. It was not possible to fit the




The mean Cortisol level over 24hrs as assessed by both the average value (371.4 ±
42.7 nmol/1 vs. 303.6 ± 38.8 nmol/1) and the MESOR (358.5 ± 48.6 nmol/1 vs. 286.5
± 29.2 nmol/1) was higher in CKD than in normal subjects. Both groups exhibited
circadian rhythm with an acrophase of 08:40 in the subjects with normal renal
function and 10:36 in those with CKD. The morning peak in Cortisol was of the same
amplitude (452 nmol/1 in normal subjects vs. 450 nmol/1 in CKD). Subjects
additionally showed ultradian variation in Cortisol levels with two subjects in each
group exhibiting eight-hour periodicity and two exhibiting twelve-hour periodicity.
Phosphate excretion
The urinary phosphate clearance rate differed between the two groups resulting in the
mass ofphosphate removed being significantly higher in normal renal function (31.4
mmol vs. 15.7 mmol, p=0.01). The volume of urine passed was not significantly
different p=0.66.
In three subjects with CKD, phosphate excretion was low during the night then
increased around 10:00 before falling to low levels again in the afternoon and
evening. The fourth subject with CKD and all the subjects with normal renal function
showed the same pattern but, in addition, had a further rise in phosphate excretion in
the afternoon around 15:00.
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Cross-correlation analysis
The cross-correlation analysis was used to highlight differences between normal
renal function and CKD but was not intended to prove cause and effect relationships.
Phosphate/Calcium
In patients with normal renal function there was a concurrent rise in calcium and
phosphate at time zero r=0.61, p<0.05. In CKD the association was significant but
negative r=-0.52; p<0.05. There was further correlation when the calcium series was
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Figure 5.10 Phosphate/Calcium cross-correlation analysis in normal renal function and CKD
140
Phosphate /PTH
The same pattern ofbi-directional correlation is seen in CKD and in normal subjects.
In normal renal function the closest correlation is seen when the PTH series is lagged
by five hours (r=-0.61 p<0.05) and there is positive correlation when the phosphate
series is lagged by one hour (r=0.44 p<0.05). A very similar pattern is seen in CKD
with maximal correlation when the PTH series is lagged by 4 hours (r=-0.72 p<0.01).
and further correlation when the phosphate series is lagged by 2 hours (r=-0.48
p<0.05). This indicates that reciprocal changes occur in PTH and phosphate






















Figure 5.11 Phosphate/PTH cross-correlation analysis in normal renal function and CKD
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Phosphate/cortisol
Essentially the same pattern was seen in CKD and normal renal function. When the
phosphate series was lagged by 1-2 hours there was a negative association between
Cortisol and phosphate (r=-0.69 p<0.01 normal; r=-0.71 p<0.01 CKD). When the
Cortisol series was lagged there was positive correlation at three hours r=0.63 p<0.05
normal; r=0.58 p<0.05 CKD). This indicates that a rise in phosphate precedes a fall
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Figure 5.12 Phosphate/cortisol cross-correlation analysis in normal renal function and CKD
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P04/Bicarbonate
In normal subjects, there is a negative association between bicarbonate and
phosphate levels when the bicarbonate series is lagged by two hours (r=-0.73 p<0.01)
and a positive association when the phosphate series is lagged by 3 hours (r=0.54
p<0.05). In CKD bicarbonate and phosphate change in the same direction with
closest correlation when the phosphate series is lagged by 1 hour (r=0.76 p<0.01),
and further correlation when the bicarbonate series is lagged by five hours (r=-0.48
p<0.05). The patterns of correlation are therefore similar but phase shifted by 2-3
hours.
Phosphate/insulin
In CKD significant negative correlation is seen at concurrent time points with an
improvement in the correlation when the insulin series is lagged by 1 hour r=-0.60
p<0.05. In normal renal function significant negative correlation is seen when the
phosphate series is lagged by five hours r=-0.67 p<0.05
No consistent relationships were seen in CKD in the cross-correlations ofphosphate
with glucose, albumin, or GH. In normal renal function, there is significant
correlation between phosphate and GH when the GH series is lagged by one hour.
In summary, opposite relationships are seen between phosphate and calcium in
normal renal function and CKD, Figure 10, while the relationships between
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phosphate and PTH and phosphate and Cortisol appear to be very similar, Figures
11,12. For bicarbonate and insulin, the cross-correlations are different in the two
groups and may represent a phase shift in the relationship. Changes in phosphate and
growth hormone are significantly correlated in normal renal function but not in CKD.
5.5 Discussion
Circadian rhythm in phosphate concentration in normal subjects is detailed in several
publications 67;68;91;92 but has not been well documented in CKD. Our data confirms
the presence ofmarked circadian and ultradian variation in plasma phosphate in all
subjects studied, and shows that variation in calcium, bicarbonate, PTH, Cortisol and
urinary phosphate excretion is also present in CKD.
It was somewhat surprising to find that ingestion of food had a limited effect on
plasma phosphate levels in these subjects, but this is consistent with the one previous
study that attempted to address this question77. The influence of the diurnal variation
in hour-to-hour changes appears to be far greater than the impact of dietary intake,
which presumably has a more long-term effect on total body phosphate. Without
farther study, it is impossible to say what the effect of phosphate binders on diurnal
variation might be.
In a previous study of glomerular filtration rate in normal individuals a circadian
rhythm was shown with lowest levels during the night , corresponding to the lowest
levels of phosphate excretion in this study. While GFR was not measured as part of
this study, it could be speculated that the diumal variation in phosphate is explained
by alterations in glomerular filtration rate. However, this cannot be the entire
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explanation, as there is insufficient total excretion of phosphate during the 24-hour
period to account for the very marked changes in plasma phosphate concentration.
The presence of diurnal variation in both PTH and Cortisol and the existence of
similar cross-correlation with phosphate in both study groups makes these hormones
likely candidates in the determination of diurnal variation. The absence of correlation
with GH in CKD suggests that this hormone is perhaps less important. Both PTH and
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Cortisol are known to be phosphaturic but the higher prevailing hormone levels in
the presence of lower phosphate excretion in CKD implies a degree of target organ
unresponsiveness. Additional mechanisms operating either at cellular level or via
effects on bone reabsorption are likely to be important in the maintenance of the
diurnal rhythm.
Acid-base balance is clearly abnormal in CKD. In normal subjects plasma
bicarbonate is higher during the day when presumably the generation ofmetabolic
waste and therefore potential for acidosis is highest. It is possible that compensatory
buffer mechanisms fail in CKD, resulting in the observed acidosis during the day.
The different patterns in the diurnal variation in calcium between the subjects with
CKD and normal renal function are reflected in the different relationship seen
between calcium and phosphate in the two groups. As it is the ionized calcium that is
biologically active, the observed differences in the acrophase of the circadian rhythm
data for calcium may be as a result of changes in ionized calcium due to acidosis.
The marked differences in the diurnal variation in bicarbonate concentration and in
calcium homeostasis between the two study groups in the presence of very similar
145
patterns for the diurnal variation in phosphate, suggests that calcium and acid-base
status are not immediately implicated in the diurnal variation in phosphate.
A difference in calcium homeostasis in males and females has been previously
described94 and a loss of the nocturnal rise in PO4 and PTH is used as a possible
explanation for the increased bone loss experienced by post-menopausal females95.
This loss of variation was not demonstrated in the two post-menopausal women,
(subjects 4 and 8) in this study, but they did appear to exhibit different calcium
kinetics from the men. If this finding were confirmed in a larger data set it may be
representative of differences in bone metabolism.
While no definitive explanation can be given for the observed diurnal variation in
phosphate, it is very clear that it is maintained in all subjects studied. The conflicting
results from the three previous studies looking at diurnal variation in haemodialysis
patients may have arisen for a number of reasons. The results of the study that
demonstrated diurnal variation in six out of nine subjects are in partial agreement
with these results76. The data from three of the six patients was fitted to a combined
linear and sinus function but no function was proposed for the other three. The linear
component of that model may be appropriate in the presence of anuria but the level
of residual function was not detailed for individual patients. It is also possible that
varying degrees of hyperparathyroidism or doses of phosphate binders were
implicated in the different patterns seen, but again the individual detail was not
published.
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The second study failed to show diurnal variation in haemodialysis patients during
incidental hospitalization. However, the timing of the samples may have missed
significant peaks and troughs, an acknowledgement that is made by the authors
77
themselves , and again no detail regarding residual renal function is available.
The third study observed that patients on afternoon and evening dialysis shifts have
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higher phosphate concentrations , a finding that would be consistent with the
presence of diumal variation, although the timing is not fully consistent with data
presented here.
Secondary hyperparathyroidism is known to occur early in the course ofCKD and
much therapeutic focus is centered on the use ofphosphate binders. In the pre-
dialysis phase when deciding to commence phosphate binders or when monitoring
the response to therapy, the timing of the blood sample should be considered.
Patients having venesection in the mid to late morning are more likely to have
favourable plasma phosphate levels compared to those venesected very early in the
morning or later in the afternoon, a factor that, at present, is not taken into account.
Differences in phosphate concentration at the beginning of a dialysis session may
have implications for haemodialysis patients as higher concentration gradients across
the dialysis membrane theoretically could increase mass removal ofphosphate in the
early part of dialysis. It is possible to render nocturnal dialysis patients, but not those
on daily dialysis, normo- or hypophosphataemic96 and, while the effect of duration of
dialysis on the multi-compartmental distribution ofphosphate is likely to be the most
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important factor, these patients are also being dialysed at the peak of their phosphate
concentration.
5.6 Conclusion
This study demonstrates the presence of diurnal variation in phosphate and regulating
hormones in advanced renal failure that is similar in nature to that seen in normal
renal function. Additionally it shows that there is diurnal variation in calcium and
bicarbonate in a pattern that differs to that seen in normal renal function. The results
presented were obtained in subjects with advanced non-oliguric renal failure. It
seems reasonable to assume that while haemodialysis patients maintain a degree of
residual renal function, the same diurnal variations will exist. It is unknown whether
the pattern will continue to be observed in oliguric long-term haemodialysis patients.
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Chapter 6
Phosphate Kinetics in Chronic
Haemodialysis
Phosphate Kinetics in Chronic Haemodialysis
6.1 Background
Hyperphosphataemia is a well-recognised complication of chronic renal failure and
is the source ofmuch concern and controversy. It is becoming increasingly apparent
that hyperphosphataemia per se is an independent risk factor formortality in the
dialysis population even when apparently adequate dialysis is being delivered.
Chronic hyperphosphataemia is important in the pathogenesis of secondary
hyperparathyroidism and its treatment with calcium containing phosphate binders
may also be a factor in the progressive calcific vascular disease, which occurs in
dialysed patients and is a potential contributant to the increased incidence of
premature cardiovascular death in this population45'46. It has been shown that a pre-
dialysis serum phosphate concentration of >2.1mmol/l is associated with increased
mortality42'97. In recognition of such factors, the British Renal Association targets a
pre-haemodialysis serum phosphate of <1.8mmol/l29. There is however no firm
evidence that reducing pre-haemodialysis phosphate levels to this degree is
beneficial, and only about 60% ofBritish haemodialysis patients achieve this
target98.
It is useful to consider the control of phosphate under normal circumstances, as it is
then easier to understand why hyperphosphataemia is such a problem in chronic
renal failure.
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Phosphate is one of the most widely distributed cations in the body. In total there is
around 700-800g in an adult body. Most of this is in the bones with around 14% in
the intracellular space. Only a small amount is present as free inorganic phosphate
and this is in equilibrium with extracellular inorganic phosphate. It is this 1% of total
phosphate that is measured in blood samples. At physiological pH, inorganic
phosphate exists in equilibrium between the monovalent and divalent forms. HPO4 "
represents 80%. The majority of phosphate is bound up in organic compounds and
phosphate is involved in many vital structural and metabolic cellular processes.
These include energy metabolism, mitochondrial function and delivery of oxygen to
tissues via 2,3 DPG. Most importantly phosphorous is the source of high-energy
bonds in ATP.
Under normal circumstances, a balance between intestinal absorption and renal
excretion maintains phosphate levels. Bone resorption at steady state is in
equilibrium with bone formation and thus plays a minor role in phosphate
homeostasis.
Intestinal absorption is a combination of active and passive processes and is
essentially unchanged in CKD, Figure 1. Intestinal uptake in normal subjects can be
seen to be a combination of a fast initial phase occurring over an hour followed by a
slower phase up to 7 hours. In CKD, the fast initial phase is deficient but overall







Figure 6.1 Uptake of labelled 32P in controls and in CKD99
In normal renal function, phosphate control at steady state is almost entirely under
renal control with 85-90% of the filtered load being reabsorbed via a sodium-
phosphate co-transporter mainly in the proximal tubule. This transporter can be
influenced by changes in dietary phosphate, PTH levels, and l,25(OH) vitamin D3.
There are many theories about the relationship between phosphate, calcium, vitamin
D and PTH in chronic renal failure. The "trade-off theory, although probably an
oversimplification, suggests that in the early stages of renal disease there is a
reduction in the renal excretion of phosphate. This invokes a rise in the PTH level
and thus a correction of the PO4 concentration. As the GFR decreases <20-30ml/min
this mechanism is no longer sufficient and PO4 rises while the PTH remains high. As
GFR decreases further to <10ml/min hyperphosphataemia becomes virtually
ubiquitous. Although this probably an oversimplification of the mechanism the
observed changes in patients with CKD support the mechanism with phosphate and
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PTH increasing dramatically as GFR falls with virtually no change in serum calcium
levels.
There are three main ways of controlling the plasma phosphate.
1. Dietary restriction
2. Use ofphosphate binders
3. Increased removal by dialysis
A normal daily Western diet contains around 25-65 mmol of phosphate100. It is
difficult to reduce this to less than approximately 17-35 mmol due to the need to
maintain an adequate protein intake of 1.0-1.2g/kg/day. Around 40-80% of ingested
phosphate is absorbed mainly in the jejunum necessitating the removal of 48-196
mmol per week. Haemodialysis typically removes 20-40mmol ofphosphate per
session, and CAPD removes approximately 10-12mmol/day. Thus, with current
dialytic schedules virtually all dialysis patients find themselves in positive phosphate
balance.
Phosphate binders in all their guises are suboptimal in effect and tolerability. As an
example 1 g of elemental calcium in the form of calcium carbonate is required to
neutralize 1.4 mmol PO4; thus in a patient with a daily excess of 14mmol of
phosphate, 10 tablets of calcium carbonate would be required which presents both an
unacceptably high calcium load and is poorly tolerated by the patient.
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Research into phosphate control has primarily focussed on haemodialysis and has
consistently highlighted some major observations. It is clear that the kinetics of
phosphate are complex and can not be explained in terms of the traditional two-pool
model as applied to urea. Secondly, it has been repeatedly demonstrated that
phosphate falls very rapidly in the first 30-90 minutes of dialysis and plateaus
thereafter. Thirdly, it is clear that in the post-dialysis period there is a significant and
rapid rebound ofphosphate such that by four hours post-dialysis phosphate levels are
equivalent to the pre-dialysis level.
This study investigated intradialytic phosphate kinetics through mathematical
modelling and explored the potential physiological processes involved.
6.2. Subjects AndMethods
The data utilised in the mathematical modelling process were generated during a
study on urea kinetics carried out by Tatersall et al at the Lister Hospital64.
Patients
Twenty-nine stable haemodialysis patients (26 male, 3 female) were studied. Their
median age was 54 years (19-81 years). They had been stable on haemodialysis for at
least three months. All patients dialysed via an arteriovenous fistula and the absence
of access recirculation was confirmed by a saline dilution method with a sensitivity
of 5%101. Residual renal solute clearance (KRU) varied from 0 to 4.0 ml/min (mean
1.2 ± 0.3) but was disregarded for the purposes of the study. Patients who were
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severely malnourished (normalised protein catabolic rate (nPCR) <0.7 and albumin
<35 g/1) or hospitalised with infection or heart failure were excluded.
Dialysis Techniques
Haemodialysis (HD) treatments were performed using a Fresenius 2008D
haemodialysis machine, bicarbonate dialysis fluid and polysulphone dialysers
(Fresenius HF80 or HF60). Blood flow rates (Qb) were 253 to 545 ml/min and
dialysate flow rates (Qd) were 500 to 800 ml/min. The same equipment was used for
haemodiafiltration (HDF) but 100 to 120ml/min filtration was performed
simultaneously. Replacement fluid was generated by filtration of the dialysate using
the Fresenius on-line HDF system.
Study Protocol
Patients were studied during a conventional haemodialysis (mean 240.7 ± 5.3 min)
and a short haemodiafiltration (mean 147.3 ± 6.5 min) on the same day of two
consecutive weeks. Dialysis prescriptions were adjusted to achieve a desired two-
pool Kt/V (urea) of 1.0 where K is the dialyser clearance rate, t is the duration of the
dialysis session and V is the urea distribution volume or total body water volume
(TBW) estimated from the Watson formula33. The duration of dialysis required to
achieve the desired Kt/V was calculated from the equation





where tp compensates for urea rebound in the post-dialytic period in accordance with
two-pool kinetics. In all treatments tp was set to 35 minutes as described
previously64.
Sampling and assay techniques
Blood samples were taken from the arterial needle before the start ofHD/HDF, from
the arterial line at six equally spaced time intervals during HD/HDF and at the end of
the treatment without slowing the blood pump. Further samples were taken at 2, 15,
30 and 60 minutes post-dialysis from the fistula needle. The washback was
performed after the two-minute sample. The ultrafiltration rate (Qu) was calculated
from pre- and post-dialysis weight. Dialyser clearance was calculated approximately
twenty minutes after the start ofHD/HDF from dialyser inlet and outlet
concentration measurements, taking haematocrit into account. Concentrations of
urea, creatinine, phosphate and bicarbonate were measured.
Data Analysis
i. Statistical Analysis. Statistical analysis was carried out using the Student t-
test for paired samples and linear correlation as appropriate. A p value <0.05
denoted the presence of a statistically significant difference. Mean values are
quoted with 95% confidence intervals unless otherwise stated.
ii. Mathematical modelling. Models were implemented using VisSim™ (Visual
Solutions Inc.) modelling software. The measured dialyser clearance (1%
meas); Qb, Qd, dialysis time (Td), sex, pre- and post-dialysis weights were




The two-pool model of urea kinetics was used as the starting point for the phosphate
model, Figure 2.
Passive
Figure 6.2. Model A. Schematic representation of two-pool kinetics. Abbreviations are: Me,
extracellular mass of solute; Ce, extracellular concentration of solute; Ve, extracellular
volume; M,, intracellular mass of solute; Q, intracellular concentration of solute; V,,
intracellular volume.
The dialyser clearance of solute (Kd) induces diffusive flux of solute (Fa) from the
extracellular space and introduces disequilibrium between the intracellular and
extracellular compartments. Solute then diffuses freely down the concentration
gradient (Fi) at a rate determined by the intracellular to extracellular transfer
coefficient (Kie). In addition, the ultrafiltration process adds convective flux of solute
(Fc). Total body water volume (V) was calculated according to the Watson formula
with an assumed intracellular to extracellular volume ratio of 2:1. The mass transfer
coefficient (K,e) between the intracellular and extracellular spaces was manipulated
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to achieve the best fit with the two-pool model. Where adjustments to the total body
water were required, the intracellular and extracellular volumes were reduced in
equal proportions, as this was considered more physiologically representative of the
effects of peripheral compartmentalisation, and thus effective solute distribution
volume. An element of cardiopulmonary recirculation (CPR) was included in the
design of the model.
Phosphate Models
Since the kinetics of urea is more straightforward, this marker was used as the
reference for establishing the compartment volumes, intracellular to extracellular
ratio and cardiopulmonary recirculation effects. Phosphate was assumed to be
distributed in the same spaces and subject to the same basic factors influencing urea
kinetics. The initial conditions were set to the prevailing phosphate concentration at
the start of simulation.
Model A
This was identical to the two-pool kinetic system as described for urea kinetics,
Figure 1.
Model B1
The established elements from model A were implemented, and a regulatory
mechanism involving a third pool was added. This regulatory mechanism
endeavoured to maintain a pre-determined target phosphate concentration that was
initially inferred by inspection of the nature of the rebound period and subsequently
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optimised. Initially it was assumed that phosphate would enter the intracellular
environment from an internal third pool and that the intracellular to extracellular
transfer coefficient for phosphate (KiePC>4) would remain constant throughout the
treatment. Using this variant of the model, the fit with the data was particularly poor
and this approach was therefore abandoned.
Model B2
In a second approach, additional phosphate flux into the extracellular space was
explored. In this model, phosphate was dialysed initially according to two-pool
kinetics. A regulatory system was invoked releasing phosphate from a third pool into
the extracellular space limiting the fall of phosphate levels below an intrinsic target
concentration. No assumptions were made regarding the source of the additional
phosphate. The phosphate generation process was assumed to be proportional to the
difference between the momentary extracellular phosphate concentration and the
intrinsic target concentration. The constant of proportionality or "gain" determined
the magnitude of the rate of phosphate generation. Values for the intrinsic target
concentration and the gain were optimised manually by direct inspection of the data
and comparison of cumulative standard deviation measurements. The rate of removal
by the dialysis process was matched by concomitant liberation ofphosphate via the
regulatory process, thus maintaining phosphate concentrations in accordance with
the data. It is probable that intracellular phosphate is protected since phosphate plays
a key role in all energy dependant processes within the cell. Intracellular phosphate
concentrations are not readily measured so the extracellular phosphate concentration
was used as a surrogate of the intracellular concentration. The mass transfer of
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phosphate across the cell membrane was assumed to be a bi-directional process thus
enabling the intracellular phosphate concentration to re-establish equilibrium with
the extracellular space in the post-dialysis period. A schematic representation of the
model is shown in figure 3. One representative treatment is shown in figure 4.
Passive
Kd diffusion
Figure 6.3. Model B. Schematic representation of three-pool kinetics. The two pool kinetic
model of model A (figure 1) forms the basis of this model with additional phosphate flux (F3)
into the extracellular space from a third pool. This occurs in proportion to the phosphate error
(I) or the difference between the momentary intracellular phosphate concentration and an
intrinsic intracellular phosphate target concentration. The magnitude of phosphate
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Figure 6.4. Representative treatment exhibiting features of model B. Two-pool kinetics are
operational for the duration of dialysis. When the prevailing phosphate
concentration falls below the target point phosphate is released from the third
pool.
Model C
This model implemented all the elements ofmodel B with the further introduction of
a fourth pool and a hysteresis element. In addition to the phosphate that is released to
maintain a target intracellular concentration, it was postulated that there must be a
critically low intracellular phosphate concentration, below which energy dependant
processes are compromised and a life-threatening situation exists. This model
considers an additional mechanism that is invoked when phosphate falls below this
161
critical limit. Under this condition, phosphate is liberated immediately at a fixed rate
F4, from a fourth pool contained within the intracellular environment. A more
sophisticated mechanism is beyond limits of that which could be deduced from the
data available.
The hysteresis element has the properties
IfCi < Cicdt AND F4 off, THEN F4 on
IfCi> CiHighLimitAND F4 on THEN F4 off
The switching point of the hysteresis element was inferred from the observed
discontinuity that could be observed in the time course of phosphate variation as
shown in figure 5.
When the intracellular phosphate concentration falls to the critically low level the
hysteresis element results in a rapid switching on of the generation process with
phosphate generated from a fourth pool local to the intracellular space. The
hysteresis element ensures liberation of phosphate over a limited concentration band,
which prevents oscillations about the critically low limit. Once intracellular
phosphate concentrations are restored, normal proportional control applies as
described for model B. The critically low limit may be encountered several times
during the course of a treatment as shown in figure 6. This is particularly likely to
occur when the pre-dialysis serum phosphate concentration is low. The model is
represented schematically in figure 7.
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Figure 6.5. Representative treatment exhibiting features of model C. Kinetics are as for
model B (figure 3) but, in addition, when the critically low limit is exceeded, fourth
pool kinetics become operational. The influx from this pool switches off when a
safe phosphate level has been re-established
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Figure 6.6. Representative treatment exhibiting features of model C with repeated activation




Figure 6.7. Schematic representation of Model C. Addition of hysteresis element to model B.
In addition to the proportional control mechanism shown in the three-pool model (figure 4),
critically low intracellular phosphate levels trigger immediate release of phosphate from a
fourth pool local to the intracellular space (F4). This independent mechanism serves to
protect the intracellular environment from dangerously low phosphate concentrations.




It was possible to achieve excellent fits with a two-pool model for the urea data in
long dialysis, figure 8 with a median intracellular to extracellular transfer coefficient
for urea (K;e urea) of 750ml/min and total body water 96.6 ± 3.2% of the predicted
Watson volume (V). In contrast, during short dialyses it was necessary to assume a
lower effective total body water 68.0 ± 4.5% ofpredicted volume, and a
corresponding reduction in Kje urea in order to achieve the same degree of accuracy.
Figure 9. The values used to compensate for cardiopulmonary recirculation (CPR)
averaged 4.3 ± 0.4% in long dialysis and 5.4 ± 0.8% in short dialysis, p<0.01.
30
Figure 6.8. Representative data from one
patient showing observed urea levels
during dialysis [•] vs. urea levels
predicted by two-pool model [represented













Figure 6.9. Representative data from one
patient showing observed urea levels
during dialysis [•] vs. urea levels
predicted by two-pool model [represented








Allowing for cardiopulmonary recirculation (CPR) and for a degree ofperipheral
compartmentalisation in the short dialysis it was possible to achieve excellent fits
between the observed urea data and the two-pool model assuming an intracellular to
extracellular transfer coefficient (Kje) of 750ml/min.
Phosphate Kinetics
Model A Two-pool kinetics
An attempt was made to fit the phosphate data to the same two-pool model. It was


















prehd tia ti2 ti3 ti4 ti5 ti6 tda td+2 td+15 td+30 td+60
time differential
Figure 6.10. Mean observed phosphate levels during dialysis for all 58 treatments vs.
phosphate levels predicted by two-pool model.
A clear discontinuity exists where the phosphate data plateaus and deviates from the two-
pool model. The degree of rebound can also be seen to be greater in the observed data than
the two-pool prediction. Symbols are: (■) observed phosphate data; (•) two-pool model.
Observed phosphate data is mean ± 95% confidence intervals.
167
During the initial part of the dialysis session, extracellular inorganic phosphate
concentrations fell rapidly, but a point was reached beyond which the measured
phosphate concentration plateaued or in some patients even began to rise. This
phenomenon did not appear to be related to alterations in acid-base status as assessed
by the serum bicarbonate concentration during dialysis, figure 11.
pre-hd tia ti2 ti3 ti4 ti5 ti6 td td+2 td+15 td+30 td+60
time differential
Figure 6.11. Serial mean plasma bicarbonate measurements throughout dialysis.
Bicarbonate levels increase throughout dialysis. No plateau is seen during dialysis in the
bicarbonate data in contrast to the phosphate data, Figure 10. Data is mean ± 95%
confidence intervals
No correlation between the bicarbonate concentration and the phosphate
concentration could be demonstrated at any point in the dialysis process. The average
cumulative standard deviation between the observed phosphate data and the two-
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pool model was 0.22 ± 0.04 mmol/1 for long dialysis and 0.22 ± 0.03 mmol/1 for
short dialysis.
Model B Three-pool kinetics to maintain a target phosphate concentration
According to model predictions, the target concentration for phosphate averaged
1.22 ± 0.08 mmol/1 for long dialysis and 1.15 ± 0.10 mmol/1 for short dialysis (p=ns).
The target concentration almost always fell within the physiological range, Figure
12, but within this range showed significant correlation with the pre-dialysis serum




Figure 6.12 Target phosphate concentration. The majority of values fell within the
physiological range (0.75-1.40mmol/i) and those that did not tended to have
higher pre-dialysis phosphate concentrations (shown in parenthesis).
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Figure 6.13 Correlation between pre-dialysis serum phosphate concentration and target
extracellular phosphate concentration according to the model. (r=0.47 p<0.001).
During the period of active phosphate regulation the dialysis process continued to
remove phosphate at an average rate of 0.16 ± 0.02mmol/min in long dialysis and
0.18 ± 0.02mmol/min in short dialysis. In order to maintain the phosphate plateau the
generation rate from the third pool must be of a similar order.
In eight long dialysis treatments and six short dialysis treatments, this three-pool
model could adequately explain the observed phosphate data. The addition of fourth
pool kinetics in these treatments provided no further improvement in the degree of fit
between the model and the observed data. The cumulative standard deviations were
0.03 ± 0.01mmol/l and 0.04 ± 0.01mmol/l for long and short treatments respectively.
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One representative treatment is shown in figures 4 and 14 with the corresponding




Figure 6.14. Representative treatment exhibiting three-pool kinetics. Symbols are: (•)
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Figure 6.15 Cumulative standard deviation curves for figure 14. Symbols are as for figure 14
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Model C Addition of a fourth pool and hysteresis element
The critically low concentration ranged from 0.41mmol/l to 1.44mmol/l with a mean
of 0.86 mmol/1 in long dialysis and 0.74 mmol/1 in short dialysis (p=ns). Correlation
was found between the critically low phosphate concentration and the pre-dialysis
phosphate concentration (r=0.67, p<0.001), figure 16.
2.0 2.5 3.0
Pre-haemodialysis serum phosphate concentration (mmol/1)
Figure 6.16 Correlation between pre-dialysis serum phosphate concentration and critically
low extracellular phosphate concentration according to the model.
(r=0.67 p<0.0001)
According to the model, the liberation of phosphate from this fourth pool ceased
when the measured phosphate concentration had risen by a mean of 0.07 ± 0.02
mmol/1.
Model C shows an excellent fit with the observed data for the 21 long and 23 short
treatments not explained by model B. The mean cumulative standard deviations were
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0.03 ± 0.01mmol/l for both long and short dialysis treatments. Two representative
treatments a and b are shown in figures 5, 6 and 17 with their corresponding













Figure 6.17. Two representative treatments (a and b) exhibiting four-pool kinetics with
corresponding cumulative standard deviation curves. In figure 17a, the pre-haemodialysis
serum phosphate concentration is 1.07mmol/l and there is a substantial contribution towards
regulation from both the third and fourth pools. In figure 17b, the pre-haemodialysis serum
phosphate concentration is 0.88mmol/l and the contribution towards regulation from the third
pool is minimal. This is presumably because this individual has little in the way of third-pool
phosphate stores.
Symbols are: (•) extracellular phosphate data. Lines are: dotted, two-pool kinetics; dashed,
three-pool kinetics; solid, four-pool kinetics.
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Summary OfAll Models.
Models A, B and C were progressively implemented until the best approximation to
the data was achieved. The application ofmodel A demonstrated a reasonable fit for
the initial part of dialysis corresponding to two-pool kinetics but a poor fit thereafter.
The implementation of model B demonstrated a close correlation between the model
and the data in a minority of treatments (14/58). The pre-dialysis serum phosphate
concentration for these 14 treatments was significantly higher than for the remainder
of treatments (p<0.01). A close fit between the model and the data for the remaining
44 treatments was achieved when the hysteresis element of model C was applied.
The cumulative standard deviation measurements for all 58 treatments in models A,
B and C are shown in Tables 1 and 2.
Table 6.1. Comparison of cumulative standard deviation measurements for the fourteen
treatments adequately explained by three-pool kinetics. Values are mean ± 95% confidence
intervals. Significance values are compared to model A (Student paired two sample for
means); * p<0.05, **p<0.01
MODEL A (TWO POOL) MODEL B (THREE POOL)
LONG DIALYSIS (8/29)
SHORT DIALYSIS (6/29)
0.17 ±0.06 0.03 ±0.01**
0.18 ± 0.13 0.04 ± 0.01*
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Table 6.2. Comparison of cumulative standard deviation measurements for the forty-four
treatments explained by four-pool kinetics. Values are mean ± 95% confidence intervals.
Significance values are compared to model A (Student paired two sample for means);
***p<0.001
MODEL A MODEL B MODELC
(TWO POOL) (THREE POOL) (FOUR POOL)
LONG DIALYSIS (21/29) 0.24 ± 0.05 0.15 ±0.05*** 0.03 ±0.01***
SHORT DIALYSIS (23/29) 0.23 ± 0.03 0.11 ±0.02*** 0.03 ±0.01***
Comparisons Between Phosphate Data In Long And Short Dialysis
Pre-dialysis phosphate concentrations were 1.74 ± 0.23 mmol/1 for long dialysis and
1.71 ±0.19 mmol/1 for short dialysis (p=ns). The minimum phosphate concentration
achieved in short dialysis treatments was significantly lower p<0.001: figure 18, than
that in long dialysis.
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Figure 6.18. Comparison of observed serum phosphate concentrations in long and short
dialysis for all 58 treatments. Symbols are: (■) short dialysis; (•) long dialysis.
*p<0.001; **p<0.01, paired t-test. Data are mean ± SEM values
I I I I I I I I I I I I
prehd tia ti2 ti3 ti4 ti5 ti6 tda td+2 td+15 td+30 td+60
time differential
There was no statistical difference in the critically low limit between the long and
short treatments suggesting that either there is a short time lag before the control
mechanisms become active or that these mechanisms are overwhelmed by higher
phosphate losses in short dialysis. The higher dialyser clearances and lower effective
V in short dialyses result in a more rapid rate of decrease in the measured
extracellular phosphate concentration in the initial stages of dialysis, Table 3.
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Table 6.3. Intradialytic parameters. Values are mean ± 95% confidence intervals.
Abbreviations are: Td, length of dialysis; CPR, cardiopulmonary recirculation; KdP04(model),
dialyser clearance of phosphate used in model calculations; KdP04(meas), dialyser
clearance of phosphate calculated during dialysis; KjeP04, intracellular to extracellular
transfer coefficient for phosphate; KdUrea(model), dialyser clearance of urea used in model
calculations; KdUrea(meas), dialyser clearance of urea calculated during dialysis; KieUrea,











KieUrea (ml/min) corrected for V
Long Short
240.7± 5.3 147.3 ±6.5 pO.OOl
4.3 ±0.4 5.4 ±0.8 p<0.01
96.6 ±3.2 68.0 ±4.5 p<0.001
158.4 ± 12.1 226.4 ±13.1 pO.OOl
171.8 ±9.5 223.0 ±17.0 pO.OOl
351.0 ±33.9 242.6 ±23.2 pO.OOl
363.8 ±32.7 363.8 ±32.7 p=ns
151.1± 9.3 214.8 ±13.5 pO.OOl
185.6 ± 10.2 285.2 ±15.2 pO.OOl
714.4 ±46.7 513.2 ±48.2 pO.OOl
739.6 ±38.7 699.1 ±41.9 p=ns
KjePC)4 was significantly higher in long versus short dialysis (pO.Ol) but this
difference was not apparent when corrected for the effects of phosphate distribution
volume (p=ns) (table 3). Post-dialysis phosphate levels in long dialysis (0.83 ±
0.07mmol/l) were higher than in short dialysis (0.65 ± 0.05mmol/l) (pO.OOl).
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Phosphate levels during the measured rebound up to 60 minutes were significantly
higher in the long dialysis group although the rate of rebound with time in the short
dialysis treatments was greater, Figure 18. Despite lower phosphate levels during
dialysis the mass of phosphate removed during short dialysis was significantly less
than during long dialysis (26.33 ± 4.38 vs. 30.89 ± 4.70 mmol: p<0.02).
6.4 Discussion
Phosphate kinetics remains a poorly studied area ofhaemodialysis research despite
the ubiquity ofhyperphosphataemia. Existing strategies to achieve phosphate control
rely heavily on dietary restriction and the use ofphosphate binders. Utilising high-
flux membranes for haemodialysis or haemodiafiltration and increasing the surface
area of the dialyser membrane can remove phosphate more efficiently, although no
improvement is seen in the pre-dialysis phosphate levels ofpatients dialysed this
way102'103. Bicarbonate replacement fluid has not been shown to be superior to
acetate in terms of phosphate removal104.
It is known that phosphate removal does not follow the same diffusion kinetics
described for urea105'106. Regardless of the duration of dialysis a characteristic
plateau phase is rapidly reached below which phosphate levels do not fall. The
reasons for this are complex and relate to the mobilisation of phosphate from
unidentified stores during the dialysis procedure. Longer dialysis treatments remove
a higher mass ofphosphate but also result in significantly higher post-dialysis
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phosphate concentrations according to our data. This is indicative ofphosphate being
mobilised to a greater extent in long dialysis. In the post-dialysis period, there is a
rebound phenomenon persisting for in excess of one hour. The rate of the rebound
with time is significantly higher in the short treatment group, which may be due to
the additive effect of re-equilibration of phosphate from peripheral compartments
that have been poorly perfused during the short dialysis treatment.
Recognition of the departure of the phosphate data from standard two pool kinetics
has led to the hypothesis of a third pool ofphosphate although its nature is not
clear105'107"109. The existence of a third pool is consistent with work demonstrating
the absence of a plateau phase when bovine blood is dialysed in vitro110. Studies in
erythrocytes demonstrate that intracellular to extracellular phosphate equilibrium
was reached at a higher extracellular phosphate concentration in the erythrocytes of
dialysis patients compared to controls suggesting adaptation to the
hyperphosphataemic environment111. This may explain the observation that the
critically low point and target point are dependent on the pre-haemodialysis
phosphate concentration, Figures 13, 16.32P and NMR studies demonstrate
glycophosphates in uraemic erythrocytes not present in healthy controls that could
conceivably act as a source ofphosphate during dialysis111'112.
In studies of haemodialysis patients, Sugasaki described a single-pool extracellular
compartment model and proposed phosphate generation from reserves, triggered by
the reduction ofphosphate during dialysis to a nadir unique to each patient. These
studies recognised the correlation of the phosphate nadir with the pre-dialysis serum
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phosphate concentration112'113- Maasrani studied four paediatric patients over eight
dialysis sessions and suggested that the plateau phase ofphosphate kinetics was
maintained by a time-dependant influx from the intracellular space110. These studies
all described the influx of phosphate in terms of a linear or exponential increase in
the rate ofphosphate generation (or gain) that did not folly explain the observed data.
Pogglitsch studied 28 haemodialysis patients and suggested that generation of
phosphate was in response to falling extracellular phosphate levels. The point at
which phosphate generation was initiated was again observed to be dependent on the
pre-dialysis phosphate concentration. This study suggested that additional phosphate
was released into the extracellular space in proportion to the difference between the
momentary phosphate concentration and a critical level (equivalent to the target
concentration in our model). This process continued into the post-dialysis period111.
This model expands these ideas with the introduction of biphasic control involving
sequential implementation of control mechanisms in response to changes in the
prevailing phosphate concentration, Figures 2-9. In model A, dynamic equilibrium
between the intracellular and extracellular compartments throughout the dialysis
process is assumed, consistent with a two-pool model. Model B implements
additional phosphate release from a third pool to maintain a pre-determined target
phosphate concentration. Although the additional phosphate enters the extracellular
space, which is consistent with the Pogglitsch model, we propose that it is changes in
the intracellular phosphate concentration that trigger the control mechanism. In
theory, the generation process from the third pool would be switched off once
intracellular phosphate concentrations reach the target level although this was not
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evident in the current data since the rebound clearly extended beyond the final
measurement at 60 minutes post-dialysis. In model C, the existence of a fourth pool
is described that is operational in the majority of treatments studied. There is a
hysteresis element deduced from the discontinuities in the data that reflects a
"switching on" effect that exists to protect against critically low intracellular
phosphate levels. Where the critically low intracellular phosphate concentration is
not encountered during dialysis (in 24% of patients in this study) the hysteresis
element is not invoked and the three-pool model can adequately explain phosphate
kinetics.
Four pools of phosphate in this model best describe the behaviour of the data and the
kinetics of phosphate clearly involves more complex mechanisms than simple
diffusion. The gut is an unlikely candidate for the third or fourth pools as all the
patients studied were fasting. Dialysis patients are likely to have pathological stores
ofphosphate, possibly in bone, as 86% of total body phosphate is in bone and
approximately 250mg phosphate is mobilised daily in the process of remodelling.
The third-pool phase of phosphate regulation can potentially be explained by efflux
from such stores, possibly from a pool of phosphate not yet incorporated into bony
matrix. If so, this phase would only be sustained in individuals with excess total body
phosphate. The recognition that most haemodialysis patients have an excess of stored
phosphate presents a challenge to achieve better phosphate control in the pre-dialysis
period. Earlier referral of patients with chronic renal failure would allow the timely
introduction of dietary phosphate restriction and phosphate binders to prevent
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patients starting their dialysis careers in positive phosphate balance. Currently used
phosphate binders may be inadequate for this task.
The observed time course of the hysteresis effect of the proposed model is difficult to
explain ifphosphate is released purely from a bone-related pool. The speed of the
hysteresis response might imply phosphate release by a mechanism such as cell lysis,
but the observation that the hysteresis can switch on and off repeatedly during a
dialysis treatment is against this. The more probable explanation is the existence of a
fourth pool local to the intracellular space that provides emergency protection against
life threatening critically low intracellular phosphate concentrations. It is possible
that glycophosphates as described in in-vitro studies111'112 could be involved in this
short-term regulation mechanism. This mechanism is likely to represent
physiological protection and may also operate in subjects with normal renal function.
This model sequentially implements the third and fourth pools allowing all
treatments in both the long and short dialysis groups to be explained by passive two-
pool, three-pool, and emergency fourth pool regulatory processes. This implies
common mechanisms operating across all dialysis treatments and supports the
physiological validity of the model. Phosphate generation from a third pool allows
removal ofmore phosphate during dialysis than permitted by passive two-pool
kinetics. This is theoretically beneficial in reducing the excessive phosphate stores
that exist in chronic haemodialysis patients. However, the switch to fourth pool
kinetics in the way described, may give cause for concern. It was observed that the
majority of dialysis patients invoke fourth pool kinetics in response to critically low
182
phosphate concentrations. These low phosphate levels may contribute to dialysis-
related symptoms and possibly to the excess morbidity and mortality seen in these
patients in the longer term. This study did not appear to result in major intra-dialytic
symptoms although this was not a primary end-point. This would be an interesting
area for further study. In order to avoid the implementation of fourth pool kinetics it
would be necessary to prevent phosphate concentrations reaching the critically low
limit. This might be achieved by longer and slower treatments100.
Daily nocturnal dialysis currently appears to be the only technique capable of safely
depleting excess phosphate stores and maintaining patients in optimal phosphate
balance, although whether in the current medico-political climate this will be
practicable for the majority remains doubtful.
From existing data, it seems clear that a large part of the pathophysiology of
hyperphosphataemia occurs in the pre-dialysis phase with patients building up
excessive stores of phosphate long before they come on to dialysis. If patients can be
identified earlier in the course of chronic renal failure, it would afford the chance to
introduce appropriate dietary advice and phosphate binders at an earlier juncture thus
preventing the build up ofphosphate that undoubtedly contributes to the excess
mortality demonstrated in these patients.
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Chapter 7
Phosphate kinetics in acute haemodialysis
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Phosphate kinetics in acute haemodialysis
7.1 Background
The study in chronic dialysis therapy (Chapter 6) showed clearly that the kinetic
behaviour of phosphate deviates markedly from a two-pool model. It seems probable
that mobilisation of phosphate from a third pool explains why phosphate levels
appear to stabilise despite ongoing dialytic losses. It is assumed that patients build up
a large store of excess phosphate starting in the pre-dialysis phase and that the ability
to compensate for alterations in extracellular phosphate during dialysis may
somehow relate to the size of this excess pool. Patients with acute renal failure are
not expected to have large phosphate stores and as such may be less able to
compensate for alterations in phosphate concentrations during dialysis.
In the four-pool study of patients undergoing chronic dialysis treatments, the fourth
pool described is a mechanism to stop phosphate from falling below a critical
intracellular level. It acts rapidly to correct critically low levels of phosphate and
operates until a "safe" level is once again reached. In patients with acute renal
failure, who are not expected to have high phosphate stores, this level may be
reached earlier during dialysis.
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7.2 Subjects and Methods
Five patients with acute renal failure of sudden onset were studied. The demographic
data and causes of renal failure are described in Table 1.
















1 74 5 days Myeloma 200 500 180 100 KF201
2 67 7 days Tubulo-interstitial nephritis 175 500 180 1000 KF201
3 60 3 days HUS 200 500 130 0 KF201
4 63 14 days Myeloma 200 500 180 1000 KF201
5 75 7 days Sepsis 200 500 180 0 KF201
Dialysis parameters
Haemodialysis was performed using Fresenius 4008 haemodialysis machines and
KF201 dialysis membranes. The duration of the treatment was set at 180 minutes
although one patient stopped dialysis at 130 minutes due to onset of atrial fibrillation
that caused a drop in blood pressure. The vascular access in all patients was via a
double lumen internal jugular line. Blood flow (Qb) was set at 200ml/min in all
subjects but was reduced to 175ml/min in one subject due to poor flows from the
line. Ultra-pure dialysate was produced on-line and the flow rate set at 500ml/min.
Samples taken from the venous limb of the haemodialysis circuit at 60 and 120
minutes were used to calculate the dialyser clearance ofphosphate. The dialyser
clearance was calculated taking haematocrit into account using method 1 as
described in Chapter 4.
186
Sample preparation and analysis
Blood samples from the arterial limb of the haemodialysis circuit were taken every
15 minutes through the course of dialysis and for up to two hours thereafter. All
samples for measurement of phosphate were prepared as described in the general
methods chapter and assayed in-house in a single run on an Olympus AU600
autoanalyser. Samples were additionally tested for urea, and bicarbonate. Serial
haematocrit was measured on heparinised capillary samples on an arterial blood gas
analyser.
Mathematical Modelling
The blood flow (Qb), dialysate flow (Qd), dialysis time (Td), ultrafiltration volume
(UFV), sex, measured dialyser clearance (K), and the raw data series for phosphate
and urea were introduced as inputs into the previously designed four pool model of
phosphate kinetics. In the same manner as for the study in chronic dialysis patients,
the components of the model were sequentially implemented until the best fit
between the data and the model was achieved. Cumulative variance measurements
were utilised to determine the accuracy of the fit.
7.3 Results
The urea data was fitted easily to a two-pool kinetic model for all patients (data not
shown) but it was once again demonstrated that phosphate did not follow the two-
pool pattern. The phosphate data from all five patients was fitted to the same four-
pool model described for chronic renal failure, with the need for implementation of
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all four pools of phosphate being apparent. The values for the adjustable parameters
are given in Table 2 and the individual curve fits are shown in figures 1-5.
Table 7.2. Parameters used to fit data to four pool model.





































































Figure 7.1-7.5 Curve fits for individual paients
Figure 7.1
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The pre-dialysis phosphate in the subjects with acute renal failure of 1.84 ± 0.27
mmol/1 is slightly higher when compared to the patients with chronic renal failure
previously studied (1.74 ± 0.05 mmol/1) but is not a significant difference. The target
phosphate concentration (1.36 ±0.13 mmol/1) again fell within the physiological
range (0.75-1.40 mmol/1) unless the pre-dialysis phosphate was very high. The pre-
dialysis phosphate correlated with the target phosphate concentration r=0.72,
p<0.001, Figure 6.
Figure 7.6. Correlation between pre-dialysis phosphate concentration and target phosphate
concentration.
The same correlation with the critically low phosphate concentration seen in the
chronic study was seen in these patients with acute renal failure. r=0.68, p=<0.001,
Figure 7, but the phosphate concentration at which this occurred was higher. (1.28 ±
0.16 mmol/1 vs. 0.86 ± 0.30 mmol/1).
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o pre-dialysisphosphate mmol/l
Figure 7.7. Correlation between pre-dialysis phosphate concentration and critically low
phosphate concentration
In the patients with acute renal failure, the post dialysis phosphate was also higher
than in the chronic renal failure study (1.17 + 0.14 vs. 0.74 ± 0.02 mmol/l).
Additionally the pre-dialysis phosphate correlated with the post-dialysis phosphate
r=0.62, p<0.001, Figure 8 which was not observed in the chronic renal failure study.
Figure 7.8. Correlation between pre-dialysis phosphate and post-dialysis phosphate
concentration
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The patients were more acidotic than in the chronic renal failure study but the same
pattern of a rise in serum bicarbonate throughout dialysis was seen, Figure 9.
Figure 7.9. Pattern of change in bicarbonate concentrations through dialysis. Error bars are ±
SEM
7A Discussion
It was expected that patients with acute renal failure would be less able to maintain
phosphate homeostasis due to a lack ofphosphate stores, and would rapidly become
hypophosphataemic during dialysis. The intra-dialytic phosphate kinetics were
expected to reveal a limited source of additional phosphate for the "third pool" and
an earlier activation of the "fourth pool" as a result.
Phosphate concentrations were well maintained in all the subjects studied with no
individual becoming overtly hypophosphataemic during dialysis. The higher intra-
and post-dialysis phosphate concentrations seen in the subjects with acute renal
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failure could be a reflection of the lower clearance employed in acute dialysis due to
the short duration of therapy and the lower pump speeds. If this were the only
mechanism, the observation of a different kinetic profile, perhaps more in keeping
with two-pool kinetics, would be expected. It appears, however, that the same kinetic
profile apparent in subjects with chronic renal failure also exists in acute renal
failure.
The nature of the "third pool" regulation in acute renal failure was similar when
compared to patients undergoing chronic dialysis and the maintenance of phosphate
concentrations during dialysis does appear to be dependant on continuing transfer of
phosphate into the extracellular space from this "third pool". The mechanism does
appear to be exhausted more readily in acute renal failure leading to the involvement
of the "fourth pool" at higher prevailing phosphate concentrations. In one subject
there seemed to be a very limited contribution from this "third pool" mechanism,
Figure 5.
The previous description of the "fourth pool" mechanism assumed that it is invoked
by a fall in intracellular phosphate concentrations below a critical level. If some of
the phosphate excess in chronic renal failure is sequestered within the cell, this could
allow for more efficient buffering of intracellular phosphate concentrations, allowing
lower extracellular phosphate concentrations during dialysis to be tolerated. In the
absence of an efficient intra-cellular buffering mechanism in acute renal failure, the
"fourth pool" mechanism would be activated at higher extracellular phosphate
concentration levels.
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An alternative explanation would be that the "fourth pool" simply becomes
operational when influx of phosphate from the third pool is insufficient. This would
again be in keeping with the finding of a higher "critical" concentration in acute
renal failure.
7.5 Conclusions
In summary, this study demonstrates that, in keeping with the findings in chronic
renal failure, a multi-pool kinetic model is required to explain phosphate removal in
acute renal failure. It provides some evidence that the "third pool" mechanism is
exhausted more readily in patients with acute renal failure supporting the premise
that there are lower levels of accessible phosphate stores. The finding that the "fourth
pool" mechanism becomes operational at higher prevailing phosphate concentrations
in acute renal failure may simply be a reflection of lower availability ofphosphate or




Intracellular Phosphate Concentrations in
Haemodialysis
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Intracellular Phosphate Concentrations in Haemodialysis
8.1 Background
In chapter 6, the four-pool model describing phosphate kinetics in haemodialysis was
described. The model identified four potential pools involved in phosphate regulation
during dialysis and assumptions were made about the possible origin of these pools.
This study was designed to find out whether or not the intra-dialytic
hypophosphataemia observed in haemodialysis patients had any effect on the
intracellular concentration of inorganic phosphate.
It appeared from the four-pool model that additional phosphate moves into the extra¬
cellular space during dialysis and one possible source of this phosphate is the
intracellular space. Only a very small proportion of intracellular phosphate exists as
free inorganic phosphate and, if the cell is the source of additional phosphate, it is
possible that there is a breakdown of organic phosphate molecules to liberate
additional inorganic phosphate.
In order to investigate this further, serial plasma and intra-erythrocytic phosphate
concentrations were measured during dialysis.
Previous studies that have attempted to assess the effect of dialysis on intracellular
phosphate concentrations have mainly utilised the erythrocyte as a model1 U;114.
While the erythrocyte is an atypical cell due to the absence ofmitochondrial activity,
it can still serve as a reasonable model due to the potential for liberation of phosphate
from 2,3,DPG, ADP or ATP. Despite the recognised limitations it remains an
attractive candidate for study due to the ease of obtaining samples and the existence
of a well-validated assay technique69.
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8.2 Subjects and Methods
Subjects and Dialysis Technique
Ten patients were studied all ofwhom were stable on the chronic dialysis program at
the Lister Hospital. None were suffering with intercurrent illness and their pre-
dialysis phosphate concentration was 1.91 ± 0.32 mmol/1. All patients received
haemodiafiltration using high-flux polysulphone membranes and replacement fluid
volumes equivalent to 35% of the plasma flow. As different durations of dialysis
were employed in the different subjects, for the purposes of clarity only the results at
0. 30, 60, 90, and 120 minutes are reported.
Laboratory Method
The method ofChalla et al69 as detailed below was used to measure plasma and
whole blood phosphate concentration. Red cell phosphate concentration was
assumed to be the difference between these two values.
Solutions
1. lmol/1 perchloric acid
2. 4.3mol/l potassium hydroxide containing 0.6mmol/l imidazole
3. 27mmol/l ammonium molybdate in 2.4mol/l HC1
4. Petroleum spirit (boiling point 80-100°C) / 2-methylpropan-l-ol 1:4 mix
5. Ethanol AR
6. 0.18mol/l stannous chloride in 1.65mol/l HC1
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7. External standard (Na2HP04) containing 4mmol/l PO4
8. Internal standard (Na2HPC>4) 0.96mmol/l in lmol/1 perchloric acid.
To measure the whole blood phosphate concentration, blood was collected from the
arterial limb of the haemodialysis circuit into lithium-heparin sample tubes and
chilled on ice. After 15 minutes, these were centrifuged at 4°C for 5 minutes at 1 OOOg
and plasma removed to yield a packed cell volume (PCV) of approximately 70%.
The plasma was saved and the red cells resuspended.
0.5ml of this suspension was then added to 1ml of ice-cold perchloric acid (lmol/1).
The tube was vortexed for 5-10 minutes then the precipitated protein removed by
centrifugation at 2500g for 15 minutes at 4°C. The supernatant was then pipetted off
into a polystyrene tube and stored in ice water for 15 minutes after which time the
pH was adjusted to 6.0 ± 1.0 using potassium hydroxide/imidazole reagent.
Acid molybdate 0.2ml was added to 0.2ml of the neutralized extract in a
polypropylene tube followed immediately by 0.4 ml petroleum
spirit/methylpropanolol. The tube was then vortexed for 1 minute at lOOOg at 4°C.
0.25ml of the upper organic layer was transferred to a polystyrene tube containing
0.25ml ethanol. The rapid extraction of the phosphomolybdate complex into the
organic solvent layer prevented hydrolysis of the organic phosphate.




A standard curve was prepared from the stock Na2HP04 containing 0.5, 1, 2, 3 & 4
mmol.
Internal standard
Solution 8 was used as the precipitating agent.
Plasma phosphate was analysed in a similar way with and without internal standard
Comparisons of the results for plasma phosphate were compared with results from a
Beckman LX20 autoanalyser to check the validity of the method.
Calculations
External standards of 0.5 mmol, 1 mmol, 2 mmol, 3 mmol and 4 mmol were used in
each experiment to calculate the external standard curve. Internal standards were
utilised where 0.96 mmol phosphate was added to each sample. The phosphate
concentration of samples was calculated from the external standard curve.
Differences between values obtained with and without the addition of internal
standard were used to calculate the percentage recovery (r). To calculate the
erythrocyte phosphate concentration, C, assay values were multiplied by 100/r then
substituted into the equation,
^ 100 B- (100 -PCV)P
PCV
Where B is the phosphate concentration in the enriched suspension and P is the phosphate
concentration in plasma.
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The samples were analysed in triplicate with the average value obtained with the
internal standard quoted.
Data analysis
GraphPad Prism (version 4.00 for Windows, GraphPad Software, San Diego
California USA) was utilised for all analyses. Repeated measures ANOVA with
Bonferroni post-test analysis was used to determine the significance of changes in
phosphate concentration with time. A p value of <0.05 was deemed significant.
Unfortunately, it proved to be extremely difficult to carry out this study due to the
intensity of the sampling intervals and the sample preparation involved. Ten studies
were initiated but results from only five were included in this analysis.
8.3 Results
The precision of the method for calculating phosphate concentrations was established
form the standard curves (y=0.28x, r =1), Figure l.The comparison ofplasma
phosphate concentrations measured using this method with values obtained on the
same plasma samples analysed using a Beckman LX20 autoanalyzer (y=0.99x, r =1),




Figure 8.1 Standard curve.
assay (mmol/l)
Figure 8.2 Plasma phosphate concentration. Comparison of assay results vs. autoanalyser
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Previous observations have shown that urea is cleared by two-pool kinetics whereas
phosphate reaches a plateau after the first 60-90 minutes of dialysis. This finding is




Figure 8.3 Comparison of urea and phosphate kinetics during dialysis. Error bars are ± SEM.
Plasma phosphate levels fell from 2.08 ± 0.43mmol/l at the beginning to 0.72 ±
0.1 lmmol/1 at 120 minutes of dialysis. Erythrocyte phosphate fell from 0.61 ±







Figure 8.4 Plasma and erythrocyte phosphate concentrations during dialysis.
Error bars are ± SEM.
The fall in plasma phosphate was significant from 0 to 30 mins and insignificant
thereafter when assessed by repeated measures ANOVA with Bonferroni post-test
analysis. The change in erythrocyte phosphate was not significant at any time.
The ratio between intracellular to extracellular phosphate at the beginning of dialysis
was 0.29 ±0.01, Figure 5 and during the remainder of dialysis was 0.43 ± 0.03,
Figure 6. When the individual time points were compared, it could be seen that the
ratio of the intracellular to extracellular phosphate concentration remained fairly
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Figure 8.5. Correlation between plasma phosphate and erythrocyte phosphate at beginning







Figure 8.6. Correlation between plasma phosphate and erythrocyte phosphate from 30
minutes to end of dialysis in the five treatments studied.
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All patients showed a marked change in plasma bicarbonate during dialysis with pre-
dialysis concentrations of 20.2 ± 1.2 mmol/1 and concentrations at 120 minutes of
25.8 ±1.6 mmol/1, Figure 7.
time (mins)




It was presumed that phosphate would move out of intracellular stores when a
critically low level ofphosphate concentration was reached. A rise in intracellular
phosphate might reasonably be expected at this point. This phenomenon was not
observed despite very low extracellular phosphate concentrations being reached.
It has previously been shown that even when there are marked perturbations in
extracellular concentration ofphosphate there is a smaller percentage difference in
intracellular phosphate concentration which is said to be consistent with the presence
ofbuffers within the cell115. The observed maintenance of the intracellular to
extracellular phosphate ratio supports the notion ofbuffering within the cell to
maintain the trans-cellular gradient.
If phosphate moved across the cell membrane by passive diffusion alone, at steady
state, it would be expected to show an intracellular to extracellular concentration
dictated by the Gibbs Donnan ratio of 0.53 as previously described116. Taking the
water content of erythrocytes (72%) and plasma (93%) into account this would give
an intracellular to extracellular ratio of 0.41, which is very close to the observed
intracellular to extracellular phosphate gradient of 0.43 ± 0.03 observed during
dialysis in this study.
If the pre-dialysis sample is excluded the observations would be consistent with
passive diffusion being the main trans-membrane transport mechanism, but other
factors must be contributing at the start of dialysis. The finding of a lower
intracellular to extracellular gradient at the beginning of dialysis suggests that there
is an excess of phosphate in the extracellular fluid at the beginning of dialysis. The
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rapid fall in extracellular phosphate in the first 30 minutes of dialysis could represent
a period of time where single pool kinetics dominates, depleting this extracellular
excess.
The acidic environment may also be important in altering the pre-dialysis
transcellular gradient as, in the presence of acidosis, the transfer ofphosphate from
the intra to extracellular space is enhanced.
It can be seen from Figure 4 that the absolute difference between intra and
extracellular concentrations becomes relatively small as dialysis progresses.
It is clear from previous work that, despite prolonged dialysis treatment, there comes
a point beyond which phosphate does not fall further, despite ongoing removal. This
data gives no evidence that the additional phosphate is liberated from the
intracellular space, at least in the erythrocyte, as there is no abrupt discontinuity
observed within the time course of the intracellular phosphate measurements.
It has previously been shown that even in the presence ofmarkedly abnormal serum
phosphate levels (down to 0.35 mmol/1) there is remarkably little effect on
concentrations ofATP. When phosphate concentrations fall even lower, buffering
mechanisms are no longer sufficient and a reduction in the levels ofATP can be
seen114. Theoretically, prolonged phosphate depletion in haemodialysis could have
similar effects. The absence ofmitochondria in the red cell, while making it an
attractive candidate cell for study might also explain why no intracellular
perturbation in phosphate concentration is observed.
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8.5 Conclusion
In conclusion, these observations support the theory that, in the erythrocyte,
intracellular to extracellular transport of phosphate occurs by passive diffusion.
There appears to be a buffering mechanism within the cell to maintain the
intracellular concentration and thus the trans-membrane phosphate gradient.
However, there is no evidence of a sharp discontinuity in the data that could










Beta2-Microglobulin Kinetics in Haemodialysis
9.11ntroduction
The "adequacy debate" is a topical issue in dialysis research. It is recognised that the
definition of dialysis adequacy with reference to indices of urea clearance, does not
accurately reflect the clearance of "middle molecules" such as beta2-microglobulin
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(11.8kD) . Recent studies have suggested that there is a strong association between
retention ofmiddle molecules and patient mortality regardless of otherwise
apparently "adequate" dialysis37.
Beta2-microglobulin is an 11.8kD protein that is an integral part of the major
histocompatability complex expressed on the surface of all cells. It synthesised at 2-
4mg/kg/day (or 980-1960mg/week in a 70kg individual) and, in the presence of
normal renal function, is freely filtered at the glomerulus before being catabolised in
the proximal tubule. There is no good evidence that (32m production is increased in
dialysis patients unless there is a co-existing pathology such as a clonal B cell
neoplasm. In situations of reduced renal function, there is retention ofbeta2-
microglobulin and removal by conventional dialysis techniques is poor. The
clearance ofbeta2-microglobulin may be enhanced by use ofhigh-flux dialysis
therapies when the maximum removal is around 130mg/week118, which clearly falls
far short of the weekly synthesis. The effect of residual renal function should not be
underestimated as even a small amount of residual renal function can have a dramatic
impact on (32m levels119. It has been demonstrated that conversion from low-flux to
high-flux dialysis120 or by switching to nocturnal dialysis118 can reduce beta2-
microglobulin levels although the levels can never be fully normalised. The removal
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during haemofiltration is thought to be higher than on haemodialysis due to the
improved clearance ofhigher molecular weight substances using convective
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therapies .
In 1985 Geiyo identified beta2-microglobulin as a constituent part of dialysis related
amyloid122, and it is widely acknowledged that accumulation ofbeta2-microglobulin
is associated with development of carpal tunnel syndrome, symptomatic destructive
arthropathies, and subchondral bone erosions and cysts. At present, there is no way
ofpredicting the presence or extent of dialysis related amyloid from the serum beta2-
microglobulin level.
Traditional low-flux therapies remove so little (12m that kinetic modelling studies
have been difficult. With the increasing prevalence ofhigh-flux therapies that
incorporate an element of convection, it has been possible to study the kinetic
behaviour ofbeta2-microglobulin in more detail.
Previous modelling studies fall into two groups.
i) The first group utilised radio-labelled beta2-microglobulin to study the kinetic
profile of beta2-microglobulin uptake and removal during haemodialysis123'124. Odell
et al studied a total of 5 anuric haemodialysis patients in two different studies and
injected them with 1231 labelled (32m. In one study, plasma activity of the tracer was
followed for 72 hours and, in a second study, low-flux haemodialysis was carried out
after 24 hours and high-flux dialysis after 48 hours. It was demonstrated that
clearance characteristics during both types of dialysis fitted a three-pool variable
volume model and that there was a significant non-renal clearance of beta2-
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microglobulin from the plasma. In the study by Vincent et al124 the excretion of 125I
labelled [32m in 5 subjects with normal renal function and 17 functionally anephric
subjects on dialysis was studied. Excretion was complete within 96 hours in subjects
with normal renal function but the tracer was seen to accumulate in subjects with
renal failure. There was a tendency for more residual tracer to be present in patients
on haemodialysis when compared to those on haemofiltration or CAPD. A two-pool
kinetic model was used to explain beta2-microglobulin removal in subjects with
normal renal function but amulti-pool model was necessary in subjects with renal
failure.
In summary, these studies show that, in patients with little native renal function,
there is a tendency for (32m to accumulate and that the presence of residual renal
function is important in removal. The studies suggest that the kinetic behaviour of
beta2-microglobulin in dialysis is more complex than can be explained by a two-pool
model. These studies have given insight into some of the issues with beta2-
microglobulin accumulation and removal but are difficult to apply in the clinical
context due to problems with the radioactive tracer and the fact that kinetic behaviour
of an injected tracermay be different to the endogenous processes.
ii) The second group used inference from modelling theory to define equations based
on blood sampling during dialysis125"128. Gotch et al published the first |32m
modelling study in 1989. This group used data from serial measurement of (32m
concentration during and after high-flux dialysis to derive a multi-pool variable
volume model. They identified the theoretical existence of a third pool representing
polymerised |32m. This multi-model was further developed by Da Lian et al who
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emphasised the contribution of fluid shifts when considering changes in beta2-
microglobulin concentrations. More recent discussion has reverted back to
consideration of a two pool model taking into account the effect of changes in
compartmental volumes127. Ward et al have recently published a study ofbeta2-
microglobulin kinetics in 10 patients receiving post-dilutional HDF. They model
p2m clearance according to a two-pool model with variable volume and conclude
that haemodiafiltration fails to deliver higher (12m removal as a result of resistance to
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transfer of P2m between body compartments .
From the existing information, it is clear that a single pool model is insufficient to
explain beta2-microglobulin kinetics. The recognition of a rebound phenomenon in
the post-dialysis period129'130 has led the majority of investigators to concluded that
there have to be at least two pools involved in the kinetic model. The importance of
residual renal function and the contribution of internal convection to beta2-
microglobulin removal are acknowledged. It is additionally recognised that there
may be a further pool of intact beta2-microglobulin that could influence the kinetics
ofbeta2-microglobulin removal during dialysis and that, theoretically, this pool
could represent the load of dialysis related amyloid.
There seem to be several distinct stages ofbeta2-microglobulin deposition131. The
first stage is beta2-microglobulin deposition on the surface of cartilage around joints.
The layer gradually thickens, but at this stage, patients are generally asymptomatic.
The characteristic sites of deposition in the musculoskeletal system may result from
an apparent affinity of P2m for collagen132 and glycosaminoglyeans13 J that are found
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preferentially in osteoarticular structures. With time, the deposits undergo chemical
modification with polymerisation of the P2m fibrils and interaction with advanced
glycosylation end-products134'135. Whether AGEs render |32m more amyloidogenic or
whether they in some way stabilise existing deposits is not known, but the absence of
AGEs in early deposits is supportive of the latter theory136. The final phase ofbeta2-
microglobulin deposition involves a chemotactic phase where monocytes and
macrophages become involved in the deposits, releasing pro-inflammatory cytokines
and leading to potential destruction of tissue137"139. It is likely that patients begin to
experience symptoms at this stage.
The amount of P2m that can be removed during dialysis may depend on the
equilibrium between free circulating p2m and these different stages of P2m
deposition. When considering the development of a potential model ofbeta2-
microglobulin kinetics it seemed logical to consider these chronic deposits ofbeta2-
microglobulin as further theoretical pools of solute that, under the right conditions,
could be mobilised by dialysis therapy.
This study ofbeta2-microglobulin kinetics used this theory as a basic premise for the
construction of a multi-pool variable volume model to explain the observed
behaviour ofbeta2-microglobulin during dialysis.
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9.2 Methods
Study Design and Patient Selection
The dialysis program at the Lister Hospital has uniquely utilised "high-flux"
techniques since the unit's inception in 1989. The Royal Free Hospital dialysis unit is
in close geographical proximity to the Lister Hospital and has a comparable
population treated predominately with a "low-flux" technique. Both centres use an
ultrapure water source and biocompatible membranes. This study became possible as
a sufficiently large cohort ofpatients now exists who have never been exposed to
"low-flux" membranes in over 5 years of dialysis. It has been demonstrated that
membrane flux not biocompatibility is the main determinant ofbeta2-microglobulin
levels140, and it was assumed that any differences between the two groups would be
due to membrane flux alone.
Beta2-microglobulin kinetics were studied in 36 patients. All patients who had
received haemodialysis for in excess of five years were eligible for the study unless
they had current sepsis, a chronic inflammatory disorder or malignancy. 24 patients
from the Lister Hospital and 12 patients from the Royal Free Hospital were recruited.
The patients at the Lister Hospital had received exclusively high-flux therapy for at
least five years while those at the Royal Free Hospital, until six months prior to the
study, had dialysed on low-flux membranes. At the time of the study, there were 14
patients on haemodiafiltration (HDF) and 10 on high-flux dialysis (HFHD) at the
Lister Hospital. Of the 12 patients at the Royal Free, 8 patients were receiving low-
efficiency haemodialysis (IFHD) and 4 were receiving high-efficiency dialysis using
high-flux membranes (HFHD). For the purposes ofbaseline data, the patients were
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grouped according to their hospital, while for the modelling studies they were
grouped according to their current modality of dialysis.
At the time of the study, the Lister Hospital had a policy of dialyser re-use. It has
been shown that the peracetic acid technique when used to reprocess high-flux
synthetic dialysers has no effect on the clearance of p2m141.
Sampling Technique
The elimination of beta2-microglobulin by dialysis was assessed from blood samples
taken every fifteen minutes during dialysis, and after a two-minute washback.
Dialyser clearance was calculated from paired arterial and venous samples taken
every 30 minutes during dialysis according to method 2 described in Chapter 4. The
entire volume of spent dialysate was collected for the measurement ofbeta2-
microglobulin. Beta2-microglobulin was measured in all samples using an
immunoturbidimetric technique (Olympus systems). This method was capable of
measuring the very low beta2-microglobulin levels present in some dialysate
samples. Samples obtained at the Royal Free dialysis unit were centrifuged and kept
refrigerated at 4°C until transported to the Lister Hospital. These samples were
analysed in a single run within 8 hours which has been demonstrated to give
consistent results. There is limited interference with this technique in the presence of
icterus (<3%), haemolysis (<5%) and lipeamia (<10%) and no documented
interference in the presence ofuraemia or in the range ofphysiological pH142.
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Kinetic Modelling
The measured dialyser clearance (K^ meas), Qb, Qd, dialysis time (Td), sex, pre- and
post-dialysis weights, and HDF rate were provided as inputs to the model.
Mathematical expressions describing amulti-pool variable volume model were
written from first principles and introduced into commercially available software
(VisSim, Visual Solutions Inc) to provide dynamic simulation of the haemodialysis
environment. The model was then further adjusted and refined to give an accurate fit
with the data as assessed by cumulative variance between the data and model.
Hypotheses regarding potential mechanisms were then developed. This is a similar
approach previously used in the modelling of phosphate kinetics in Chapter 6.
The kinetic model for patients on low-efficiency dialysis was expected to reveal little
clearance ofbeta2-microglobulin. The model in high-flux dialysis and
haemodiafiltration was anticipated to be similar, but with different clearance
characteristics relative to the different contributions of diffusion and convection.
In a previous study140 in similar patient groups, a considerable difference in beta2-
microglobulin levels between high-flux and the low-flux dialysis was seen (22.3 ±
5.4 mg/1 vs. 43.4 ± 13.7 mg/1). Based on these observations the power of this study




The demographics for the patients recruited from the two centres are shown in Table
1.
Table 9.1 Demographics of patients recruited to study on basis of hospital
Lister Royal Free
Male:Female 17:7 6:6
Age (years) 65.4±12.7 57.0+16.5 p=ns
Time on dialysis (years) 7.8+2.2 13.0+10.5 p=0.03
Pre-dialysis p2m level (mg/l) 28.7±8.0 36.5±12.4 p=0.03
The demographics, dialysis parameters and pre-dialysis bloods for the groups of
patients based on dialysis modality are shown in Table 2.
Patients receiving low-efficiency intermediate-flux dialysis had been on dialysis for
significantly longer, had higher pre-dialysis P2m concentrations, lower percentage
reduction in (12m level, lower P2m clearance and lower mass removal of p2m when
compared to those on high-flux dialysis or HDF. The only significant difference
between the patients on high-flux dialysis and HDF was in the plasma clearance of
P2m achieved by the membrane, but this did not translate into a lower pre-dialysis
P2m level, a higher mass removal of P2m or higher percentage reduction in P2m
levels.
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Male:Female 3:5 11:3 10:4
Age (years) 54.7±18.1 68.2112.5 61.4112.3
Time on dialysis (years) 15.8±12.0 7.311.5* 8.4±2.6A
KRU (ml/min) 0.01±0 0.5610.83 0.3510.94
Qb (ml/min) 331,3±72.8 376.4179.0 417.9±72.3A
Qd (ml/min) 706.1 ±129.4 796.4113.36* 80010*
Td (min) 225.3±17.6 204.4141.7 186.4132.7*
UF (ml) 2085±723.3 216311106 20871831.0
Pre-dialysis 32m (mg/ml) 41,0±13.0 27.116.8* 30.1±8.2A
Urea clearance (ml/min) 219.6124.2 260.2135.1* 240.6131.3
% (32m reduction 26.9110.0 54.8114.6* 61.4116.0*
Mass urea removed (mmol) 365.51214.3 460.41188.5 417.31129.4
32m clearance (plasma) (mg/min) 6.416.6 50.1118.1* 81.8119.9**
32m clearance (whole blood) (mg/min) 3.9113.1 81.9138.2* 95.3138.2*
Mass 32m removed (mg) 69.6140.6 147.0187.3* 148.2157.1*
Mass 32m removed /min (mg/min) 0.310.2 0.710.3* 0.810.3*
• *p<0.01, Ap<0.05 when compared to IFHD
• #p<0.05 when HFHD compared to HDF.
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Kinetic modelling
From simple inspection of the data, it was immediately clear that (32m is not removed
by first order kinetics. The clearance achieved is always significantly less than would
be predicted by the instantaneous clearance measurements across the dialyser. This
suggests that there is refilling of the vascular compartment during dialysis that acts
against the expected fall of (32m. When dealing with urea kinetics this refilling
occurs by intracellular to extracellular transfer governed by the transfer coefficient
Kie. (32m is confined mainly to the intravascular and interstitial spaces so any
transfer would be either from the interstitial space or from generation or liberation of
(32m at the cell surface. This could occur either from degeneration of the solid phase
or from de novo generation.
In the first instance, a two-pool variable volume model akin to that proposed by
i ?o
Ward et al was constructed to assess the degree of fit with the data. It was not
possible to achieve a good fit between the data and the model on this basis. It was
decided therefore to begin the modelling again from first principles.




In all patients it was assumed that at steady state there was a constant generation rate,
G, ofbeta2-microglobulin of 0.16mg/kg/hr that fed into the interstitial space. In
addition it was assumed that all patients had a degree of endogenous extra-renal
clearance, Knr, assumed to deplete the concentration in the interstitium, and a degree










Figure 9.1 Situation at steady state with beta2-microglobulin influx from steady state
generation and removal via extra-renal routes and residual renal function.
Where G is the endogenous generation rate, Knr is the native extra-renal
clearance, and Kris the clearance due to residual renal function.
It was assumed that when dialysis is commenced, removal of beta2-microglobulin
from the intravascular space occurs according to the laws of inter-related diffusion








Figure 9.2. Single pool model of beta2-microglobulin removal. Abbreviations as for figure 1
plus Kd0 is the diffusive clearance in absence of ultrafiltration, Tr is the
transmittance coefficient and QL is the ultrafiltration rate.
An attempt was made to fit the data to this one-pool model but after the first 15-20
minutes the data deviated markedly from this, Figure 3, and thus this model was
abandoned.
0 100 200 300
time (mins)
Figure 9.3. Representative treatment comparing data to Model 1 (single pool model).
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Model 2
It was therefore assumed that there is movement of beta2-microglobulin from the
interstitial compartment to the intravascular space by a process of diffusion in
response to the fall in intravascular concentration. This would occur according to the
concentration difference between the interstitial and intravascular compartments and
the mass transfer coefficient across the capillary wall. Additionally, it was assumed
that P2m would transfer from the interstitial space to the intravascular space by
convection as a result of fluid movement in response to ultrafiltration and vascular
refilling. For the purposes of the model, it was assumed that 20% of the final
ultrafiltered volume would originate from the intravascular space and 80% from the
interstitial space. Obviously additional fluid fluxes occur between the intracellular
and interstitial spaces but it was felt this added too much complexity to the model at
this stage, Figure 4.
Flux 1
Ki(Cin-Cp)+(TrintQuint)
Figure 9.4. Model 2. Situation during dialysis when fall in intravascular beta2-microglobulin
occurs. Abbreviations as for figures 1+2 plus Ki is interstitial to intravascular
mass transfer coefficient, Cin is the interstitial concentration, Cp is the
intravascular concentration, Trint is the transmittance coefficient for internal
transfer and Quint is the internal ultrafiltration rate.
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This two-compartment model was implemented but it was found that, although the fit
improved up to around 40 minutes of dialysis, there were at least two further points
where the data deviated from predicted, Figure 5.
data
two pool model
0 100 200 300
time (mins)
Figure 9.5. Representative treatment comparing data to Model 2 (two pool model).
It appeared therefore from the time course of the data that single pool kinetics
probably operated for the first 15-20 minutes of dialysis and, during this time, beta2-
microglobulin was cleared solely from the intravascular compartment. After this
period, transfer from the interstitial compartment began to take place by diffusion, in
accordance with two-pool kinetics. There was also assumed to be additional transfer
of beta2-microglobulin by convection due to refilling of the vascular compartment
from the interstitial space. The features of this two-pool model were implemented in
all cases. It was assumed that the mass transfer coefficient between the interstitial




After the initial 40-45 minutes of dialysis the rate of decrease ofbeta2-microglobulin
fell. This could have been due to a reduction in the dialyser clearance ofbeta2-
microglobulin, but there was no evidence of this from repeated estimations of
clearance calculated during dialysis from simultaneous arterial and venous samples.
An increased concentration could also reflect contraction of the intravascular
compartment due to ultrafiltration but, based on serial haematocrit measurements,
this did not appear to be a sufficient explanation. Another possibility is a rise in
concentration due to an increased rate ofbeta2-microglobulin influx into the
intravascular compartment. This either could occur because of an increased rate of
generation ofbeta2-microglobulin de novo, or could be due to breakdown ofbeta2-
microglobulin stores. Based on previous research which does not suggest large
19"^
increases in beta2-microglobulin generation during dialysis , it was felt that the
latter mechanism was more probable. It was assumed that the rate of transfer of
beta2-microglobulin from this "store" would be in proportion to the ease with which
the store could be mobilised and the magnitude of the store itself. A total clearance
value K2 was attributed to this flux. It was assumed that once this flux was initiated it
continued at a constant rate for the remainder of dialysis. The mass transfer co¬






Figure 9.6 Model 3a Situation when beta2-microglobulin released from "store" into interstitial
space
In the first attempt at the model, flux 2 was added to the interstitial space, Figure 6,
but it was not possible to achieve a good fit with the observed data. This model was
therefore abandoned. In a second attempt, flux 2 was added directly to the









Figure 9.7 Model 3b. Situation when beta2-microglobulin released from "store" into
intravascular compartment
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The addition of this mechanism improved the fit once more, figure 8, but there was
still one further discrepancy in the data that required to be explained.
CM
0 100 200 300
time (mins)
Figure 9.8. Representative treatment showing improvement in fit with implementation of flux
from storage pool.
Model 4
In most of the patients, there was one final discrepancy in the data that occurred
towards the end of dialysis. Removal by dialysis was ongoing as evidenced by the
measured dialyser clearances but the influx ofbeta2-microglobulin into the
intravascular space was occurring at an even higher level than before. It was
postulated that this represents a phase of treatment where stores ofbeta2-
microglobulin that have possibly been more resistant to breakdown finally become
available for dialysis and occurred at around 90 minutes into dialysis.
The magnitude of this response could correlate in some way with the extent ofbeta2-
microglobulin deposition and therefore dialysis related amyloid. No inference was
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made about the origin of this additional influx (represented by K3) and it was not
assumed to depend on the prevailing intravascular concentration, Figure 9.
Figure 9.9. Model 4. Implementation of flux from potential dialysis related amyloid stores.
When this final flux was added to the model, it was possible to achieve excellent fits
between the data and the model, Figure 10. The cumulative variance curve that gives
a quantitative assessment of the goodness of fit is shown in figure 11. The
cumulative variance at Td+2 for this treatment was 6.9.
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Figure 9.10. Representative treatment with Model 4 (four component model) implemented.
time (mins)
Figure 9.11. Cumulative variance curve for representative treatment shown in figure 10.
There were 25 patients who fitted the four-component model and 11 who did not.
Whether or not a fit was achieved was determined by visual inspection of the curves
9 9
and the calculation of a cumulative variance of < 20mmol /I at td+2.
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There were several distinct differences between the two groups ofpatients shown in
table 3.
Table 9.3. Summary of patient characteristics
Fit Non-fit
HFHD/HDF:IFHD 25:0 3:8
Measured plasma 32m clearance (ml/min) 69.2±21.9 13.0±14.6 p<0.001
% 32m reduction 61.5±11.9 27.7±10.2 p<0.001
Initial 32m (mg/l) 28.8±7.6 38.0112.1 p<0.01
Qb (ml/min) 396.8±78.0 334.0166.0 p<0.05
Qd (ml/min) 798.0±10.0 755.0192.6 p<0.01
Td (min) 194.4±38.7 217.5124.1 p=ns
The clear difference between the groups was the membrane utilised during dialysis
and thus the beta2-microglobulin clearance. All the patients in the fit group dialysed
using a high-flux membrane Arylane H9, HF80, 18GWS, Polyflux 21S or PAN11.
The majority of the patients in the non-fit group used HF60LS or HF80LS although
there were also one each ofHF80, KF201 and 18GWS.
Using the clearance measurements for inulin as an approximation for P2m clearance,
the mass transfer coefficient-area (KoA) for each of these membranes can be
estimated. It is clear that the membranes in the fit group have a far higher KoA for
(32m compared to the membranes in the non-fit group with the exception of the
18GWS. Issues with regards to the ability of this membrane to remove middle
molecules have previously been noted143. The one patient using an HF80 membrane
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in the non-fit group had reused the membrane 18 times which perhaps explains this
discrepancy as no other patient had reused a membrane this many times. The urea
clearance obtained by this membrane was also far lower than would have been
predicted.
Where the measured instantaneous (32m clearance across the dialyser was <28ml/min
it was not possible to fit the data to the model. For all patients with a measured (32m
clearance >28 ml/min the fit was achieved with a mean cumulative variance of 13.7
± 10.0 at Td+2.
The magnitude of the different fluxes and dialysis characteristics for the 25
treatments that fitted the model are shown in table 4. There was a significant
correlation between the pre-dialysis (32m level and the magnitude of flux 1 (p=0.03).
This suggests that when there is a high prevailing |32m level there is a large pool of
accessible (32m that is readily available for dialysis. The magnitude of flux 3
correlated with the percentage P2m reduction indicating that the mobilisation of |32m
is necessary to achieve maximal (32m removal. There was, however no correlation
with the pre-dialysis P2m level. Using multiple regression analysis it was not
possible to find any other significant relationships between any of the clearance
parameters, mode of dialysis, type of dialyser and magnitude of fluxes 2 or 3. Based
on this model is only possible therefore to comment with any certainty on the size of
the circulating P2m pool at the onset of dialysis.
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Arh9 8.1 37 13 0 45.21 23.88 75
Arh9 18 62 43 90 109.33 24.98 67.3
Arh9 14 40 44 100 62 26.69 73.3
Arh9 6 18 35 0 61.27 35.22 69.2
Arh9 16 40 40 110 70 27.97 32.7
Arh9 13 55 55 70 87.63 35.76 64.9
Arh9 20 70 10 0 69.52 29.2 43.3
Arh9 8 34 12 0 55.98 26.19 70
Arh9 12 40 50 0 66.03 33 79.8
Arh9 14 50 45 0 68.17 29.8 41.8
Arh9 12 55 35 60 69.53 28.65 56.8
Hf80 15 30 8 0 58.85 19.88 75.5
Hf80 16 17 30 90 101.47 25.92 75.5
Hf80 13 85 32 110 105.31 30.25 55.7
Hf80 2.8 29 25 90 66.08 32.16 70.6
Hf80 25 41 13 0 60.09 15.23 77.4
Hf80 9 30 29 0 38.01 39.49 85.3
Hf80 1 3 11 0 37.15 25.4 70
Hf80 12 36 6 70 70.32 21.79 60.7
KF201 5 30 10 50 57.58 24.53 77.3
PAN 11 4.3 31 0 90 92.21 54.97 43.1
POLYFLUX 21S 6 11 2 0 28.25 31.58 60.3
18gws 8 40 22 0 70.48 24.15 69.5
18gws 30 100 65 110 98.25 23.86 59.8
18gws 4 38 10 100 75.96 30.04 70.8
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10.4 Discussion
The model described here gave a good fit with virtually all patients receiving high-
flux dialysis therapies. It assumed that there is a large amount ofbeta2-microglobulin
sequestered in the body, some ofwhich is directly accessible at the beginning of
dialysis, and some that requires time to be released. A pictorial representation of this
is given in figure 12.
Figure 9.12 Pictorial representation of proposed model
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As dialysis progresses it appears, from blood-side measurements, that the clearance
of p2m falls. This can be explained in one of three ways. The first is that the
clearance truly does fall due to changes in the membrane but this is disproven by the
serial estimations of clearance across the dialysis membrane, which is not seen to fall
significantly. The second possibility is that blood concentrations rise artefactually
due to contraction of the intravascular space, but the magnitude of the changes in
haematocrit seem to argue against this. The third possible explanation, and the one
that we propose here, is that there are a number of different pools of (32m in the body
that become available at different times depending on the duration and intensity of
the dialysis session. As each of these pools becomes available, they have the effect of
increasing the prevailing P2m concentration, which results in the measured
extracellular (32m concentration falling less slowly.
As stated in the introduction, several different studies have postulated that there are
different stages of (32m amyloid deposition. Assuming that some of the (32m is
circulating in monomeric form this would become available for dialysis relatively
quickly, and would be represented by flux 1. P2m that is bound reversibly could be
represented by flux 2, which operates from around 40 minutes of dialysis. The P2m
that is complexed and deposited with other substances (Ap2m) would be relatively
more stable and much less likely to be available for dialysis unless the duration and
intensity were increased. This would be consistent with the presence of flux 3, which
does not become operational until at least 90 minutes of dialysis have elapsed. If
there was any way of predicting the load of dialysis related amyloid from the model
it would be by inspection of the magnitude of these fluxes. Unfortunately, at present,
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there does not appear to be any way of utilising this information in a clinically
relevant way.
The finding that some of the high-flux membranes did not operate in a high-flux
manner is concerning. In one of the situations, it can be explained on the basis of
reuse where clearly the membrane was less efficient in terms ofboth small and
middle molecule clearance. In the other situation however, the membrane was being
used for the first time and clearly did not deliver the projected performance. Within a
dialysis unit it is therefore ofutmost importance that the efficiency ofhigh-flux
membranes in terms ofmiddle molecule clearance as well as small solute clearance
is assessed.
The inter-compartmental resistance to beta2-microglobulin removal has previously
been suggested as a potential problem in the clearance ofbeta2-microglobulin during
dialysis128. The failure of haemodiafiltration to reduce the pre-dialysis levels of
beta2-microglobulin is a direct result of this phenomenon. Even in the presence of a
more efficient membrane, it is not possible to remove more P2m unless the treatment
time is increased to permit mobilisation of P2m from stores. In addition to increasing
the duration of therapy, the provision of a more frequent dialysis schedule is likely to
enhance P2m removal, as more of the P2m load will be mobilised and available for
removal. In the short term, this might be reflected in higher circulating P2m levels. I
am not aware at this time of any studies that have addressed this question
specifically. One further method of achieving enhanced P2m removal is through the
use of specific absorption columns. Studies of these have shown improved removal
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of (32m144 and possibly an improvement in joint-related symptoms but it is not clear
if the benefit relates to removal of (32m itself or to related uraemic toxins145.
9.5 Conclusions
The model proposed here is a multi-compartmental model that is based on the
premise that beta2-microglobulin exists in many different phases of accumulation
and deposition. The model sequentially implements fluxes from different pools of
beta2-microglobulin depending on their relative resistance to mobilisation. It seems
probable that current convective therapies will remain insufficient to achieve neutral
(32m balance unless the duration and/or frequency of therapy are increased.
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Chapter 10
The Use of SAP Scans in
Chronic Dialysis Patients
The Use of SAP Scans in Chronic Dialysis Patients
10.1 Background
It has been recognised for over three decades that patients on long-term dialysis are
at risk of developing dialysis related amyloidosis (A(32m) with the first report of
carpal tunnel syndrome in a dialysis patient in 1975146. This type of amyloid has a
propensity for musculoskeletal tissues manifesting as bone cysts and destructive
arthropathies, especially carpal tunnel syndrome. The largest studies of amyloid
prevalence in haemodialysis have looked at post-mortem findings, with the
histological prevalence estimated to be 48% in patients dialysed for a median of 4
years57. There are also reports ofvisceral involvement although this occurs almost
exclusively in patients dialysing for in excess of 10 years and is less often
symptomatic147. The studies that have attempted pre-mortem assessment have largely
used either tissue biopsy or x-ray documentation as diagnostic tools148. The use of
biopsy techniques is limited by the potential for sampling error and the invasive
nature of the technique. Imaging of dialysis related amyloid by plain x-rays, CT
scanning or ultrasound is sub-optimal, particularly for early disease. MRI is probably
the most useful radiological investigation, but even this does not yield infallible
results149'150.
Since thel980s the technique of Serum Amyloid P component (SAP) scanning has
been developed at The National Amyloidosis Centre allowing a non-invasive, highly
specific, semi-quantitative assessment of total amyloid load151"153. SAP is present as a
component of all types of amyloid deposit and is derived from circulating serum
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amyloid P (which represents 0.04% of serum protein but 15% of amyloid
deposits)154. SAP combines non-covalently to amyloid fibrils in a calcium-dependant
manner and is in dynamic equilibrium with the SAP in the circulation. The function
of SAP is not known but there are suggestions that it prevents proteolytic breakdown
of amyloid deposits155.
SAP Scan Technique
Following intravenous injection of '" [-labelled SAP, distribution of the tracer is seen
in the circulating pool of native SAP. In normal subjects the half-life of the tracer in
the plasma averages 31 hours but in patients with massive amyloidosis the half-life is
very much shorter. Where there are amyloid deposits, the tracer enters these due to
the dynamic equilibrium between the circulating and deposited SAP and, once
localised there, is cleared much more slowly than it is from plasma. The presence of
this sequestered SAP in amyloid deposits is then identified on scintigraphic imaging.
The SAP scan is most effective in picking up amyloid deposits in joints distant from
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Figure 10.1. SAP scan in a normal individual
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Clinical Utility of SAP Scans
The value of the scans has been demonstrated in patients with all types of systemic
amyloidosis where studies show regression of amyloid deposits following treatments
aimed at reducing the level of circulating amyloid P component precursors156'157,
Figure 2.
Figure 10.2 Serial SAP scans after treatment for systemic AL amyloid showing regression of
amyloid deposits, left, before treatment, right, 6 years later after chemotherapy.
http://www.ucl.ac.uk/medicine/amyloidosis/research/index.html
In the dialysis population, there has been little rigorous research on the use of SAP
scans to determine the presence and extent of beta2-microglobulin associated
amyloid (Ap2m) deposition. The original studies carried out by Nelson et al in 38
dialysis patients suggested that the sensitivity of the technique was good, but did note
that there was poor definition of amyloid deposits in the hips even when symptoms
were apparent. The specificity of the scan appeared good as there was no uptake of
tracer in six patients who had dialysed for less than 1.5 years, but could also be
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questioned due to the uptake of tracer by the spleen in 36% of patients151. This was
interpreted at the time as being evidence of splenic amyloid but, in a subsequent
post-mortem study, splenic amyloid has only been detected in 5% ofpatients . Some
concern has also been raised about the inability of the SAP scan to differentiate
between A(32m and non-beta2-microglobulin amyloid deposits due to the ubiquity of
SAP in amyloid deposits of all types.
The majority of evidence for the use of SAP scans in patients with renal failure
comes from studies looking at the regression of amyloid deposits following
successful renal transplantation, but even these studies are limited. In one study,
there was a reduction in the extent of A(32m seen on serial SAP scans in eight out of
nine transplanted patients, studied over a five year period158. Other studies examining
the effect of transplantation on Ap2m have concluded that there is no doubt that the
symptoms of Ap2m resolve in the post-transplant period, but that there is no definite
evidence of regression in amyloid deposition159"161.
/32m scintigraphy
Due to the potential problems with SAP scintigraphy, alternative tracers that are
more specific for |32m amyloid have been proposed. Floege et al report improved
specificity for Ap2m with the use of 131I-(32m, niIn-(32m and luIn-rh(32m
scintigraphy . These tracers are not currently available for use in the UK but do
offer the potential for increased diagnostic accuracy in dialysis patients. These
tracers are not suitable for use in the post-transplant period as they suffer from rapid
excretion of the tracer in the presence of residual renal function.
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The pathophysiology ofAfi2m is incompletely understood and the best strategies for
preventing and treating A(i2m have not yet been fully established. As more patients
spend long periods of time on haemodialysis the clinical need for assessment of
amyloid load is likely to increase.
The study presented in this thesis aimed to determine whether high-flux therapies
have beneficial effects on the formation of dialysis related amyloid as detected by
SAP scanning. An additional aim was to correlate the results of the SAP scans to the
study ofbeta2-microglobulin kinetics. There has been little rigorous research
studying beta2-microglobulin kinetics and dialysis related amyloid in tandem and, to
my knowledge, none in such well-defined populations. It is unlikely to be practical to
perform SAP scans on more than a small number of haemodialysis patients due to
geographical and financial considerations, so the development of a method to predict
amyloid load from beta2-microglobulin kinetics without the need for a SAP scan
would be an important advance.
10.2 Methods
Fifteen patients were studied, all ofwhom had participated in the study ofbeta2-
micrglobulin kinetics described in the preceding chapter. Not all subjects included in
the previous study could be recruited to this study due to the extent of their co¬
morbidities and the difficulty of travelling to London on two consecutive days. Seven
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of the fifteen patients were from the Lister Hospital and dialysed using
haemodiafiltration (6) or high-flux dialysis (1). The remainder were from the Royal
Free Hospital with four receiving high-flux dialysis and four intermediate-flux
dialysis. SAP scans were carried out at the National Amyloidosis Centre. The
patients received an injection of 123I-labelled purified serum amyloid P component
(SAP) following a routine dialysis session then re-attended the following day for
whole body SAP scintigraphy. The results were scored based on activity at six joints
(knees, wrists, shoulders) and were assessed by a single observer who had no
knowledge of the patient's dialysis history. The following scoring system was used
to give a maximum score for an individual patient of 18.
No activity = 0
mild signal = 1
moderate signal = 2
strong signal = 3
10.3 Results
The scores obtained from the SAP scans and the dialysis parameters for the 15
patients are given in table 1. All except one of the patients had evidence of dialysis
related amyloid on the SAP scan, but only four were symptomatic. An example of



































































































































































































Figure 10.3 SAP scan showing uptake at wrists
Factors that may be relevant to the presence or absence ofAP2m are the prevailing
level of beta2-microglobulin, the age at which a patient commenced
haemodialysis163, the duration of haemodialysis treatment, the level of residual renal
function, the flux of the dialyser and the microbiological purity of the haemodialysis
water.
Pre-dialysis beta2-microglobulin level
The pre-dialysis beta2-microglobulin level was significantly higher in the patients
receiving intermediate-flux dialysis but there was no difference between the patients
at the Lister Hospital and those on high-flux dialysis at the Royal Free. The
prevailing pre-dialysis level of beta2-microglobulin did not predict the score
achieved on SAP scan (p=0.47) and, additionally, did not predict the presence or
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absence of symptoms of Ap2m. The pre-dialysis P2m level did not correlate
significantly with the level of residual renal function, the measured dialyser
clearance of P2m or the length of time on dialysis but there was a significant negative
















Figure 10.4. Correlation between pre-dialysis beta2-microglobulin concentration and age
Age
The age of the patients was 59.3 ± 14.9 years. The patients at the Lister Hospital
were significantly older than those receiving intermediate-flux dialysis at the Royal
Free Hospital, but there was no difference in the ages of the two groups at the Royal
Free or between the patients at the Lister Hospital and those on high-flux dialysis at
the Royal Free.
At detailed above there was a significant negative correlation between age and the
pre-dialysis beta2-microglobulin level, Figure 4. There was no apparent relationship
between age and the scan score or the presence or absence of symptoms.
R =0.46; p<0.01
10 20 30 40 50 60 70 80 90
age (years)
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Duration of Dialysis Therapy
The patients had been on dialysis for 12.7 ± 7.8 years. Those on intermediate-flux
dialysis had been receiving dialysis therapy for significantly longer than those on
high-flux dialysis or HDF. The duration of dialysis therapy correlated with the SAP
scan score p<0.001. Additionally, the patients who had symptomatic dialysis related
amyloid had been dialysing for significantly longer than the patients who did not
(20.0 ± 11.5 vs. 10.1 ± 4.1 years; p=0.02).
Residual Renal Function
Very few of these patients had any residual function remaining so this was
disregarded for the purposes of this analysis, and KRU for all subjects was assumed
to be zero. It is clear that there is a wide variation in SAP scan score for the same
level of residual function.
Membrane Flux
The pre-dialysis (32m level was higher in patients receiving intermediate-flux dialysis
when compared to those receiving high-flux dialysis or HDF, but the membrane flux
did not predict the scan score or the presence or absence of symptoms of A(32m.
All seven patients (6 receiving haemodiafiltration, 1 receiving high-flux dialysis) at
the Lister Hospital had evidence of amyloid deposition but none had symptomatic
arthropathy or had required carpal tunnel surgery. The duration of dialysis and the
age of the patients in this group were not different when compared to all patients
dialysing at the Royal Free Hospital or to the subset ofpatients with symptomatic
arthropathies. However, when compared to the patients receiving intermediate-flux
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dialysis, the patients on HDF were significantly older and had been on dialysis for a
shorter period of time, Table 2.
Table 10.2 Clinical Parameters according to place of dialysis and membrane flux
Lister Royal Free Royal Free
HDF/HFHD High-Flux Intermediate-Flux
Pre-dialysis (32m (mg/l) 27.614.9* 27.71 3.4* 44.3116.6
Symptoms 0/7 1/4 3/4
Scan Score 3.71 1.8 2.211.7 4.514.5
Time on dialysis (years) 10.914.6* 7.41 1.6* 21.219.9
Age (years) 66.9 1 6.6* 62.0114.1 43.5113.3
*=p<0.05 when compared to Royal Free Intermediate-Flux
Predictors of SAP scan score
Multiple regression analysis with backward elimination of variables revealed
duration of dialysis therapy, and age to be the most significant factors in the
prediction of the SAP scan score, with duration of dialysis being the strongest
predictor, Table 3.
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Table 10.3 Regression model to predict scan score
Variable Coefficient Standard error
of coefficient
t P
Constant -5.723 1.170 -4.89 0.000
Length of time on dialysis 0.38798 0.03883 9.99 0.000





Sum of squares Mean squares F P
Regression 3 90.117 30.039 34.36 0.000
Residual error 11 9.616 0.874
Using age and length of time as predictors the regression equation is
Scan score = -5.72 + 0.388 * length of time on dialysis + 0.0925 * age
And R2=90.3%
Correlation between Kinetic modelling and SAP scans
In the eleven of these fifteen patients in whom it had been possible to model beta2-
microglobulin kinetics, an attempt was made to correlate the findings of the
mathematical model with the results of the SAP scans, Table 4. Using multiple
regression analysis there was no clear relationship between any modelled parameter
and either the scan score or the presence or absence ofA|32m. Particularly there was
no relationship between the magnitude of flux 3 and the scan score.
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Flux 1 Flux 2 Flux 3
1 7 No 2.8 29 25
2 5 No 18 62 43
3 2 No 12 36 6
4 4 No 13 55 55
5 2 No 12 55 35
6 3 No 5 30 10
7 3 No 1 3 11
8 2 Yes 8 34 12
9 4 No 8.1 37 13
10 0 No 20 70 10
11 3 No 6 11 2
10.4 Discussion
It is generally accepted that in the era of low-flux dialysis therapies the longer a
patient spent on dialysis, the higher the beta2-microglobulin level became, and the
higher was the likelihood of developing AP2m. There is a widely held view that the
introduction ofhigh-flux therapies may have altered this natural progression of
disease60. The results presented here are entirely consistent with the first observation,
but give no evidence that high-flux therapies prevent the deposition ofAP2m as
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detected on a SAP scan. The results indicate that the only factors that influence the
amount of A(32m detectable on a SAP scan are the duration of dialysis therapy and
the age of the patient.
Duration of dialysis therapy
The average duration of dialysis in these fifteen patients was 12.7 years [range 5.0-
35.4 years] so the prevalence of symptomatic Ap2m would be expected to be high.
The finding that 93% of patients had evidence of Ap2m on a SAP scan is consistent
with previous observations but the 27% prevalence of symptoms is lower than
estimates in the literature. The patients with symptoms had been on dialysis
significantly longer than the rest of the group as a whole, but not longer than the
subset of patients on haemodiafiltration.
Age
The observation of a relationship between chronological age and propensity to
develop AP2m is consistent with all previous work in this field. In vitro studies
suggest that the propensity for dialysis related amyloid to deposit in musculoskeletal
tissues may be due to its obligate co-deposition with collagen132. It is possible that
degenerative change in the osteoarticular structures acts as a nidus for deposition of
p2m. The presence of osteoarticular damage is certainly one plausible explanation
for the increase in peri-articular amyloid deposition in the elderly.
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Against this explanation is the finding that the prevailing levels ofbeta2-
microglobulin are lower in the older patients. Kabanda et al have previously noted
lower beta2-microglobulin levels in the elderly and showed in multiple regression
analysis that age was negatively correlated to (32m concentrations when corrected for
residual renal function and time on dialysis164.
Whilst, at first, these two observations seem contradictory, they perhaps suggest that,
in the elderly, the dynamic equilibrium in beta2-microglobulin is shifted away from
circulating |32m and towards deposition of A|32m deposits. This could be due to the
presence of a favourable environment for formation of A|32m.
A second potential factor is the higher level of advanced glycosylation end products
in the elderly. Advanced glycation end products (AGEs) are formed by the Maillard
Reaction where nonenzymatic glycation and oxidation (glycoxidation) reactions
occur between carbohydrates and proteins. This reaction renders proteins more
resistant to degradation. Levels of these modified proteins are elevated in situations
of impaired renal function in diabetics and non-diabetics alike. The concentration of
AGEs additionally rises in an age-dependant manner even in the presence of normal
renal function165. Beta2-microglobulin seems to bind preferentially to AGE-modified
collagen which can then be further modified by non-enzymatic glycosylation134. This
tendency could provide a further explanation of the observed association between
peri-articular amyloid deposition and increasing age.
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Biocompatibility
Haemodiafiltration is considered to be a more biocompatible process and less likely
to activate the immune system. This would be one possible explanation for the
absence of symptoms in patients on haemodiafiltration. However, there is no
evidence that the patients with symptomatic amyloid deposition in this study had
been exposed to a less biocompatible environment. Modified cellulose or synthetic
membranes had been used in both centres for at least five years and the water quality
was comparable. It seems therefore that, consistent with previous observations140, the
membrane flux rather than the biocompatibility of the dialysis process predicts the
likelihood of developing symptomatic dialysis related amyloid.
Membrane Flux and the Importance of Co-precipitants
One of the quoted advantages ofhaemodiafiltration is its ability to clear increased
quantities ofbeta2-microglobulin, but it is by no means certain that this will lead to a
reduced incidence of A(32m. This study suggests that the use ofHDF or other high-
flux therapies is still associated with the deposition of A(32m but that the symptoms
experienced by patients are different.
If the symptoms of A(32m are related more to the substances that are co-deposited
with beta2-microglobulin it may be that high-flux therapies prevent the accumulation
of another, as yet unidentified, uraemic retention product that is acting in concert
with the deposition ofbeta2-microglobulin to cause symptomatic dialysis related
amyloid. In dialysis patients it is known that the presence of apolipoprotein E,
glycosaminoglyeans and proteoglycans exacerbates the formation ofbeta2-
microglobulin deposits166. Further work suggests that, in the early stages of beta2-
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microglobulin deposition there is a limited inflammatory reaction, but, as time goes
on, the interaction with AGEs leads to chemotactic attraction ofmacrophages and
release of pro-inflammatory cytokines137'138. It may be at this stage that destruction
of the articular tissues occurs and symptoms develop. High-flux dialysis and
haemodiafiltration may be acting to prevent or delay this final phase.
10.5 Conclusion
One of the most striking findings in this study is that there is no obvious correlation
between the amount of dialysis related amyloid detected on a SAP scan, the
prevailing level ofbeta2-microglobulin and the presence of symptomatic
arthropathies. This leads to the assumption that the deposition ofbeta2-microglobulin
as amyloid is not the only factor responsible for the development of symptomatic
amyloid-related disease in long-term dialysis patients. If it is the final inflammatory
phase that causes the symptoms of Ap2m this would be consistent with the
observations in the post-transplant period of improved symptomatology without
definite evidence of regression of amyloid deposition160'161'167.
This study has not identified a way in which to predict the extent of A|32m from
blood analysis, and has highlighted potential problems with the use of SAP scanning
as a diagnostic tool in the context ofhaemodialysis. The technique seems good at
detecting amyloid deposits but correlates poorly with symptomatic disease. As high-
flux therapy and HDF become more prevalent, it may be possible to study patients
after the conversion from low-flux to high-flux therapy to determine if there is any
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General Discussion and Conclusions
The work presented in this thesis arose from a recognition of the failure ofmodern
dialysis therapy to deliver all that it offered in the early days of the technique. While
the longevity of patients receiving haemodialysis has improved, the technique is not
providing a good quality of life. Patients are at risk ofprofound morbidity and early
death, principally from premature cardiovascular disease. The solutes that I chose as
my principle areas of study are well recognised to be retained in the uraemic state
and have been widely implicated in the pathophysiology of dialysis complications.
Knowing how best to monitor dialysis adequacy is another challenge as it is clear
that traditional urea kinetic modelling is an imperfect tool.
11.1 Mathematical Modelling
The technique ofmathematical modelling has been shown in these studies to be a
very useful and clinically applicable tool in the context of haemodialysis therapies. In
order for clinicians to understand the reasons for sub-optimal delivery of dialysis, it
is first necessary to understand the mechanism of solute removal. In my experience,
this is an aspect of renal medicine that is poorly taught and poorly understood. Many
papers on modelling of the dialysis process suffer from the complexity of the
equations presented, and become very inaccessible to anyone outside of the field of
knowledge. By using the modelling technique presented in this thesis I have been
able to express the ideas in a manner that can be understood in principle, without
needing an advanced knowledge of the underlying kinetic mechanisms. In this way, I
believe the process ofmodelling dialysis therapy has been demystified and is made
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more accessible to all. The technique ofbuilding the model from first principles has
allowed the nature of solute removal to be understood in more detail and deviations
from a predicted pattern identified. It is only when the barriers to solute removal are
identified that strategies can be devised to improved on standard practice.
11.2 Phosphate
The modelling study in chronic dialysis patients has shown clearly that the retention
ofphosphate in chronic haemodialysis patients is a major obstacle to the
achievement of controlled serum phosphate levels. It seems probable that the
mechanism behind the multi-pool nature of phosphate kinetics has its origins in the
pre-dialysis period. Chronic phosphate overload, which is probably occurring from
stage 3 or 4 CKD onwards, presumably deposits in various tissues throughout the
body. Once a patient comes onto dialysis, there is a potential pathway for removal of
solute and some of the phosphate moves out of these stores. Unfortunately due to the
relatively low amounts ofphosphate that can be removed on conventional dialysis,
and the large size of the store, it is almost impossible to achieve neutral phosphate
balance on a thrice-weekly dialysis schedule. It seems clear that either more frequent
dialysis scheduling or longer, slower treatments would improve phosphate removal.
The work on diurnal variation makes this discussion more interesting. It is clear that
patients dialysed during the night will be dialysing at the peak of their phosphate
concentration and may therefore have an advantage in terms of diffusive clearance.
The study presented in this thesis examined patients with stage 5 CKD to prevent any
confounding issues from fluctuations in phosphate concentration brought about by
dialysis. It is not entirely certain that these findings can be applied to the dialysis
259
population but it would seem reasonable to assume that similar findings will exist as
long as patients maintain a degree of residual renal function. Care should therefore
be taken when interpreting phosphate concentrations to consider the timing of the
sample. The current pre-dialysis guidelines of a phosphate <1.8mmol/l should also
stipulate the timing of this sample. The maximum target phosphate concentration
should perhaps be lower than this level to take into account the peak in phosphate
concentration that occurs at night.
11.3 Beta2-microglobulin
The modelling study presented has again demonstrated a multi-pool kinetic model
that explains (32m removal during haemodialysis. The model presented is attractive
when considered in terms of potential stages of (32m deposition. The internal transfer
of solute that occurs during the haemodialysis process again limits removal ofbeta2-
microglobulin. In the presence ofhigh membrane clearance there appears to be more
potential for the mobilisation ofbeta2-microglobulin from stores but additionally the
duration of dialysis therapy seems to be of importance as it takes some time for the
different fluxes to become operational.
The use ofhigh-flux therapies does seem to make a difference to the symptoms
experienced by patients but does not alter the likelihood of amyloid deposition as
might have been predicted. It seems most probable that high-flux therapies reduce
symptoms by altering the potential for co-deposition of substances that promote an
inflammatory response.
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From the point of view of the SAP scans, it was disappointing that they did not add
much to the clinical diagnosis ofAp2m. It is probable that the utility of this imaging
technique will become more apparent when monitoring progression of disease using
different dialysis techniques and schedules. Further studies using serial scanning of
patients changing from low-flux dialysis to high-flux dialysis or haemodiafdtration,
and studies of patients changing from thrice weekly to daily dialysis are likely to be
give valuable information about the potential to modify the disease process.
11.4 New Dialysis Techniques
The majority of clinicians now accept the potential benefits that high-flux therapy
can offer and, where there is an adequate water supply, this technique is often
utilised. There are still a large number of dialysis units that are unable to deliver
high-flux therapy due to concerns about the quality of the water supply and the
potential for backfxltration. This is clearly an issue that needs to be addressed,
particularly where there is an opportunity to develop new dialysis facilities.
There is increasing evidence that haemodiafiltration will produce clinical benefit
although the absolute proof of this is lacking at present. It is the most physiologically
valid of all the available dialysis therapies and with increasing experience of the
technique, it is likely to become more prevalent. Longer-term outcome studies such
as the Membrane Permeability Outcome (MPO) study that is underway in Europe
may still prove it to be a superior technique.
We are probably now at the limit ofwhat thrice-weekly dialysis can achieve and it is
now time to think about the structure of service delivery. It is not surprising that an
intermittent therapy that permits wide fluctuations in physiological parameters does
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not deliver the optimum outcomes. In an effort to make dialysis treatments more
physiological, there are two main issues to consider - the duration of therapy and the
frequency of therapy.
11.5 The Time vs Frequency Debate
Time
It is clear that time is an important factor in achieving adequate dialysis. This was
largely discounted in the original NCD study as the difference between short and
long dialysis failed to reach significance. This led to a continual reduction in
treatment times in the USA which did not really occur in Europe or Japan . It
became apparent that outcomes varied in different countries and much of the
difference has been attributed to the discrepancies in treatment times. In Japan where
treatment times were longest, there was a significant reduction in mortality when
compared to Europe and the USA. The results from the DOPPS study showed that
when treatment time was >240 mins vs. <240 mins the relative risk of death was 0.81
p=0.0005. There was also a clear interaction between length of dialysis and delivered
dose with the best outcomes in patients with highest Kt/V and longest treatment
times169, Figure 1.
1.15 Figure 11.1
The relationship between treatment
time, Kt/V and outcome.
[Reproduced with permission from 169]
180 210 240 270
Treatment time (min)
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The experience from Tassin is in line with this with improved outcomes when a
IT
schedule involving long hours (8 hrs 3x weekly) is utilised .
The modelling ofphosphate and beta2-microglobulin kinetics helps to explain why
the duration of dialysis is so important. For solutes such as urea, the duration of
therapy is probably not vital providing the membrane characteristics and blood flow
are optimised. The improved survival with increased Kt/V(urea) probably does not
relate to removal ofurea per se but is rather a surrogate marker for improved removal
of other uraemic toxins. For solutes with resistance to internal transfer, as
demonstrated for phosphate and beta2-microglobulin, allowing enough time for
internal movement of solute is essential. Increasing the blood flow or membrane
clearance characteristics will not necessarily lead to reductions in the pre-dialysis
concentrations of these solutes as total mass removal is dictated as much by internal
transfer of solute as it is by clearance across the dialyser membrane. There is
currently a lot of interest in reducing the duration of dialysis therapies, which is
justified on the basis of the maintenance of the urea removal characteristics. A note
of caution should be sounded however, as the modelling studies presented here
indicate that a reduction in duration is likely to be accompanied by a disproportionate
reduction in middle molecule clearance. This appears to be demonstrated in a
comparison of phosphate clearance in nocturnal dialysis (6-8 hours 6 or 7x per week)
versus short daily dialysis (1.5-2.5 hrs 6 or 7x per week)96. Short daily dialysis is
seen to be little better than conventional haemodialysis in terms of control of
hyperphosphataemia but nocturnal long hours haemodialysis delivers marked
improvements in phosphate clearance. I am unaware of any similar studies that have
been conducted comparing beta2-microglobulin clearance in short daily with
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nocturnal haemodialysis but it would be expected that a similar pattern would be
found.
Frequency
Increasing the frequency of dialysis brings it more in line with the physiological
situation of continuous clearance. There is increasing evidence that both short daily
dialysis and nocturnal daily dialysis improve control of solute concentrations and
additionally improve blood pressure and general well being. It also appears that
patients experience less in the way ofdisequilibrium symptoms with far less of a
"dialysis hangover" when compared to a thrice weekly program. The propensity for
development of dialysis related amyloid may be reduced with daily dialysis regimes
as there is some evidence that more frequent scheduling has a beneficial effect on the
levels of AGEs170;171.
The future of the Time vs Frequency Debate
At present, there are no randomised controlled trials that address the issues of time
vs. frequency and many of the existing observational studies can be criticised on the
basis of patient selection or duration of follow-up. However, the results of the studies
reported to date makes this a very interesting area for further study.
The National Institute of Health are currently recruiting for several studies to assess
the impact ofmore frequent scheduling of dialysis on outcome. The results of these
studies are likely to be of considerable interest. There are four trials that are relevant
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in this field. The first two are randomised controlled trials while the other two are
observational studies.
1. The impact of short daily dialysis (1.5-2.75 hrs 6x per week) vs. standard
thrice weekly (3-4 hrs) dialysis
2. Comparison of nocturnal dialysis (6 hrs 6x per week) with conventional
dialysis delivery (3-4 hrs 3x per week)
3. Comparison ofDaily Nocturnal Haemodialysis With Daily Haemodialysis
4. Comparison ofFour and Eight Hours Dialysis Sessions in Thrice Weekly
Haemodialysis
In the current political climate, delivering these types of dialysis schedules within the
NHS would present a huge challenge as the dialysis units are not funded or equipped
for such operation. The only practical way to deliver a more frequent program of
dialysis therapy is to develop the home dialysis services. With this development will
come increased pressure on vascular access services to ensure that patients have
stable vascular access and innovative techniques such as the use of a buttonhole
needling technique may need to be developed in order to preserve vascular access. In
the trials that have reported to date, failure of vascular access was not a major
problem172.
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11.6 New Measures ofDialysis Adequacy
By increasing the frequency of dialysis, it is possible to increase the weekly Kt/V by


















DOQI target for N = 3
eKt/V each dialysis
Figure 11.2 The effect of increasing adequacy and increasing frequency on weekly Kt/V.
[Reproduced with permission from173]
New equations are needed to describe these new frequent treatments as, if clearance
is continuous, the URR will be zero and the Kt/V cannot be calculated as the system
is constantly in steady state with no fluctuations. The currently favoured option is the
standardised Kt/V.
, ,. , „ _r continuous removal rate G
standardised Kt/V
average peak concentration average peak concentration
To calculate the standardised Kt/V from a measured single pool Kt/V the following







where N is the number of treatments per week, spKt/V is the measured single pool Kt/V and
eKt/V is the equilibrated Kt/V.
This equation does not take into account residual renal function or changes in volume
status and assumes equally spaced dialysis treatments. It is therefore not entirely
accurate.
This still only gives information about small solute clearance and from the modelling
studies presented here, it is clear that this falls far short ofproviding a description of
a truly adequate treatment. Alternative or perhaps complementary adequacy
measures such as beta2-microglobulin clearance have been proposed, but while there
are still a large number of centres where high-flux dialysis and haemodiafiltration are
not utilised, it is unlikely that estimates ofmiddle molecule clearance will be
accepted as standard measures of dialysis adequacy for some time yet.
The studies presented here give weight to the notion of duration of dialysis being of
utmost importance in the achievement of adequate solute clearance when there are
large deposits of solute to remove. Perhaps when the body is in equilibrium and
solute generation matches solute removal the more important factor will be
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frequency of therapy, as this will prevent the unphysiological peaks and troughs in
solute concentration.
Only by monitoring the control of variables with different dialysis schedules will the
question about the "best" therapy be answered. For patients who have been receiving
dialysis for long periods of time the best delivery at present would appear to be daily
long hours dialysis, but perhaps in the future when patients begin their dialysis
careers on a more frequent schedule, a shorter daily regime will be adequate as they
will not have the same excess stores of solute.
11.7 The Future ofModelling in Haemodialysis.
I believe that we are entering an exciting period of dialysis delivery in terms of
addressing the real problems experienced by our patients. It is apparent that the
traditional "one size fits all" approach to dialysis therapy is no longer appropriate and
dialysis parameters need to be tailored to individual patients. As physicians, we are
faced with the challenge ofmaximising the potential benefits of an imperfect
treatment and need to facilitate alternative ways of delivering the service. It is
imperative that the barriers to solute removal are understood to prevent the mistakes
of the past being repeated as occurred with the reduction in dialysis duration. By
understanding the kinetics underlying the dialysis process it is much more possible to
recognise the barriers to solute removal and to design therapies that are specific to
controlling these variables. Modelling studies can give insight into the mechanisms
underlying solute clearance and can be used to predict the likely outcome from a
particular dialysis schedule. As new dialysis schedules become more widespread it
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will be possible to model solute clearance in the longer and more frequent therapies
to determine if they truly deliver the benefits that they theoretically appear to offer. If
discrepancies are then identified between the predicted behaviour and actual dialysis
delivered, further investigation can be targeted to elucidate the problem. It will also
be important to ensure that in striving for optimal solute clearance, we do not expose
patients to depletion syndromes and this can easily be investigated using intradialytic
modelling.
By improving the understanding of solute kinetics, the long-term goal is to improve
the outcome for patients with end-stage renal failure on dialysis and to reduce the
unacceptably high morbidity and mortality that these patients currently experience.
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Phosphate kinetics during hemodialysis:
Evidence for biphasic regulation
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Department of Nephrology, Lister Hospital, Herts, England, United Kingdom
Phosphate kinetics during hemodialysis: Evidence for biphasic
regulation.
Background. Hyperphosphatemia in the hemodialysis pop¬
ulation is ubiquitous, but phosphate kinetics during hemodialy¬
sis is poorly understood.
Methods. Twenty-nine hemodialysis patients each received
one long and one short dialysis, equivalent in terms of urea
clearance. Phosphate concentrations were measured during
each treatment and for one hour thereafter. A new model of
phosphate kinetics was developed and implemented in Vis-
Sim™. This model characterized additional processes involved
in phosphate kinetics explaining the departure of the measured
data from a standard two-pool model.
Results. Pre-dialysis phosphate concentrations were similar
in long and short dialysis groups. Post-dialysis phosphate con¬
centrations in long dialysis were higher than in short dialysis
(P < 0.02) despite removal of a greater mass of phosphate
(P < 0.001). In both long and short dialysis serum phosphate
concentrations initially fell in accordance with two-pool kinet¬
ics, but thereafter plateaued or increased despite continuing
phosphate removal. Implementation of an additional regula¬
tory mechanism such that a third pool liberates phosphate to
maintain an intrinsic target concentration (1.18 ± 0.06 mmol/L;
95% confidence intervals, CI) explained the data in 24% of
treatments. The further addition of a fourth pool hysteresis
element triggered by critically low phosphate levels (0.80 ±
0.07 mmol/L, CI) yielded an excellent correlation with the
observed data in the remaining 76% of treatments (cumulative
standard deviation 0.027 ± 0.004 mmol/L, CI). The critically
low concentration correlated with pre-dialysis phosphate levels
(r = 0.67, P < 0.0001).
Conclusion. Modeling of phosphate kinetics during hemodi¬
alysis implies regulation involving up to four phosphate pools.
The accuracy of this model suggests that the proposed mecha¬
nisms have physiological validity.
Hyperphosphatemia is a well-recognized complication
of chronic renal failure (CRF), and is important in the
pathogenesis of secondary hyperparathyroidism. Chronic
Key words: hyperphosphatemia, kinetic modeling, intracellular fluid,
extracellular fluid, two-pool model, three-pool model, four-pool model.
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hyperphosphatemia and its treatment with calcium-con¬
taining phosphate binders also may be a factor in the
progressive calcific vascular disease, which occurs in dia-
lyzed patients and is a potential contributor to the in¬
creased incidence of premature cardiovascular death in
this population [1]. It has been shown that a pre-dialysis
serum phosphate concentration of >2.1 mmol/L is asso¬
ciated with increased mortality [2, 3], In recognition of
such factors, the British Renal Association has instituted
a target pre-hemodialysis serum phosphate value of 1.2
to 1.7 mmol/L [4]. There is no firm evidence that reducing
pre-hemodialysis phosphate levels to this degree is bene¬
ficial, however, and only about 30% of British hemodial¬
ysis patients achieve this target [5]. Non-compliance with
diet and phosphate binders is often cited as the major
cause of poor phosphate control, but shortened dialysis
times undoubtedly contribute. We have studied intradia-
lytic phosphate kinetics in long and short dialysis. We
have used a mathematical modeling approach to investi¬
gate the degree to which serum phosphate levels during
hemodialysis may be controlled, and to infer the main
elements of the regulatory process.
METHODS
Patients
Twenty-nine stable hemodialysis patients (26 male, 3
female) were studied. Their median age was 54 years
(19 to 81 years) and they had been stable on hemodialysis
for at least three months. All patients dialyzed via an
arteriovenous fistula and the absence of access recircula¬
tion was confirmed by a saline dilution method with a
sensitivity of 5% [6]. Residual renal solute clearance
(KRU) varied from 0 to 4.0 mL/min (mean 1.2 ± 0.3)
but was disregarded for the purposes of the study. Pa¬
tients who were severelymalnourished (normalized pro¬
tein catabolic rate (NPCR) <0.7 and albumin <35 g/L) or
hospitalized with infection or heart failure were excluded.
Dialysis techniques
Hemodialysis (HD) treatments were performed using
a Fresenius 2008D hemodialysis machine, bicarbonate di-
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Vysis fluid and polysulphone dialyzers (Fresenius HF80 or
R>0). Blood flow rates (Qb) were 253 to 545 mL/min and
aialysis fluid flow rates (Qd) were 500 to 800mL/min. The
same equipment was used for hemodiafiltration (HDF),
but 100 to 120mL/min filtration was performed simultane¬
ously. Replacement fluid was generated by filtration of
the dialysate using the Fresenius on-line HDF system.
Study protocol
Patientswere studied during a conventional hemodial¬
ysis (mean 240.7 ± 5.3 min) and a short hemodiafiltration
(mean 147.3 ± 6.5 min) on the same day of consecutive
weeks [7]. Dialysis prescriptionswere adjusted to achieve
a desired two-pool Kt/V (urea) of 1.0, where K is the
dialyzer clearance rate, t is the duration of the dialysis
session, and V is the urea distribution volume or total
body water volume (TBW). The dose of dialysis required
to achieve the desired Kt/V (dKt/V) was calculated from
the equation:
t = desired Kt/V X 4- tpj (Eq. 1)
where tp compensates for urea rebound in the post-
dialytic period in accordance with two-pool kinetics. In
all treatments tp was set to 35 minutes as described
previously [7],
Sampling and assay techniques
Blood samples were taken from the arterial needle
before the start of HD/HDF (tia), from the arterial line
at five equally spaced time intervals during HD/HDF
(ti2-ti6) and at the end of the treatment without slowing
the blood pump (td). Further samples were taken at 2,
15, 30 and 60 minutes post-dialysis from the fistula nee¬
dle. The washback was performed after the two-minute
sample. The ultrafiltration rate (Qf) was calculated from
pre- and post-dialysis weight. The blood flow rate (Qb)
wasmeasured after the dialysis by timed volumetric mea¬
surement under the same conditions as obtained during
dialysis. Dialyzer clearance was calculated approxi¬
mately twenty minutes after the start of HD/HDF from
the dialyzer inlet and outlet concentration measure¬
ments, taking hematocrit into account. Concentrations
of urea, creatinine, phosphate and bicarbonate were
measured using a Hitachi-717 autoanalyzer.
Data analysis
Statistical analysis. Statistical analysis was carried out
using the Student t test for paired samples and linear
correlation as appropriate. A P value <0.05 denoted the
presence of a statistically significant difference. Mean
values are quoted with 95% confidence intervals unless
otherwise stated.
Mathematical modeling. Models were implemented
using VisSim™ (Visual Solutions Inc.) modeling soft¬
ware. This environment offered the possibility to import
the observed data, facilitating direct comparison against
the models. The measured dialyzer clearance (Kdmeas),
Qb, Qd, dialysis time (Td), sex, pre- and post-dialysis
weights were provided as inputs to the model.
For each of the models the standard deviation between
the data and themodel was calculated via the expression:
2 (Ce_Data(i) — Ce_Model(0)2 ^Cl" ^
This provided an objective measure of the degree of fit
over the whole treatment and measured rebound period.
Urea model
The two-pool model of urea kinetics during hemodial¬
ysis is well validated and assumes a dynamic equilibrium
between intracellular and extracellular compartments.
The model can be represented schematically (Fig. 1),
graphically (Fig. 2), and mathematically (Appendix).
The dialyzer clearance of solute (Kd) induces diffusive
flux of solute (Fd) from the extracellular space and intro¬
duces disequilibrium between the intracellular and extra¬
cellular compartments. Solute then diffuses freely down
the concentration gradient (Fi) at a rate determined by
the intracellular to extracellular transfer coefficient (Kie).
In addition the ultrafiltration process adds convective
flux of solute (Fc). Total body water volume (V) was
calculated according to the Watson formula [8] with an
assumed intracellular to extracellular volume ratio of
2:1. The mass transfer coefficient (Kie) between the intra¬
cellular and extracellular spaces was manipulated to
achieve the best fit with the two-pool model. Where
adjustments to the total body water were required the
intracellular and extracellular volumes were reduced in
equal proportions as this was considered to be more
physiologically representative of the effects of peripheral
compartmentalization and thus effective solute distribu¬
tion volume. An element of cardiopulmonary recircula¬
tion (CPR) was included in the design of the model.
Phosphate models
Since the kinetics of urea is more straightforward, this
marker was used as the reference for establishing the
compartment volumes, intracellular to extracellular ra¬
tio, and cardiopulmonary recirculation effects. Phos¬
phate was assumed to be distributed in the same spaces
and subject to the same basic factors influencing urea
kinetics. The initial conditions were set to the prevailing
phosphate concentration at the start of simulation.
Model A. This model was characterized by a simple
two-pool kinetic system as described for urea kinetics.
A schematic representation of the model is shown in
Figure 1 with the derivation of the model provided in
the Appendix.
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Fig. 1. Model A: Schematic representation of two-pool kinetics. Abbreviations are: M,., extracellular mass of solute; Ce, extracellular concentration
of solute; Ve, extracellular volume; M,, intracellular mass of solute; Q, intracellular concentration of solute; V,, intracellular volume; Fi, intercompart-
mental flux; Fd, diffusive flux across dialyzer membrane; Fc, convective flux across dialyser membrane; Kd, dialyzer clearance; Kis, cell membrane
mass transfer coefficient.
Time, minutes
Fig. 2. Graphic representation of two-pool kinetics. Symbols are: (solid
line) extracellular concentration according to the model; (dotted line)
intracellular concentration according to the model.
Model B. The established elements from model A were
implemented, and a regulatory mechanism involving a
third pool was added. This regulatory mechanism en¬
deavored to maintain a predetermined target phosphate
concentration that was initially inferred by inspection
of the nature of the rebound period and subsequently
optimized. Initially it was assumed that phosphate would
enter the intracellular environment from an internal
third pool and that the intracellular to extracellular trans¬
fer coefficient for phosphate (KieP04) would remain con¬
stant throughout the treatment. Using this variant of the
model, the fit with the data was particularly poor and
this approach was therefore abandoned.
In a second approach additional phosphate flux into
the extracellular space was explored. In thismodel, phos¬
phate was dialyzed initially according to two-pool kinet¬
ics. A regulatory system was invoked releasing phosphate
from a third pool into the extracellular space limiting the
fall of phosphate levels below an intrinsic target concen¬
tration. No assumptions were made regarding the source
of the additional phosphate. The phosphate generation
process was assumed to be proportional to the difference
between themomentary extracellular phosphate concen¬
tration and the intrinsic target concentration. The con¬
stant of proportionality or "gain" determined the magni¬
tude of the rate of phosphate generation. Values for the
intrinsic target concentration and the gain were opti¬
mized manually by direct inspection of the data and
comparison of cumulative standard deviation measure¬
ments. The rate of removal by the dialysis process was
matched by concomitant liberation of phosphate via the
regulatory process, thus maintaining phosphate concen¬
trations in accordance with the data. It is probable that
intracellular phosphate is protected, since phosphate
plays a key role in all energy dependant processes within
the cell. Intracellular phosphate concentrations are not
readily measured so the extracellular phosphate concen¬
tration was used as a surrogate of the intracellular con¬
centration. The mass transfer of phosphate across the
cell membrane was assumed to be a bi-directional pro¬
cess, thus enabling the intracellular phosphate concen¬
tration to re-establish equilibrium with the extracellular
space in the post-dialysis period. A schematic representa¬
tion of the model is shown in Figure 3 with the derivation
of the model provided in the Appendix. One representa¬
tive treatment is shown in Figure 4.
Model C. This model implemented all the elements
of model B with the further introduction of a fourth pool
and a hysteresis element. We postulated that in addition
to the phosphate that is released to maintain a target
intracellular concentration, there must be a critically low
intracellular phosphate concentration, below which energy
dependant processes are compromised and a life-threat¬
ening situation exists. The existence of such a protective





Fig. 3. Model B: Schematic representation of three-pool kinetics. The two-pool kinetic model of model A (Fig. 1) forms the basis of this modelwith additional phosphate flux (F3) into the extracellular space from a third pool. This occurs in proportion to the phosphate error (£) or the
difference between themomentary intracellular phosphate concentration and an intrinsic intracellular phosphate target concentration. Themagnitude















Fig. 4. Representative treatment exhibiting
features of model B. Two-pool kinetics are
operational beyond the duration of dialysis.
When the prevailing phosphate concentration
falls below the target point phosphate is re¬
leased from the third pool. The critically low
limit is not reached in this treatment.
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Fig. 5. Representative treatment exhibiting
features ofmodel C. Kinetics are as for model
B (Fig. 4) but, in addition, when the critically
low limit is exceeded, fourth pool kinetics be¬
come operational. The influx from this pool
switches off when a safe phosphate level has
been re-established.
mechanism was evident from the clear discontinuity that
could be observed in the time course of phosphate varia¬
tion, as shown in Figure 5. The switching point of the
hysteresis element can be inferred from the observed
discontinuity. When the intracellular phosphate concen¬
tration falls to the critically low level, the hysteresis ele¬
ment results in a rapid switching on of the generation
process with phosphate generated from a fourth pool
local to the intracellular space. The hysteresis element
ensures liberation of phosphate over a limited concentra¬
tion band, which prevents oscillations about the critically
low limit. Once intracellular phosphate concentrations
are restored, normal proportional control applies as de¬
scribed for model B. The critically low limit may be
encountered several times during the course of a treat¬
ment, as shown in Figure 6. This is particularly likely to
occur when the pre-dialysis serum phosphate concentra¬
tion is low. The model can be represented schematically
(Fig. 7) and mathematically (Appendix).
RESULTS
Urea kinetics
It was possible to achieve excellent fits with a two-
pool model for the urea data in long dialysis (Fig. 8A)
with a median intracellular to extracellular transfer coef¬
ficient for urea (Kie urea) of 750 mL/min and total body
water 96.6 ± 3.2% of the predicted Watson volume (V).
In contrast, during short dialyses it was necessary to
assume a lower effective total body water 68.0 ± 4.5%
of predicted volume, and a corresponding reduction in
Kie urea in order to achieve the same degree of accuracy.
(Fig. 8B) The values used to compensate for cardiopul¬
monary recirculation (CPR) averaged 4.3 ± 0.4% in long
dialysis and 5.4 ± 0.8% in short dialysis (P < 0.01).
Phosphate kinetics
Model A: Two-pool kinetics. An attempt was made
to fit the phosphate data to the same two-pool model.
It was clear that phosphate kinetics were markedly dif¬
ferent (Fig. 9). During the initial part of the dialysis ses¬
sion extracellular inorganic phosphate concentrations fell
rapidly, but a point was reached beyond which the mea¬
sured phosphate concentration plateaued or in some pa¬
tients even began to rise. This phenomenon did not ap¬
pear to be related to alterations in acid-base status as
assessed by the serum bicarbonate concentration during
dialysis (Fig. 10). No correlation between the bicarbon¬
ate concentration and the phosphate concentration could
be demonstrated at any point in the dialysis process.
The average cumulative standard deviation between the
observed phosphate data and the two-pool model was
0.22 ± 0.04 mmol/L for long dialysis and 0.22 ± 0.03
mmol/L for short dialysis.
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Fig. 6. Representative treatment exhibiting
features of model C with repeated activation
of fourth pool kinetics.
Fig. 7. Model C. Addition of hysteresis element to model B. In addition to the proportional control mechanism shown in the three-pool model
(Fig. 3), critically low intracellular phosphate levels trigger immediate release of phosphate from a fourth pool local to the intracellular space (F4).
This independent mechanism serves to protect the intracellular environment from dangerously low phosphate concentrations. Abbreviations are
in the legend to Figures 1 and 3.
Me
(Ce Ve)
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Fig. 8. Representative data from one patient
showing observed urea levels during dialysis
(•) versus urea levels predicted by two-pool
model (represented by the line) in (A) long
dialysis and (B) short dialysis. Allowing for
cardiopulmonary recirculation (CPR) and for
a degree of peripheral compartmentalization
in the short dialysis, it was possible to achieve
excellent fits between the observed urea data
and the two-pool model, assuming an intra¬
cellular to extracellular transfer coefficient
(Kie). In A, Kie = 750 mL/min; CPR = 4%;
volume = 100%. In B, Kie = 413 mL/min;
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Fig. 9. Mean observed phosphate levels during dialysis for all 58 treat¬
ments versus phosphate levels predicted by two-pool model. A clear
discontinuity exists where the phosphate data plateaus and deviates
from the two-pool model. The degree of rebound can also be seen to
be greater in the observed data than the two-pool prediction. Symbols
are: (■) observed phosphate data; (•) two-pool model. Observed phos¬
phate data are mean ±95% confidence intervals. For the key to the
time differential axis, see "Sampling and assay techniques."
Model B: Three-pool kinetics to maintain a targetphos¬
phate concentration. According to model predictions the
target concentration for phosphate averaged 1.22 ± 0.08
mmol/L for long dialysis and 1.15 ± 0.10 mmol/L for
short dialysis (P = NS). The target concentration almost
always fell within the physiological range (Fig. 11A), but
within this range showed significant correlation with the
pre-dialysis serum phosphate concentration (r = 0.47,
P < 0.001; Fig. 11B).
During the period of active phosphate regulation the
dialysis process continued to remove phosphate at an
average rate of 0.16 ± 0.02 mmol/min in long dialysis
and 0.18 ± 0.02 mmol/min in short dialysis. To maintain
the phosphate plateau the generation rate from the third
pool must be of a similar order.
In eight long dialysis treatments and six short dialysis
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Fig. 10. Serial mean plasma bicarbonate measurements throughout
dialysis. Bicarbonate levels increase throughout dialysis. No plateau is
seen during dialysis in the bicarbonate data in contrast to the phosphate
data (Fig. 9). Data are mean ± 95% confidence intervals.
plain the observed phosphate data. The addition of
fourth pool kinetics in these treatments provided no fur¬
ther improvement in the degree of fit between the model
and the observed data. The cumulative standard devia¬
tions were 0.03 ± 0.01 mmol/L and 0.04 ± 0.01 mmol/L
for long and short treatments, respectively. One repre¬
sentative treatment is shown in Figures 4 and 12B with
the corresponding cumulative standard deviation curves
shown in Figure 12B.
Model C: Addition of a fourth pool and hysteresis ele¬
ment. The critically low concentration ranged from 0.41
mmol/L to 1.44mmol/L with a mean of 0.86 mmol/L in
long dialysis and 0.74 mmol/L in short dialysis (P =
NS). Correlation was found between the critically low
phosphate concentration and the pre-dialysis phosphate
concentration (r = 0.67, P < 0.001) (Fig. 13). According
to the model the liberation of phosphate from this fourth
pool ceased when the measured phosphate concentra¬
tion had risen by a mean of 0.07 ± 0.02 mmol/L.
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Fig. 11. (A) Target phosphate concentration. The majority of values
fell within the physiological range (0.75 to 1.40 mmol/L) and those that
did not tended to have higher pre-dialysis phosphate concentrations
(shown in parenthesis). (B) Correlation between pre-dialysis serum
phosphate concentration and target extracellular phosphate concentra¬
tion according to the model (r = 0.47, P < 0.001).
Model C shows an excellent fit with the observed data
for the 21 long and 23 short treatments not explained
by model B. The mean cumulative standard deviations
were 0.03 ± 0.01 mmol/L for both long and short dialysis
treatments. Two representative treatments are shown in
Figures 5, 6 and 14 with their corresponding cumulative
standard deviation curves shown in Figure 14.
Summary of all models
Models A, B and C were progressively implemented
until the best approximation to the data was achieved.
The application of model A demonstrated a reasonable
fit for the initial part of dialysis corresponding to two-
pool kinetics but a poor fit thereafter. The implementa¬
tion of model B demonstrated a close correlation be¬
tween the model and the data in a minority of treatments
(14 of 58). The pre-dialysis serum phosphate concentra¬
tion for these 14 treatments was significantly higher than
for the remainder of treatments (P < 0.01). A close fit
between the model and the data for the remaining 44
treatments was achieved when the hysteresis element of
model C was applied. The cumulative standard deviation
measurements for all 58 treatments in models A, B and
C are shown in Tables 1 and 2.
Comparisons between phosphate data in long and
short dialysis
Pre-dialysis phosphate concentrations were 1.74 ±
0.23 mmol/L for long dialysis and 1.71 ± 0.19 mmol/L
for short dialysis (P = NS). The minimum phosphate
concentration achieved in short dialysis treatments was
significantly lower (P < 0.001; Fig. 15) than that in long
dialysis. There was no statistical difference in the criti¬
cally low limit between the long and short treatments,
suggesting that either there is a short time lag before the
control mechanisms become active or that these mecha¬
nisms are overwhelmed by higher phosphate losses in
short dialysis. The higher dialyzer clearances and lower
effective V in short dialyses result in a more rapid rate
of decrease in the measured extracellular phosphate con¬
centration in the initial stages of dialysis (Table 3).
KieP04 was significantly higher in long versus short dial¬
ysis (P < 0.01), but this difference was not apparent
when corrected for the effects of phosphate distribution
volume (P = NS; Table 3). Post-dialysis phosphate levels
in long dialysis (0.83 ± 0.07 mmol/L) were higher than in
short dialysis (0.65 ± 0.05 mmol/L; P < 0.001). Phosphate
levels during the measured rebound up to 60 minutes
were significantly higher in the long dialysis group al¬
though the rate of rebound with time in the short dialysis
treatments was greater (Fig. 15). Despite lower phos¬
phate levels during dialysis the mass of phosphate re¬
moved during short dialysis was significantly less than
during long dialysis (26.33 ± 4.38 vs. 30.89 ± 4.70 mmol;
P < 0.02).
DISCUSSION
Phosphate kinetics remains a poorly studied area of
hemodialysis research despite the ubiquity of hyperphos¬
phatemia. Existing strategies to achieve phosphate con¬
trol rely heavily on dietary restriction and the use of
phosphate binders. The average daily intake of phos¬
phate in a Western diet is 26 to 67 mmol with a "renal"
diet expected to provide 18 to 36 mmol, with 10 to 30
mmol of this actually absorbed [9], It is difficult to
achieve a lower phosphate intake due to the necessity
of maintaining adequate protein intake, so patients on
hemodialysis are likely to remain in positive phosphate
balance despite the use of phosphate binders. Utilizing
high-flux membranes for hemodialysis or hemodiafiltra-
tion and increasing the surface area of the dialyzer mem¬
brane can remove phosphate more efficiently, although
Spalding et al: Phosphate kinetics in HD 663
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Fig. 12. (A) Representative treatment exhib¬
iting three-pool kinetics. Symbols are: (•) ex¬
tracellular phosphate data. Lines are: dotted,
two-pool kinetics; solid, three-pool kinetics.

































0.0 0.5 1.0 1.5 2.0 2.5 3.0
Pre-hemodialysis serum phosphate
concentration, mmol/L
Fig. 13. Correlation between pre-dialysis serum phosphate concentra¬
tion and critically low extracellular phosphate concentration according
to the model (r = 0.67, P < 0.0001).
no improvement is seen in the pre-dialysis phosphate
levels of patients dialyzed this way [10,11], Bicarbonate
replacement fluid has not been shown to be superior to
acetate in terms of phosphate removal [12].
It is known that phosphate removal does not follow
the same diffusion kinetics described for urea [13, 14],
Regardless of the duration of dialysis a characteristic
plateau phase is rapidly reached below which phosphate
levels do not fall. The reasons for this are complex and
relate to the mobilization of phosphate from unidentified
stores during the dialysis procedure. Longer dialysis
treatments remove a higher mass of phosphate, but also
result in significantly higher post-dialysis phosphate con¬
centrations according to our data. This is indicative of
phosphate being mobilized to a greater extent in long
dialysis. In the post-dialysis period there is a rebound
phenomenon persisting for in excess of one hour. The
rate of the rebound with time is significantly higher in
the short treatment group, which may be due to the
additive effect of re-equilibration of phosphate from pe¬
ripheral compartments that have been poorly perfused
during the short dialysis treatment.
Recognition of the departure of the phosphate data
from standard two-pool kinetics has led to the hypothesis
of a third pool of phosphate although its nature is not
clear [13-17], The existence of a third pool is consistent
with work demonstrating the absence of a plateau phase
when bovine blood is dialyzed in vitro [18], Studies in
erythrocytes demonstrate that intracellular to extracellu¬
lar phosphate equilibrium was reached at a higher extra¬
cellular phosphate concentration in the erythrocytes of
dialysis patients compared to controls, suggesting adap¬
tation to the hyperphosphatemic environment [19], This
may explain the observation that the critically low point
and target point are dependent on the pre-hemodialysis
phosphate concentration. (Figs. 11B and 13). 32P and
NMR studies demonstrate glycophosphates in uremic
erythrocytes not present in healthy controls that could
conceivably act as a source of phosphate during dialysis
[19, 20],
In studies of hemodialysis patients, Sugasaki described
a single-pool extracellular compartment model and pro¬
posed phosphate generation from reserves, triggered by
the reduction of phosphate during dialysis to a nadir
unique to each patient. Their studies recognized the cor¬
relation of the phosphate nadir with the pre-dialysis se¬
rum phosphate concentration [20, 21], Maasrani studied
four pediatric patients over eight dialysis sessions and
suggested that the plateau phase of phosphate kinetics
was maintained by a time-dependent influx from the
intracellular space [18], These studies all described the
influx of phosphate in terms of a linear or exponential
increase in the rate of phosphate generation (or gain)
that did not fully explain the observed data. Pogglitsch
studied 28 hemodialysis patients and suggested that gen¬
eration of phosphate was in response to falling extracel¬
lular phosphate levels [19]. The point at which phosphate
generation was initiated was again observed to be depen¬
dent on the pre-dialysis phosphate concentration. This
study suggested that additional phosphate was released
into the extracellular space in proportion to the differ¬
ence between the momentary phosphate concentration
and a critical level (equivalent to the target concentration
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Fig. 14. Two representative treatments (A and B) exhibiting four-pool kinetics with corresponding cumulative standard deviation curves (C and
D). (A) The pre-hemodialysis serum phosphate concentration is 1.07 mmol/L and there is a substantial contribution toward regulation from both
the third and fourth pools. (C) The pre-hemodialysis serum phosphate concentration is 0.88 mmol/L and the contribution toward regulation from
the third pool is minimal. This is presumably because this individual has little in the way of third-pool phosphate stores. Symbols are: (•)
extracellular phosphate data; (dotted line) two-pool kinetics; (dashed line) three-pool kinetics; (solid line) four-pool kinetics.
Table 1. Comparison of cumulative standard deviation
measurements for the fourteen treatments adequately
explained by three-pool kinetics
Model A Model B
(two pool) (three pool)
Long dialysis (8/29) 0.17 ±0.06 0.03 ±0.01"
Short dialysis (6/29) 0.18 ±0.13 0.04 ± 0.01*
Values are mean ±95% confidence intervals. Significance values are com¬
pared to model A (Student paired two sample for means).
•P < 0.05, "P < 0.01
in our model). This process continued into the post-
dialysis period [19].
Our model expands these ideas with the introduction
of biphasic control involving sequential implementation
of control mechanisms in response to changes in the pre¬
vailing phosphate concentration. (Figs. 1-7). In model A
dynamic equilibrium between the intracellular and extra¬
cellular compartments throughout the dialysis process is
assumed, consistent with a two-pool model. Model B
implements additional phosphate release from a third
pool tomaintain a pre-determined target phosphate con¬
centration. Although the additional phosphate enters the
extracellular space, which is consistent with Pogglitsch
et al's model [19], we propose that it is changes in the
intracellular phosphate concentration that trigger the
control mechanism. In theory, the generation process
from the third pool would be switched off once intracel¬
lular phosphate concentrations reach the target level,
although this was not evident in the current data since
the rebound clearly extended beyond our final measure¬
ment at 60 minutes post-dialysis. In model c, we addi¬
tionally describe the existence of a fourth pool that is
operational in the majority of treatments studied. There
is a hysteresis element deduced from the discontinuities
in the data that reflects a "switching on" effect that exists
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Table 2. Comparison of cumulative standard deviatio
measurements for the 44 treatments explained by
four-pool kinetics
Model A Model B Model C
(two pool) (three pool) (four pool)
Long dialysis (21/29) 0.24 ± 0.05 0.15 ±0.05' 0.03 ±0.01'
Short dialysis (23/29) 0.23 ± 0.03 0.11 ±0.02' 0.03 ±0.01'
Values are mean ± 95% confidence intervals. Significance values are com¬
pared to model A (Student paired two sample for means).
'P < 0.001
Time differential
Fig. 15. Comparison of observed serum phosphate concentrations in
long and short dialysis for all 58 treatments. Symbols are: (■) short
dialysis; (•) long dialysis; *P < 0.001 and **P < 0.01, paired t test.
Data are mean ± SEM values.
to protect against critically low intracellular phosphate
levels. Where the critically low intracellular phosphate
concentration is not encountered during dialysis (in 24%
of patients in this study), the hysteresis element is not
invoked and the three-pool model can adequately ex¬
plain phosphate kinetics.
Four pools of phosphate in our model best describe
the behavior of our data, and the kinetics of phosphate
clearly involves more complex mechanisms than simple
diffusion. The gut is an unlikely candidate for the third
or fourth pools as all the patients we studied were fasting.
Dialysis patients are likely to have pathological stores
of phosphate possibly in bone as 86% of total body
phosphate is in bone and approximately 250 mg phos¬
phate is mobilized daily in the process of remodeling.
The third-pool phase of phosphate regulation can poten¬
tially be explained by efflux from such stores, possibly
from a pool of phosphate not yet incorporated into bony
matrix. If so, this phase would only be sustained in indi¬
viduals with excess total body phosphate. The recogni¬
tion that most hemodialysis patients have an excess of
stored phosphate presents a challenge to achieve better
Table 3. Intradialytic parameters
Long Short P value
Td min 240.7 ±5.3 147.3 ±6.5 <0.001
CPR % 4.3 ±0.4 5.4 ±0.8 <0.01
%Watson volume (V) 96.6 ±3.2 68.0 ±4.5 <0.001
KdP04(model) mmollmin 158.4 ±12.1 226.4 ±13.1 <0.001
KdP04(meas) mmollmin 171.8 ±9.5 223.0 ±17.0 <0.001
KieP04 mLlmin effective 351.0 ±33.9 242.6 ±23.2 <0.001
KieP04 mLlmin corrected for V 363.8 ±32.7 363.8 ±32.7 NS
KdUrea(model) mmollmin 151.1 ±9.3 214.8 ±13.5 <0.001
KdUrea(meas) mmollmin 185.6 ±10.2 285.2 ±15.2 <0.001
KijUrea mLlmin effective 714.4 ±46.7 513.2 ±48.2 <0.001
KieUrea mLlmin
corrected for V 739.6 ±38.7 699.1 ±41.9 NS
Values are mean ± 95% confidence intervals. Abbreviations are: Td, length
of dialysis; CPR, cardiopulmonary recirculation; KdP04(model), dialyzer clear¬
ance of phosphate used in model calculations; KdP04(meas), dialyzer clearance
of phosphate calculated during dialysis; KieP04, intracellular to extracellular
transfer coefficient for phosphate; KdUrea(model), dialyzer clearance of urea
used in model calculations; KdUrea(meas), dialyzer clearance of urea calculated
during dialysis; KjeUrea, intracellular-to-extracellular transfer coefficient for
urea.
phosphate control in the pre-dialysis period. Earlier re¬
ferral of patients with chronic renal failure would allow
the timely introduction of dietary phosphate restriction
and phosphate binders to prevent patients starting their
dialysis careers in positive phosphate balance. Currently
used phosphate binders may be inadequate for this task.
The observed time course of the hysteresis effect of
our proposed model is difficult to explain if phosphate
is released purely from a bone-related pool. The speed
of the hysteresis response might imply phosphate release
by a mechanism such as cell lysis, but the observation that
the hysteresis can switch on and off repeatedly during a
dialysis treatment is against this action. The more proba¬
ble explanation is the existence of a fourth pool local to
the intracellular space that provides emergency protec¬
tion against life threatening, critically low intracellular
phosphate concentrations. It is possible that glycophos-
phates as described in some in vitro studies [19,20] could
be involved in this short-term regulation mechanism.
This mechanism is likely to represent physiological pro¬
tection and also may operate in normal controls.
Our model sequentially implements the third and
fourth pools, allowing all treatments in both the long
and short dialysis groups to be explained by passive two-
pool, three-pool, and emergency fourth-pool regulatory
processes. This implies common mechanisms operating
across all dialysis treatments and supports the physiologi¬
cal validity of the model. Phosphate generation from a
third pool allows the removal of more phosphate during
dialysis than is permitted by passive two-pool kinetics.
This is theoretically beneficial for reducing the excessive
phosphate stores that exist in chronic hemodialysis pa¬
tients. However, the switch to fourth pool kinetics in the
way we have described may give cause for concern. We
have observed that the majority of dialysis patients in-
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voke fourth pool kinetics in response to critically low
phosphate concentrations. These low phosphate levels
may contribute to dialysis-related symptoms and possi¬
bly to the excess morbidity and mortality seen in these
patients in the longer term. Our study did not appear to
result in major intradialytic symptoms, although this was
not a primary end-point. This would be an interesting
area for further study. To avoid the implementation of
fourth pool kinetics it would be necessary to prevent phos¬
phate concentrations reaching the critically low limit,
which could be achieved by longer and slower treatments
[9]. Daily dialysis currently appears to be the only tech¬
nique capable of safely depleting excess phosphate stores
and maintaining patients in optimal phosphate balance,
although whether this will be practical for the majority
remains doubtful.
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APPENDIX
Model A: Passive diffusion
The mass of P04 in the intracellular and extracellular compartments
Therefore,
M; = CiQ and Mc = CeV„ (Eq. 3)
where Q, Ce and V;, Ve represent the concentrations and volumes of
the intracellular and extracellular spaces, respectively. The rate of
change ofmass in the extracellular compartment depends on the fluxes
Fi, the diffusive flux across the dialyzermembrane Fd and the convective
component Fc as depicted in Figure 1.
dm«
- fir~Fi
IT ^ dMi CFc and = —Fi
dt




(Q - Ce)KIe - CeK,
(Eq. 4)
(Eq. 5)
where Kie is the mass transfer coefficient of the cell membrane with
respect to phosphate and Kd is the dialyzer clearance.
Since both the volume and concentration of the extracellular com¬
partment are changing, then
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= V.(0) - (Vdt
dCe
... (Q - QKie - Q.Kd - CeQu
dt V,(t)
Similarly for the intracellular space,
dMj _ d(QVi) _
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Model B: Passive diffusion + regulated intracellular P04
The derivation of model B is identical to Model A with the addition
of flux F3. F, represents a source of P04 from the third pool that feeds
into the extracellular space.
As a first approximation it is assumed that the flux F3 is proportional
to the difference between the intracellular concentration of phosphate
and a desired set point, C*t. Hence, an expression for flux F3 may be
written as:
F3 — (Q — Qsd) • G3 (Eq. 12)
The constant of proportionality is given by the gain G3, which governs
the rate at which phosphate is liberated from the third pool. The
differential equation describing the extracellular compartment is thus:
dQ




The kinetics of the intracellular compartment are identical to that of
Model A above.
Model C: Passive diffusion, intracellular regulation +
immediate action
Model C considers an additional mechanism that is invoked when
phosphate falls below a critical limit. Under this condition, phosphate
is liberated immediately at a fixed rate F4, from a fourth pool contained
within the intracellular environment. A more sophisticated mechanism
is beyond limits of that which could be deduced from the data available.
The hysteresis element has the properties:
IF Q < Qcni AND F4 off, THEN F4 on (Eq. 14)
IF C < CiHiohi imi, AND F4 on, THEN F4 off (Eq. 15)
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Dialysis quality and quantity: How much and
how often?
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Abstract
Hemodialysis is accepted as standard therapy for end-stage renal failure but despite four decades of
experience the morbidity and mortality associated with the treatment remains unacceptably high.
Quality of dialysis is traditionally measured with reference to urea clearance but it is becoming
increasingly apparent that other solutes across the range of molecular size are also important. More
prolonged or more frequent therapy may improve dialysis delivery and enhance survival in patients
with end-stage renal disease.
Key words: Hemodialysis, adequacy, frequency
Dialysis permits the patient to be fully rehabilitated, to have a satisfactory
nutritional intake and a sufficient production of red blood cells, to maintain
normal blood pressure values and to prevent the development of neuropathy1
INTRODUCTION
The definition of adequate dialysis proposed by de Palma
in 1971 is still highly relevant but remains a distant goal.
Understandably, the pioneers of dialysis were more con¬
cerned with preserving life than with reducing morbidity,
but from the time de Palma detailed his objectives to the
present day, it has remained clear that dialysis therapy
is suboptimal when measured against these standards.
The functions of the healthy kidney include removal of
metabolic waste products, maintenance of water, electro¬
lyte and acid-base homeostasis, blood pressure regula¬
tion, mineral and bone homeostasis, and regulation of
erythropoiesis. Excretory function is replaceable by dial¬
ysis, albeit only partially and nonselectively and mainte¬
nance of acid-base, fluid and electrolyte, and mineral
homeostasis remain approximate and difficult to individ¬
ualize. Dialysis cannot replace other functions, only some
of which can be delivered by other means e.g., adminis¬
tration of vitamin D analogs and erythropoietin. Of the
Correspondence to: Dr E. Spalding, Glasgow Royal
Infirmary, Castle Street, Glasgow Gil, UK.
E-mail: eg.fleming@ntlworld.com
myriad of possibilities, the adequacy of dialysis therapy is
traditionally based on the clearance of urea from the
blood, because blood urea levels are easy to measure
and are related to protein catabolism. However, the need
to consider dialysis adequacy in its more global context is
increasingly being recognized.
The concept of adequacy
Wolf (1951) provided the first description of hemodial¬
ysis (HD) adequacy. Focusing on the performance of the
membrane, he described the concept of dialysance and
noted varying dialysance values for different solutes.2 Mi¬
chaels (1966) provided further assessment of dialyzer
function with his analysis of the mass transfer coeffi¬
cient.3 The first attempt to correlate dialyzer function and
patient outcome appeared with the square meter/hour the¬
ory (Babb, 1971). The following year, the same group
proposed the "middle molecule hypothesis,"5 suggesting
that adequate removal of larger molecules, which diffuse
more slowly across a membrane, requires dialysis sessions
of longer duration and that accumulation of these "middle
molecules" causes some of the toxic effects of renal failure.
The National Co-operative Dialysis Study
(NCDS) and urea kinetic modeling
In 1974, Gotch and Sargent proposed urea kinetic mod¬
eling (UKM) as a technique for monitoring HD adequacy.
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The method was used in the protocol of the NCDS. This
landmark study had a 2 x 2 factorial design with patients
randomized to a low or high time-averaged urea (TACurea)
to examine the effect of small solute clearance, and a long
(4.5 hr) or short (3hr) dialysis treatment as a surrogate
for middle molecule clearance. The results (1983)6
showed better outcomes at lower TACurea values but
suggested no significant benefit from longer treatment
times. This may have hastened the move toward shorter
treatment times in the United States. The study could be
criticized on several counts. It was short (24-48 weeks),
there were small numbers (165), all patients were <60,
and none were diabetic. In addition the high TACurea arm
of the study was terminated early due to excess mortality.
In 1985, Gotch and Sargent reanalyzed the NCDS data7
and quoted the first marker of "adequate" HD on the basis
of the parameter Kt/V, where K is the dialyzer clearance,
t is the time on dialysis, and V is the urea distribution
volume. Their analysis suggested that improvements in
outcome continued up to a Kt/V of 1.0 and patients with a
Kt/V <0.8 did poorly. This was the first time that body
mass (expressed as V), and hence nutritional status was
related to outcome. Keshaviah (1993) fitted an exponen¬
tial curve to the same data, suggesting continuing benefit
at Kt/V >0.8.8 The use of UKM to prescribe dialysis dose
allows assessment of dialysis efficiency by comparing the
prescribed dose with the delivered dose, correlation with
markers of nutritional status, and individualization of
treatments on the basis of body mass. Problems may arise
from the use of potentially inaccurate estimates of dialyzer
clearance (K) and the use of anthropometric estimates
of V Because of this, several other measures of dialysis
adequacy have been used.
Urea reduction ratio (URR)
In 1991, Lowrie and Lew advocated the use of the URR to
simplify the monitoring of dialysis adequacy.9 A URR of
63% gives essentially the same amount of dialysis as a
single pool Kt/V of 1.2 and the 2 parameters are often
quoted together. While this simplifies the practicalities,
the URR gives no information about nutritional status,
cannot compare the prescribed dose with the delivered
dose, takes no account of the effects of ultrafiltration and
is difficult to adjust when off-target.
Two-pool UKM and equilibrated Kt/V
The single-pool Kt/V is only a valid mathematical de¬
scription of solute clearance from a homogenous pool.
The multicompartmental nature of the circulation during
time
Figure 1 Small solute kinetics during hemodialysis.
dialysis is demonstrated by the rebound increase in solute
concentration after the cessation of dialysis. The rebound
has several components: in the presence of access
recirculation, reequilibration takes several seconds to
complete as blood mixes in the vascular access; cardio¬
pulmonary recirculation lasts for around 2min; reequi¬
libration between body compartments can take several
hours, depending on the solute, but for urea, it takes
around 30 to 40min. Failure to account for the rebound
in dose estimation may result in overestimation of deliv¬
ered dose. Formal estimation of 2-pool Kt/V takes into
account rebound, but is cumbersome for use in routine
practice and requires analytical software to implement.
The equilibrated Kt/V (eKt/V—Figure 1) is a compromise.
It can be inferred from the single-pool estimate by one
of several accepted methods.10"12 For any given dialysis
treatment, the eKt/V will be lower than the corresponding
single-pool Kt/V
National Institutes of Health (NIH)
consensus conference and the evolution of
guidelines
In 1993, an NIH Consensus conference13 was convened
in response to the high mortality among U.S. dialysis pa¬
tients. Among the conclusions was that this excess mor¬
tality may be at least partly explained by suboptimal HD
dosing related to problems with vascular access, nonad-
herence to dialysis prescription, and under-prescription.
The recommendation was made that "until randomized
controlled trials have been completed, delivered HD dose
[should] at least equal a measured fractional urea clear¬
ance Kt/V value of 1.2 (single pool)." This afterwards
found echoes in Renal Association Clinical Practice
Guideline on Adequacy of Hemodialysis (1996), and
the K/DOQI (1997) and subsequent guidelines.
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The HEMO study
A number of uncontrolled studies had suggested benefits
from delivered doses in excess of 1.2spKt/V Japanese
Registry data demonstrated reduced mortality with in¬
creasing Kt/V up to a level 1.8.14 It was suggested that the
improved outcomes in Tassin were at least partly attrib¬
utable to a higher dose (mean 1.67spKt/V).15 In an at¬
tempt to provide clarity, NIH commissioned the HEMO
study. One-thousand eight-hundred and forty-six preva¬
lent dialysis patients were recruited into a 2 x 2 prospec¬
tive randomized study of standard-dose (eKt/V 1.05) vs.
high dose (eKt/V 1.45) groups (to assess the effects of
small solute clearance) and low-flux vs. high-flux mem¬
branes (to assess the effects ofmiddle molecule clearance)
and followed them for a mean of 2.84 years. No signifi¬
cant difference was found between the dose groups with
respect to all-cause mortality, though in subgroup analy¬
sis, women in the high-dose group had a lower mortality
(p = 0.02) than those in the standard-dose group.16 Differ¬
ences in body size could not be implicated,17 but suspi¬
cion of a denominator effect remains. Likewise, there was
no significant difference between mortality in the high-
flux and low-flux groups, although in subgroup analysis,
in the group of patients who had dialyzed for over 3.7
years before inclusion in the trial, there was a 36% re¬
duction in mortality (p = 0.001). The effect did not seem
to relate to differences in residual renal function. In
addition high serum p2-microglobulin levels predicted
mortality. Design issues included the exclusion of heavy
patients, overrepresentation of African Americans, and
lack of account for dialyzer reuse and water quality.18
Nevertheless, the HEMO study appears to have defined
the practical limits of the adequacy targets for conven¬
tional thrice-weekly HD. So why has mortality among HD
patients remained so high? Why is survival after transplan¬
tation progressively compromised by increasing dialysis
vintage before transplantation?19 These and similar issues
suggest that we have much to learn still about what con¬
stitutes adequate dialysis. In this context, the HEMO study
has served to fuel numerous debates: are we using the ap¬
propriate dosing parameters? Are current dosing targets
applicable across all patient subgroups and under all cir¬
cumstances? What is the relative importance of session
time and frequency? Is it justifiable to continue using low-
flux membranes in the light of potential benefits of high-
flux ones? Some of these issues are further discussed below.
A denominator effect?
The use of V to normalize dialysis dose (Kt) has been
questioned.20'21 V is an independent predictor of survival
across a large range of delivered dialysis doses, an effect
that has been attributed to malnutrition in a high-risk
group of patients with a low body mass.21-24 The dialysis
dose (Kt) required to achieve the target Kt/V is less in
patients with a low body mass. Malnourished patients,
who have an inappropriately low V, are therefore likely to
be underdialyzed. There may be more fundamental is¬
sues. Dialysis attempts to replicate renal excretion of met¬
abolic waste products, whose generation is proportional
to the metabolic rate. Basal metabolic rate is proportional
to Ma, where M is the body mass and a the mass index,
which, at around 0.67 to 0.75, implies that smaller pa¬
tients have proportionally higher metabolic rates and
hence require proportionally more dialysis than their
larger counterparts. Normalizing by Ma (or V3) or by
body surface area (BSA), would abolish this effect. It is
standard practice to normalize the glomerular filtration
rate (GFR) for BSA. Normalizing dialyzer clearance by the
same factor would seem to be a logical extrapolation.
Following the same reasoning, the generation of meta¬
bolic waste relates not only to an individual's basal met¬
abolic rate but also to their degree of physical activity and
catabolic state. Very active or catabolic individuals may
well require more dialysis. Finally V is frequently esti¬
mated anthropometrically usually by the Watson equa¬
tions, which are different for men and women, such that
women of a particular height and weight have a smaller
V than similarly sized males. Hence, women will tend to
be prescribed a lower Kt to deliver the same Kt/V, which
risks underdialysis in some. The use of V estimated by
formal UKM is not subject to the same criticism.
Flux, convection and Hemodiafiltration
Native renal function is mainly a convective process that
is tempered by specific absorption mechanisms and is
continuous in nature. The ideal renal replacement ther¬
apy should therefore mimic this as closely as possible.
Hemodiafiltration is a step closer to this ideal. This was
first described in the 1970s as a technique using high-flux
membranes and combined convective and diffusive
transport. This allowed rates of removal of low-molecu¬
lar-weight solutes similar to those achieved in conven¬
tional HD but much augmented clearance of "middle
molecules."25 HDF requires the replacement of large
volumes of filtered fluid with a substitution fluid, free
from chemical and bacteriological contamination. With
the availability of systems allowing online sterile fluid
production, the technique is now economically viable.
Subsequent experience with online HDF has suggested
potential benefits including reduced serum (32-microglob-
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ulin levels arid an associated delay in the clinical mani¬
festations of dialysis-related amyloidosis, improved car¬
diovascular stability on dialysis,26 and possibly improved
survival.27
Treatment time
Following the NCDS, less importance was attributed to
treatment time as an independent outcome determinant.
This fuelled a progressive reduction in treatment times par¬
ticularly in the U.S.A., which, as alluded to earlier, was
subsequently identified as a factor in the excess mortality of
U.S. dialysis patients.13 Treatment time, although not a pri¬
mary intervention, did not emerge as an independent de¬
terminant of outcome in the HEMO study. Flowever, there
are indications that treatment time plays a role in determin¬
ing outcome independent of Kt/V and ultrafiltation rate.28
Treatment frequency
The current norm of thrice-weekly scheduling was borne
of pragmatism rather than evidence. Indeed, there is ev¬
idence of an increased rate of sudden and cardiovascular
death after the "long gap" (Friday to Monday and Satur¬
day to Tuesday) in USRDS data.29 There is increasing in¬
terest in more frequent treatment and increasing evidence
that daily dialysis, short-hours, and particularly long-
hours nocturnal dialysis improves small and "middle-
molecule" solute concentrations, blood pressure, and gen¬
eral well being.30 It also appears that such patients expe¬
rience a minimal "dialysis hangover" in stark contrast to
those dialyzed thrice weekly.31 New approaches are re¬
quired to allow comparison of the dialysis doses delivered
by different frequency schedules and indeed by different
modalities. The currently favored option is the standard
Kt/V,32 which is based on the notion that outcomes are
similar in standard thrice weekly HD and peritoneal di¬
alysis because of similar mean peak plasma urea levels.
For intermittent treatments, this quantity can be viewed
as their weekly continuous equivalent. By increasing the
frequency of dialysis, it is possible to increase the weekly
standard Kt/V to a far greater extent than by increasing
the adequacy of the individual dialysis session (Figure 2).
There is a great need for controlled data relating to dial¬
ysis frequency, and the National Institute of Health have
recently initiated 2 studies to assess the impact of more
frequent scheduling on outcome.
How much is enough?
At present, there is a general consensus in the guidelines.
Kidney Disease Outcomes Quality Initiative (K-DOQI)
Figure 2 Relationship of weekly standard Kt/V to equilibrated
Kt/V per dialysis session and frequency of dialysis sessions.
(Adapted with permission from Gotch FA: The current place of
urea kinetic modelling with respect to different dialysis mod¬
alities. Nephrol Dial Transplant 1998; 13(Suppl 6): 10-14.)
(2006) recommends a minimum single-pool Kt/V of 1.2,
with a target of 1.4; the U.K. guidelines recommend
an equilibrated Kt/V of 1.2 (spKt/V 1.3), with similar
recommendations from the European Best Practice
guidelines (2002). On the basis of the HEMO study, it
would seem appropriate to prescribe increased doses in
women who are not doing well on standard doses, and to
use high-flux membranes in patients destined for long-
term treatment. Although not yet compelling, the case is
building up for the use of high-flux membranes as a stan¬
dard. In spite of this consensus, mortality among HD pa¬
tients remains high, and because we appear to have
exhausted the benefits of increasing dialysis dose on a
per-treatment basis using a thrice-weekly schedule, we
now need to explore the potential benefits of increased
treatment frequency. Certainly, the logic of thrice-weekly
treatments with their long weekend gap needs to be ques¬
tioned in patients with little residual function. Alternate-
day treatment might be a more reasonable baseline. In-
creased-frequency center-based treatment is likely to be
impractical and significant expansion of home-based
therapy needs to be explored. But this will not suit
all. Perhaps, the traditional "one size fits all" approach
to dialysis therapy needs to be revised.
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